 
       
BIOFLOW-V: 
BIOTRONIK – A Prospective Random ized Multicenter Study to 
Assess the Sa Fety and Effectiveness of the Orsiro Siro Limus 
Eluting Coronary Stent System in the Treatment Of Subjects With 
up to Three  De Novo  or Restenotic Coronary Artery Lesions – V 
 
  
Clinical Investigational Plan 
Final Version 4.0, February 11, 2016 
 
IDE#G140078 
        
This document contains confidential in formation for use only by investigators 
participating in the clinical study.  Therefore, this docum ent should be maintained in a 
secure location and should not be copied or made available for review by any 
unauthorized personnel.  

  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 2 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
 
Investigational Device Orsiro Sirolimus Eluting Coronary Stent System 
Sponsor and 
Manufacturer BIOTRONIK, Inc. Vascular Intervention Clinical Studies 6024 Jean Road Lake Oswego, Oregon 97035 United States of America 
BIOTRONIK AG 
Center for Vascular Intervention Ackerstrasse 6 8180 Bülach Switzerland 
Sponsor Contact  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Development Harvard Clinical Research Institute 
 
 
 
 
  

  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 3 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
STUDY PRINCIPAL INVESTIGATORS SIGNATURE PAGE  
 
IDE# G140078 
 I, the undersigned, have read and understood the Clinical Investigational Plan for 
the study entitled:  
 
BIOFLOW-V : 
BIOTRONIK – A Prospective Randomized Mu lticenter Study to Assess the Sa Fety and 
Effectiveness of the Orsiro Siro Limus Eluting Coronary Stent System in the Treatment 
Of Subjects With up to Three  De Novo  or Restenotic Coronary Artery Lesions – V 
 
 
BIOTRONIK, Inc. 
BIOTRONIK AG 
 
And agree with its contents. I declare that  I will comply with  all the Clinical 
Investigational Plan’s requirements. Th e Clinical Investigational Plan, the 
Investigator’s Agreement and any additiona l information provided by BIOTRONIK 
will serve as a basis for cooperati on in the clinical investigation 
  
US Study Principal 
Investigator  
Investigator’s Signature  
Date  
  
OUS Study Principal Investigator  
Investigator’s Signature  
Date  
  

  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 4 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
PRINCIPAL INVESTIGATOR SIGNATURE PAGE 
 
IDE# G140078 
 
I have reviewed this protoc ol for the study entitled: 
 
 
BIOFLOW-V : 
BIOTRONIK – A Prospective Randomized Mu lticenter Study to Assess the Sa Fety and 
Effectiveness of the Orsiro Siro Limus Eluting Coronary Stent System in the Treatment 
Of Subjects With up to Three  De Novo  or Restenotic Coronary Artery Lesions – V 
 
 
BIOTRONIK, Inc. 
BIOTRONIK AG 
 
 The signature below documents the receipt and review of the BIOFLOW-V clinical 
study protocol and any attachments, a nd provides the necessary assurances that 
this study will be conducted according to  all stipulations of the protocol, 
including all statements regarding confid entiality, and according to local legal 
and regulatory requirements and applicab le US Federal Regulations, ISO 14155, 
ICH and GCP guidelines 
  
Investigator Name 
(print or type)   
Investigator’s Signature  
Date  
  
  
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 5 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Table of Contents 
 
1. Protocol Synopsis ................................................................................................ 10  
2. Study Administ ration ........................................................................................... 17  
3. Introducti on .......................................................................................................... 20  
3.1. Investigational Devi ce Descrip tion ............................................................... 21  
3.1.1.  PRO-Kinetic Ener gy Stent  ....................................................................... 21  
3.1.2.  Sirolimu s .................................................................................................. 23  
3.1.3.  Poly-L-Lacti c Acid .................................................................................... 24  
3.1.4.  Delivery S ystem ....................................................................................... 25  
3.1.5.  Investigational De vice Matr ix ................................................................... 25  
3.2. Control Device Descripti on .......................................................................... 26  
3.2.1.  Control Device  Matrix............................................................................... 26  
3.3. Indications for Use ....................................................................................... 26  
3.4. Contraindica tions ......................................................................................... 27  
3.5. Orsiro Clinical Da ta Summa ry ..................................................................... 27  
4. Study Objectives and Endpoi nts ........................................................................ 32  
4.1. Study Object ives ......................................................................................... 32  
4.2. Primary E ndpoint ......................................................................................... 32  
4.3. Secondary E ndpoints .................................................................................. 32  
5. Study De sign ........................................................................................................ 33  
5.1. Clinical Si tes ................................................................................................ 34  
5.2. Number of S ubjects ..................................................................................... 34  
5.3. Study Participat ion Stat us ........................................................................... 34  
5.3.1.  Status Defi nitions ..................................................................................... 34  
5.3.2.  Subject Study  Exit .................................................................................... 35  
5.3.2.1.  Subject Lost to  Follow- up ................................................................. 36  
6. Subject Sel ection ................................................................................................. 38  
6.1. Eligibility Cr iteria .......................................................................................... 38  
6.1.1.  Clinical Inclusion Criteria .......................................................................... 38  
6.1.2.  Angiographic Inclus ion Criter ia ................................................................ 38  
6.1.3.  Clinical Exclusio n Criter ia ........................................................................ 39  
6.1.4.  Angiographic Exclus ion Criter ia ............................................................... 40  
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 6 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
7. Trial Procedures an d Assessme nts ................................................................... 42  
7.1. Schedule of Events ..................................................................................... 42  
7.2. Screening and Baseli ne Procedu res ........................................................... 44  
7.3. Concomitant M edications  ............................................................................ 45  
7.4. Index Proc edure .......................................................................................... 47  
7.4.1.  Subject Preparation and Baseline Angiography ....................................... 47  
7.4.1.  Randomizat ion ......................................................................................... 47  
7.4.2.  Target Lesion(s) Pre-Dilatat ion ................................................................ 47  
7.4.3.  Stenting .................................................................................................... 48  
7.4.4.  End of Pr ocedure ..................................................................................... 48  
7.4.5.  Bailout Proc edures .................................................................................. 49  
7.4.6.  Bailout-Staged Pr ocedur e ........................................................................ 49  
7.5. Post-Procedure to Ho spital Dis charge ........................................................ 49  
7.5.1.  Immediately Post-Procedure .................................................................... 49  
7.5.2.  Clinical and Laborator y Assessm ents ...................................................... 49  
7.6. Antiplatelet/Anticoagu lation Regi men .......................................................... 50  
7.7. Follow-Up A ssessment s .............................................................................. 50  
7.7.1.  One (1) Month Clinical Follo w-Up (30 ± 7 Days)  ...................................... 51  
7.7.2.  Six (6) Month Clinical Follo w-Up (180 ± 14 Days)  ................................... 51  
7.7.3.  Twelve (12) Month Clinic Visit (360 ± 30 Days)  ....................................... 51  
7.7.4.  Long-Term Clinical Follow-Up at 2, 3, 4 and 5 Years Post-Procedure 
(Annually ± 60 Days) .............................................................................................. 52  
7.8. Unscheduled St udy Vi sit.............................................................................. 52  
7.9. Angiographic Co re Laboratory ..................................................................... 52  
8. Statistical Considerations and Analysis Plan .................................................... 53  
8.1. Prior Da ta .................................................................................................... 53  
8.2. Bayesian A nalysis ....................................................................................... 55  
8.3. Softwar e ...................................................................................................... 55  
8.4. Criteria for Success ..................................................................................... 56  
8.5. Sample Size De terminatio n ......................................................................... 56  
8.6. Statistical Anal ysis Sets............................................................................... 60  
8.6.1.  Intent-to-Treat Anal ysis Populat ion .......................................................... 60  
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 7 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
8.6.2.  Per-Protocol P opulati on ........................................................................... 60  
8.7. Endpoint Analyses and Repor ting of Re sults .............................................. 60  
8.8. Analysis of Primary Endpoint ....................................................................... 60  
8.9. Handling of Missing Data in the Analysis of Prim ary Endpoi nt .................... 62  
8.10.  Analysis of Second ary Endpoin ts ................................................................ 63  
8.11.  Analysis of Baseline Demographics and Procedural Char acteristics .......... 64  
8.12.  Subgroup Anal ysis ...................................................................................... 64  
9. Adverse Even ts .................................................................................................... 65  
9.1. Definitions .................................................................................................... 65  
9.1.1.  Adverse Ev ents ........................................................................................ 65  
9.1.2.  Adverse Device  Effect.............................................................................. 65  
9.1.3.  Serious Advers e Event  ............................................................................ 66  
9.1.4.  Serious Adverse De vice Effe ct ................................................................ 66  
9.1.5.  Anticipated Adve rse Event  ....................................................................... 66  
9.1.6.  Unanticipated Adverse Device Effect  or Unanticipated Serious Adverse 
Device E ffect .......................................................................................................... 67  
9.1.7.  Device Failures, Malfun ctions and Misuse ............................................... 67  
9.2. Documentat ion ............................................................................................ 67  
9.3. Related ness ................................................................................................ 68  
9.4. Reporting of Serious Adverse Ev ents .......................................................... 68  
9.5. Reporting of Adve rse Event s ....................................................................... 69  
9.5.1.  Reporting Adverse De vice Effe cts ........................................................... 70  
9.5.2.  Reporting of Unanticipat ed Adverse Device Effects or Unanticipated 
Serious Adverse De vice Effe cts ............................................................................. 70  
9.6. Reporting of Study E ndpoint Adverse Events .............................................. 71  
9.7. Reporting Respons ibilitie s ........................................................................... 72  
10. Data Handling and R ecord Keep ing ................................................................ 74  
10.1.  Electronic Data  Captur e .............................................................................. 74  
10.2.  Electronic Case Report Form Comple tion ................................................... 74  
10.3.  Investigator Record s ................................................................................... 74  
10.4.  Sponsor Re cords ......................................................................................... 75  
11. Study Commi ttees ............................................................................................ 75  
11.1.  Steering Co mmittee ..................................................................................... 75  
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 8 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
11.2.  Data Monitoring Committ ee ......................................................................... 76  
11.3.  Clinical Events Committee ........................................................................... 76  
12. Ethical and Regulatory Considerat ions .......................................................... 77  
12.1.  Role of the Study Sponsor ........................................................................... 77  
12.2.  General Du ties ............................................................................................ 77  
12.3.  Subject Confi dentiality ................................................................................. 77  
12.4.  Informed Consent and Institutional Re view Board or Ethics Committee ..... 78  
12.5.  Monitoring .................................................................................................... 78  
12.5.1.  Visits  ........................................................................................................ 78  
12.6.  Protocol Co mpliance ................................................................................... 79  
12.6.1.  Protocol Viol ations ................................................................................... 79  
12.6.2.  Protocol Devi ations .................................................................................. 80  
12.7.  Device Accountabi lity and St orage .............................................................. 80  
12.7.1.  Labeling ................................................................................................... 80  
12.8.  Supplemental A pplicati ons .......................................................................... 81  
12.9.  Other Institutions  and Physici ans ................................................................ 81  
12.10.  Subject Insu rance .................................................................................... 81  
13. Risk Anal ysis .................................................................................................... 82  
13.1.  Potential Risks ............................................................................................. 82  
13.2.  Potential B enefits ........................................................................................ 83  
13.3.  Risk Mitiga tion ............................................................................................. 83  
13.4.  Sex and Gender in Cor onary Heart Disease ............................................... 84  
14. Use of Information a nd Publicat ion ................................................................ 85  
15. Premature Termination of the St udy ............................................................... 86  
16. Appendix A: Abbreviati ons and Acro nyms .................................................... 87  
17. Appendix B: De finitions ................................................................................... 90  
18. Referenc es ...................................................................................................... 108  
 
  
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 9 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
List of Tables 
 
Table 3-1. Orsiro Stent System – Devi ce Matrix for the BIOFLOW-V Study ................. 25  
Table 3-2. Xience Family of Stent Systems – Devices Matr ix for the BIOFLOW-V Study
 .............................................................................................................................. ........ 26  
Table 3-3. Orsiro Clinic al Trials Summary  ..................................................................... 28  
Table 7-1. Schedule  of Events ...................................................................................... 42  
Table 7-2. Concomitant Medica tion Regimen Reco mmendations  ................................. 46  
Table 8-1. Subjects ’ Poolabil ity ..................................................................................... 55  
Table 8-2. TVF/MACE Rates at 9 or 12 Months, DES vs. BMS .................................... 58  
Table 9-1. Adverse Events Reporting ............................................................................ 69  
Table 9-2. Investigator R eporting Responsib ilities ........................................................ 72  
Table 9-3. Sponsor Repor ting Responsib ilities ............................................................. 73  
 
List of Figures 
 
Figure 3-1. Image of Orsiro/PRO -Kinetic Ener gy Stent  ................................................. 22 
Figure 3-2. Metal Ion Release with PROBIO® Coatin g .................................................. 23 
Figure 3-3: Structural Fo rmula of Si rolimu s ................................................................... 23 
Figure 3-4. Orsiro Sirolimus  Eluting Stent  System  ........................................................ 25 
Figure 5-1. Trial Design of  the BIOFLOW- V Tria l .......................................................... 34 
Figure 6-1. Clinical St udy Design Flowchart .................................................................. 41 
 
  
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 10 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
1. PROTOCOL SYNOPSIS 
STUDY TITLE BIOFLOW-V: BIOTRONIK – A Prospective Randomized 
Multicenter Study to Assess the Sa Fety and Effectiveness of the 
Orsiro Siro Limus Eluting Coronary Stent System in the Treatment 
Of Subjects With up to Three  De Novo  or Restenotic Coronary 
Artery Lesions – V. 
INVESTIGATIONAL 
DEVICE  BIOTRONIK Orsiro Sirolimus Eluting Coronary Stent System. 
OBJECTIVES  To assess the safety and efficacy of  the Orsiro Sirolimus Eluting 
Coronary Stent System in the tr eatment of subjects with up to 
three native d e novo  or restenotic (standar d PTCA only) coronary 
artery lesions compared to the Xience coronary stent system. 
STUDY DESIGN  BIOFLOW-V is a prospective, mu lticenter, randomized, controlled 
trial combining data on the randomized subjects with data from two historical studies by empl oying a Bayesian approach. 
Subjects with coronary artery disease (CAD) that qualify for 
percutaneous coronary interventi on (PCI) with stenting will be 
screened per the protocol inclusio n and exclusion criteria to 
achieve a total of up to 1,400 randomized subjects.  Eligible 
subjects will be randomized in a 2:1 ratio to undergo percutaneous 
coronary revascularization with either  the Orsiro Sirolimus Eluting 
Stent System (treatment  group) or the Xience Everolimus Eluting 
Stent System (control group). 
BIOFLOW-V randomized subjects will be combined with historical 
Orsiro, Xience Prime
™ and Xience Xpedition™ randomized 
subjects from the BIOFLOW-II and BIOFLOW-IV trials by employing a Bayesian statistical approach.  Only subjects that meet all clinical and angiographi c eligibility cr iteria of the 
BIOFLOW-V trial will be included in the analysis. 
SUBJECT 
POPULATIONS  Subjects with CAD due to de novo  lesions or restenotic lesions 
from percutaneous transluminal co ronary angioplasty (PTCA) in 
native coronary arteries with a refe rence vessel diameter of 2.25–
4.0 mm and lesion length of ≤ 36 mm. 
NUMBER OF 
SUBJECTS  Sufficient number of subjects will  be provisionally enrolled in the 
trial to achieve a total of up to  1,400 randomized subjects (933 
Orsiro: 467 Xience).  It is expect ed that approximately 50% will be 
enrolled in the United States. 
NUMBER OF 
CLINICAL SITES Up to 100 clinical site s in the United States and 50 clinical sites 
outside of the United States. 
  
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 11 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
CLINICAL 
INCLUSION 
CRITERIA  Subjects must meet all of the follo wing criteria to participate in the 
trial: 
1. Subject is ≥18 years or the minimum age required for legal 
adult consent in the country of enrollment. 
2. Subject is an acceptable candidate for PCI. 3. Subject is an acceptable candidate for CABG. 4. Subject has clinical evidenc e of ischemic heart disease, 
stable or unstable angina pecto ris or documented silent 
ischemia. 
5. Subject is eligible for dual anti-platelet therapy treatment 
with aspirin plus either, clopido grel, prasugrel, ticagrelor or 
ticlopidine. 
6. Subject has provided written informed consent. 7. Subject is willing to co mply with study follow-up 
requirements. 
ANGIOGRAPHIC 
INCLUSION 
CRITERIA  Each target lesion/vessel must  meet all of the following 
angiographic criteria for the subjec t to be eligible for the trial: 
1. Subject has up to three target lesions in up to two separate 
target vessels (two target lesions in one vessel and one 
target lesion in a separate vessel). 
2. Target lesion must be de novo  or restenotic lesion in native 
coronary artery; restenotic lesion must have been treated 
with a standard PTCA only. 
3. Target lesion must be in ma jor coronary artery or branch 
(target vessel). 
4. Target lesion must ha ve angiographic evidence of ≥ 50% 
and < 100% stenosis (by oper ator visual estimate).
If the target lesion is < 70%  stenosed, there should be 
clinical evidence of ischemia such as a positive functional study (e.g. exercise treadmill test, thallium stress test, SPECT, or stress echo), cardiac computed tomography (CT), electrocardiography, frac tional flow reserve, or post 
infarct angina. 
5. Target vessel must have a Thrombolysis In Myocardial 
Infarction (TIMI) flow > 1. 
6. Target lesion must be ≤ 36 mm in length by operator visual 
estimate. 
7. Target vessel must have a reference vessel diameter of 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 12 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
2.25–4.0 mm by operator visual estimate. 
ANGIOGRAPHIC 
INCLUSION 
CRITERIA (CONT.) 8. Target lesion must be am enable to treatment with a 
maximum of two overlapping stents. 
CLINICAL 
EXCLUSION 
CRITERIA  Subjects will be excluded from t he trial if any of the following 
criteria are met: 
1. Subject has clinical sympt oms and/or electrocardiogram 
(ECG) changes consistent with acute ST elevation 
myocardial infarction (STEMI) within 72 hours prior to the 
index procedure. 
Note:  Hemodynamically stable non-STEMI (NSTEMI) subjects 
are eligible for study enrollment.  
2. Subject is hemodynamically unstable. 
3. Subject is pregnant and/or breastfeeding or intends to 
become pregnant during the dur ation of the study. 
4. Subject has a known allergy to  contrast medium that cannot 
be adequately pre-medicated, or any known allergy to 
thienopyridine, aspirin, both heparin and bivalirudin, L-605  
cobalt-chromium (Co-Cr) alloy or one of its major elements 
(cobalt, chromium, tungsten and nickel), acrylic, fluoropolymers, silicon carbi de, PLLA, sirolimus or 
everolimus. 
5. Revascularization of any tar get vessel within 9 months prior 
to the index procedure or prev ious PCI of any non-target 
vessel within 30 days prior to  the index procedure. 
6. Planned treatment of a lesi on not meeting angiographic 
inclusion and exclusion criter ia during the index procedure 
or after the i ndex procedure. 
7. Planned surgery wit hin 6 months of i ndex procedure unless 
dual antiplatelet therapy can be maintained throughout the 
peri-surgical period. 
8. History of a stroke or transi ent ischemic attack (TIA) within 6 
months prior to the index procedure. 
9. Subjects with active bleeding disorders, active 
coagulopathy, or any other reas on, who are ineligible for 
DAPT. 
10. Subject will refuse blood transfusions. 11. Subject has documented left ventricular ejection fraction 
(LVEF) < 30% as evaluated by angiography, 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 13 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
echocardiogram, radionuclide ventriculography or any non-
invasive imaging method within 90 days prior to the index 
procedure. 
CLINICAL 
EXCLUSION 
CRITERIA (CONT.) 12. Subject is dialysis-dependent. 
13. Subject has impaired renal function (i.e., blood creatinine > 
2.5 mg/dL or 221 μmol/L determined within 7 days prior to 
the index procedure). 
14. Subject has leukopenia (i .e. < 3,000 white blood cells/mm3), 
thrombocytopenia (i.e. < 100,000 platelets/mm3) or 
thrombocytosis (i.e. > 700,000 platelet/mm3). 
15. Subject is receiving oral or intravenous immunosuppressive 
therapy (inhaled steroids are permitted), or has known life-
limiting immunosuppressive or  autoimmune disease (e.g., 
human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted). 
16. Subject is receiving chroni c anticoagulation (e.g. coumadin, 
dabigatran, apixaban, rivaroxa ban or any other agent). 
17. Subject has life ex pectancy of < 1 year. 
18. Subject is participating in another investigational (medical 
device or drug) clinical study.  Subjects may be concurrently 
enrolled in a post-market study , as long as the post-market 
study device, drug or protocol  does not interfere with the 
investigational treatment or  protocol of this study. 
19. In the investigator’s opinion,  subject will not be able to 
comply with the follow-up requirements. 
ANGIOGRAPHIC 
EXCLUSION 
CRITERIA  Subjects will be excluded from the trial if any of the target 
lesions/vessels meets any of t he following angiogr aphic criteria: 
1. Target lesion is lo cated within a saphenous vein graft or arterial 
graft. 
2. Target lesion is a restenotic le sion that was previously treated 
with a bare metal or drug eluti ng stent (in-stent restenosis). 
3. Target lesion has any of the following characteristics: 
a. Lesion location is within the left main coronary artery, or 
within 3 mm of the origin of  the left anterior descending 
(LAD) or left circumflex (LCX). 
b. Involves a side branch of  > 2.0 mm in diameter.  
Note: Lesions within 3 mm of the origin of the right coronary 
artery may be treated. 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 14 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
4. Target vessel/lesion is exce ssively tortuous/angulated or is 
severely calcified, that would pr event complete inflation of an 
angioplasty balloon.  This as sessment should be based on 
visual estimation. 
ANGIOGRAPHIC 
EXCLUSION 
CRITERIA (CONT.) 5. Target vessel has angiographic evidence of thrombus. 
6. Target lesion is totally occluded (100% stenosis). 7. Target vessel was treated with br achytherapy any time prior to 
the index procedure.  
PRIMARY 
ENDPOINT  Target lesion failure (TLF) rate at 12 months post–index 
procedure.  TLF is defined as a ll cardiac death, target vessel Q-
wave or non–Q-wave myocardial infarc tion (MI), or clinically driven 
target lesion revascularization (TLR). 
SECONDARY 
ENDPOINTS  Secondary endpoints include the following measures: 
1. Device success, defined as attainment of < 30% residual 
stenosis of the target lesion using the assigned study stent 
only. 
Note: Post-dilatation is allowe d to achieve device success. 
2. Lesion success, defined as attainment of < 30% residual 
stenosis of the target lesi on using any percutaneous 
method. 
3. Procedure success, defined as a ttainment of < 30% residual 
stenosis of the target lesion using the assig ned study stent 
only without occurrence of in-hos pital major adverse cardiac 
events (MACE; composite of a ll-cause death, Q-wave or 
non–Q-wave MI, and any clinically-driven TLR). 
The following secondary clinical endpoints will be evaluated prior 
to discharge, at 1, 6 and 12 months and annually thereafter 
through 5 years follow-up: 
4. Death. 
5. MI. 6. Cardiac death or MI. 7. MACE and individual  MACE components (MACE: 
composite of all-cause death,  Q-wave or non–Q-wave MI, 
and any clinically-driven TLR). 
8. TLF and individual TLF com ponents (TLF: composite of 
cardiac death, target vessel Q-wave or non–Q-wave MI, and 
any clinically-driven TLR). 
9. Target vessel failure (TVF ) and individual TVF components 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 15 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
(TVF: composite of cardiac deat h, target vessel Q-wave or 
non–Q-wave MI, and any clinically-driven TVR).  
SECONDARY 
ENDPOINTS 
(CONT.) 10. Stent thrombosis (all, definit e, definite/pro bable, probable, 
possible) according to Acad emic Research Consortium 
(ARC) criteria for acute, subacute, late, very late and cumulative stent thrombosis.  
SUBJECTS 
FOLLOW -UP Randomized subjects will be foll owed through 5 years post–index 
procedure, with clinical  follow-up at 1 month,  6 months, 12 months 
and annually thereafter through 5-years.  An office visit is required 
for the 12-month follow-up.  All visi ts except the 12-month visit may 
be performed by telephone interview. 
TREATMENT 
STRATEGY   Eligible subjects will be randomized in a 2:1 ratio to receive 
either the Orsiro Sirolimus Eluting Stent or the Xience 
Everolimus Eluting Stent.  Rand omization will be stratified 
by study center. 
 Subjects may receive treatm ent for up to three target 
lesions, one or two target lesions per target vessel, for a 
maximum of two target vessels.  
Note: Concurrent treatment of non-target lesions during the 
index procedure is not allowed. 
 All target lesions are to be treated with the assigned study 
stent per randomization. 
 All target lesions are to be treated during a single index 
procedure. Pre-dilatation of t he target lesion(s) must be 
performed.  Direct stenting of the target vessel(s) is not 
allowed.    
 Post-dilatation may be performe d at the investigator’s 
discretion. 
 Cardiac biomarkers CK and/or  CKMB (CKMB is required [or 
troponin if CKMB is not availabl e]) will be measured at 6–24 
hours post index procedure.   
 Dual antiplatelet therapy (DAPT) is recommended for a 
minimum of 6 months and highly recommended for 12 
months in subjects not at a high risk of bleeding. 
 All subjects will receive a mi nimum of 150 mg aspirin within 
24 hours prior to the procedure and continued on a 
minimum of 75 mg aspirin daily  indefinitely post-procedure. 
 Subjects will receive a loadin g dose of 600 mg clopidogrel, 
within 24 hours prior to the procedure or immediately post-
procedure (within 30 minutes ).  Clopidogrel may be 
substituted with prasugrel at a loading dose of 60 mg or 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 16 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
ticagrelor at a loading dose of  180 mg.  No loading dose is 
required for subjects on chr onic thienopyridine therapy.   
Following the procedure, subjec ts will receive treatment with 
the same thienopyridine agent for a minimum of 6 months, highly recommended for 12 months for subjects not at high risk for bleeding, as follows: 
Clopidogrel:  75 mg daily  
Prasugrel:  10 mg daily; a lower dose of 5 mg daily is 
allowed for subjects < 60 kg.  
Ticagrelor:  90 mg twice daily. 
Ticlopidine:  250 mg twice daily. 
OUS investigators may follow medication administration 
recommendations in accordanc e with the European Society 
of Cardiology (ESC ) guidelines, national guidelines and/or 
hospital standard of care. 
  
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 17 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
2. STUDY ADMINISTRATION 
SPONSOR  BIOTRONIK, Inc. 
Vascular Intervention Clinical Studies 6024 Jean Road Lake Oswego, Oregon 97035 United States of America 
 
 
 
 
 
 
BIOTRONIK AG Center for Vascular Intervention Ackerstrasse 6 8180 Bülach Switzerland 
 
 
 
US
 STUDY PRINCIPAL 
INVESTIGATOR   
 
 
OUS  STUDY PRINCIPAL 
INVESTIGATOR   
 
 
STEERING COMMITTEE 
CHAIRPERSON   
 
ELECTRONIC DATA 
CAPTURE VENDOR  
 MedNet Solutions, Inc. 
110 Cheshire Lane  Minnetonka, Minnesota 55305 

  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 18 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
United States of America 
DATA COORDINATING 
CENTER  
 Harvard Clinical Research Institute 
930 Commonwealth Ave Boston, Massachusetts 02215 United States of America  
 
 
 
 
S
TATISTICAL CENTER  Harvard Clinical Research Institute 930 Commonwealth Avenue Boston, Massachusetts 02215 United States of America 
 
D
ATA MONITORING 
COMMITTEE 
CHAIRPERSON   
 
 
  
 
 
 
CLINICAL EVENTS 
COMMITTEE  
 Harvard Clinical Research Institute 
930 Commonwealth Avenue 
Boston, Massachusetts 02215 
United States of America  
 
 
 
 
A
NGIOGRAPHIC CORE 
LABORATORY  
 MedStar Health Research Institute 
CRI Angiographic Core Lab Washington Hospital Center 110 Irving St, NW, Suite 4B-1, Washington, District of Columbia 20010, USA United States of America  
 

  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 19 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
MONITORING  
 Harvard Clinical Research Institute 
930 Commonwealth Avenue Boston, Massachusetts 02215 United States of America  
 
 
 
 
 
 
 
 
   
 
 
 
BIOTRONIK AG Center for Vascular Intervention Ackerstrasse 6 8180 Bülach Switzerland 
BIOTRONIK, Inc. 
Vascular Intervention Clinical Studies 6024 Jean Road Lake Oswego, Oregon 97035 United States of America 
  

  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 20 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
 
3. INTRODUCTION 
Each year, approximately 7.2 mi llion people worldwide die fr om coronary artery disease 
(CAD),1 with 11.1 million deaths per year projected by 2020.2 Since the first 
percutaneous transluminal co ronary angioplasty (PTCA), this procedure has become a 
widely accepted treatment modalit y for coronary artery disease.  For the majority of 
patients with CAD, treatment  with PTCA provides high in itial procedural success, 
symptomatic relief, improvement in functional capacity, and survival rates similar to 
those of coronary artery bypass grafti ng (CABG).  However, all percutaneous 
techniques, regardless of mode of interventi on, have relatively high rates of repeat 
interventions at long-term fo llow-up, a limitation that is attributable to restenosis or 
angiographic re-narrowing of the vessel’s lumen.3 Distinct from atherosclerotic lesions, 
restenosis following conventio nal angioplasty results from elastic recoil, vessel 
contraction, thrombus formation, smooth muscle cell proliferation and excessive 
production of extracellular matrix.  Depending on the subject population and 
angiographic diagnostic criter ia, reported incidence of re stenosis after PTCA ranges 
from 30% to 50%.4 Such rates of recurrence have serious economic consequences. 
The first type of stent used in percutaneou s coronary intervention (PCI) was a bare 
metal stent (BMS), designed to a ddress restenosis following PTCA.5 BMS reduced the 
angiographic and clinical restenosis rates in de novo  lesions compared with PTCA 
alone as well as decreased the need for CABG.  BMS substantially reduced the 
incidence of abrupt artery cl osure, but restenosis still o ccurred in about 15% to 30% of 
cases, necessitating repeat procedures.6,7,8,9 
The development of drug elutin g stents (DES) significantly im proved on the principle of 
BMS by adding an antipro liferative drug that is either di rectly immobilized on the stent 
surface or released from a polymer matrix, allowing for controlled drug release at the 
site of injury to inhibit neoi ntimal hyperplasia.  The intr oduction of DES greatly reduced 
incidence of restenosis and resulted in a better safety profile compared with BMS with 
systemic drug administration.  These advanta ges and lower cost compared with surgical 
interventions made DES an attractive optio n for treating coronary artery disease.10 
However, despite significant improvement in revascularizat ion rates, certain clinical 
events were reported more frequent ly for DES compared with BMS,11,12 especially late 
and very late stent thrombosis, a life-threat ening complication that relates to occurrence 
of myocardial infarction (MI) and death.13,14 The pathophysiology of very late stent 
thrombosis includes hypersensitivity, inflamma tory infiltrates, delayed endothelialization, 
delayed vascular healing, malapposed and uncovered struts, and vessel remodeling 
due to inflammation and neoar therosclerosis, which are more common with DES than 
BMS.15,16,17,18,19 
To address these limitations, newer technol ogies have been developed, including BMS 
with thinner struts of cobalt-chromium and passive coating, fully absorbable stents, 
second-generation DES with improved stent design and ne w limus analogues, and DES 
with biodegradable polymer s.  Unlike non-biodegradable polym ers, which reside on the 
surface of the stent indefinit ely, biodegradable polymers di ssolve after a certain period 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 21 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
of time, leaving only the BMS platform in t he vessel wall, which is designed to improve 
late clinical incomes by reducing infla mmation burden and improving arterial healing.20 
Several randomized controlled trials have dem onstrated better late clinical outcomes 
among subjects receiving DES with biodeg radable polymers compared with DES with 
conventional durable polymers.21,22,23 Nine-month follow-up data from the LEADERS 
trial, involving 1,707 subjects randomiz ed to a biolimus eluting stent with a 
biodegradable polymer or to a sirolimu s eluting stent with a durable polymer, 
demonstrated no significant difference in the primary endpoint of major adverse cardiac 
events (MACE; includes cardiac death, MI or target-vessel revascularization; 9.2% vs. 
10.5%).24 Furthermore, an optical coherence tom ography (OCT) sub-study at 9 months 
demonstrated a statistically si gnificant lower rate of uncovered struts for subjects 
treated with a biolimus eluting stent with biodegr adable polymer,25 and 4-year data 
demonstrated superiority of the stent with bi odegradable polymer with respect to MACE  
(18.7% vs. 22.6%).26 A marked reduction of stent thro mbosis was also observed (80% 
relative risk reduction of very late stent thrombosis), with a statistically significant 
(superiority) difference in definite stent thrombosis between 1 and 4 years (0.4% vs. 
2.0%). 
3.1. Investigational Device Description 
The ORSIRO stent system is a drug eluting balloon expandable stent, mounted on a 
delivery system.  It is a co mbination product comprised of two regulated components: 
1. The device:   
 Bare Metal Stent:  PRO-Kinetic Energy (PKE) Stent (IDE# G110147) 
 Delivery System:  Fast-exchange with a Polyamide 12 semi-compliant balloon 
2. The drug-polymer coating:  
 A formulation of the drug substance Sirolimus with  
 A bioresorbable Poly-L-lactic acid (PLLA) polymer excipient 
Full details can be found in t he Instructions for Use (IFU) that are provided with each 
system. 
3.1.1. PRO-Kinetic Energy Stent 
The backbone of the Orsiro stent system is  the PRO-Kinetic Energy stent, the BMS 
platform of which is left in the vessel wall after the biodegradable polymer has 
dissolved.  It is a tubular, ba lloon-expandable stent sculpted by  laser from a single tube 
of L-605 Co-Cr alloy.  As show n in Figure 3-1, the stent consists of circular segments at 
each end, followed by a transition zone and helic oidally arranged struts in the middle.  
Each loop of the helix is connected to the ne xt loop by 3 longitudi nal struts.  The stent 
surface is fully coated with a layer of amorphous silicon carbide (PROBIO®). 
  
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 22 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Figure 3-1. Image of Orsiro /PRO-Kinetic Energy Stent 
 
The PRO-Kinetic ENERGY stent received CE marking in September 2008.  
BIOTRONIK is conducting an in vestigational device exempti on (IDE) study in the United 
States to evaluate the safety and efficacy of the PRO-Kinetic Energy stent (IDE 
#G110147). 
Outside of the United States , BIOTRONIK conducted a mult icenter, prospective, non-
randomized observational registry (ENERGY Registry) to evaluate long-term safety and 
clinical performance of the Co-Cr PRO-Kinetic Energy Cor onary Stent System in a large 
patient population.  The pr imary endpoint for the ENERGY registry is 6-month MACE 
rate, which includes cardiac death, clinically-d riven target lesion revascularization (TLR) 
and MI/acute MI (ST-elevated/ non–ST-elevated).  A total of  1,016 subjec ts with 1,074 
lesions in 48 centers were enr olled from April to November  2010.  Clinical follow-up was 
scheduled at 6 and 12 months.  Six-month clinical data were  available for 986 enrolled 
subjects and 12-month data were  available for 916 subjects. 
At 6 months, MACE rate was 6.3% (62/986), in cluding a 3.7% (36/986) rate of TLR; no 
probable stent thrombosis; and a 0.9% (9/ 986) rate of definite and possible stent 
thrombosis.  At 12 months, MACE rate wa s 8.8% (81/916), includi ng a 4.6% (42/916) 
rate of TLR; no probable st ent thrombosis; and a 1.1% ( 10/916) rate of definite and 
possible stent thrombosis.  Major adverse ca rdiac events at 12 mont hs in pre-defined 
subgroups included 11.4% (17/149)  for subjects with diabetes, 7.0% (16/229) for small 
vessels, and 9.5% (40/419) for subjects wit h acute coronary syndrome.  There was no 
statistically significant diffe rence between these subgroups. 
PROBIO® Coating 
The entire surface of the underlying bare-metal stent is  coated with amorphous silicon 
carbide that is saturated with hydr ogen (a-SiC:H), referred to as PROBIO® coating, in a 
physical vapor deposition process.  The co ating has a transparent appearance with a 
thickness in the range of 100 nm.  The a- SiC:H-coating material  has been used since 
2000 on all of BIOTRONIK’s coronary stents, including the Rithron XR coronary stent 
system approved for commercial distribution in  the United States on April 29, 2005 
(P030037), the Astron, Astron Pulsar, and Pulsa r-18 Nitinol stents bei ng evaluated in an 
IDE clinical study (IDE#G100002), and the PRO-Ki netic Energy stent being evaluated in 
an IDE clinical study (IDE #G110147). 

  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 23 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED U SE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
The silicon carbide material encapsulates the stent and minimizes interaction between 
the metal stent and surrounding tiss ue.  Finally, the release of  potentially allergenic ions 
from a silicon carbide–coated stent is redu ced in comparison to an uncoated metal stent 
(Figure 3-2).   
Figure 3-2. Metal Ion Release with PROBIO® Coating 
 
In vitro  studies have shown up to 96% redu ction of allergenic metal ions when the stent surface is coated 
with silicon carbide (data on file, BIOTRONIK AG). 
3.1.2. Sirolimus 
Sirolimus is the drug substance utilized in t he Orsiro stent system .  It is a natural 
macrocyclic lactone (Figure 3-3), first isolated from Streptomyces hygroscopicus  in the 
mid-1970s.  It was approved by the US F ood and Drug Administration (FDA) for 
prophylaxis of renal transplant rejection in 1999.  Sirolimus has potent antiproliferative, anti-inflammatory and immunosuppressive effe cts.  It acts by 
inhibiting activation of mammalian target of rapamycin (mTOR), ultimately causing arrest of the cell cycle by preventing progression from phase G1 to S.  The restenosis process is thus inhibited due to 
decreased proliferation of T cells as well 
as decreased proliferation and migration of smooth muscle cells.
27,28 Sirolimus 
eluting stents have been shown to reduce neointimal thickening compared with both BMS and polymer-coated stents, in a broad array of various animal models and clinical studies.
29,30,31,32,33 Com pet i t or  A 
cobalt nickel alloyCom pet i t or  B  
cobalt chromium alloyCobal t N i ck el Tungst en Chr om i um
PRO-Kinetic Energy 
with PROBIO® coating25 000
20 00015 000
10 000
5 000
0Concentration in ng/l
Figure 3-3: Structural Formula of 
Sirolimus 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 24 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
The first DES to be approved for marketing was the Cypher Sirolimus Eluting Stent 
System.  The Cypher stent is associated with significant improvement in angiographic 
outcomes, including reduced rates of restenosis and need for revascularization 
compared with BMS,10,34 with durable benefit fo r up to 5 years based on current clinical 
data.  The efficacy of the Cypher  and the improved Cypher Select+ Sirolimus Eluting 
Stent Systems (SESS) has been proven in popu lations ranging from highly selected 
subjects with single de novo  lesions to unselected all-comers.35,36,37,38 Since the 
preliminary results from the fi rst-in-man feasibility clinical investigation were presented, 
the Cypher SESS has bec ome available in more than 80 countries (including Europe, 
Japan and the United St ates), receiving CE marking in 2002 and FDA approval in 2003.  
It is one of the most studied drug eluting stents, having bee n evaluated in more than 
200 clinical trials involving more than 155,00 0 subjects.  It was used to treat more than 
3 million patients with CAD39 until sales were discontinued in 2011. 
Like the Cypher stent, the Orsi ro stent system also elutes Sirolimus.  Both stents have 
similar drug loads of 1.4 µg/mm2.   
3.1.3. Poly-L-Lactic Acid 
Poly-L-lactic acid (PLLA) is the polymer us ed as the excipient in the Orsiro stent 
system.  The Orsiro stent body surface is co mpletely coated by a matrix consisting of 
the carrier PLLA and the drug substance Sirolimus (BIOlute).  The matrix has a maximal 
thickness on the ab-luminal surface of 25 µm .  The largest stent design has a maximal 
coating mass of 42.6 µg per millim eter of stent length.  PLLA  is a highly biocompatible 
material.  There is existing published experie nce with PLLA as a stent and stent coating 
material in humans.46,40,41 Previously, this material was used in osteosynthesis and as 
suture material.  
This highly biocompatible polymer gently d egrades over 3 years, avoiding increased 
inflammation, and ultimately metabolizes into CO 2 and H 2O via the Krebs cycle.  Studies 
in mini pigs have shown no residual PLLA and benign histology at 3 years. 
The first successful in-human experience with a fully biodegradable stent was described 
by Tamai et al. in 2000.42 The study included 15 subjects  with 19 lesions treated with a 
monopolymer poly-L-lactic acid Igaki-Tamai stent with a zigz ag helical coil pattern.  No 
death, MI or stent thrombos is occurred for up to 6 mont hs, and only one subject with 
two lesions underwent repeat revascularization. 
Another fully biodegradable stent using PLLA is  the everolimus eluting ABSORB stent.  
Two-year outcomes of the first-generation, fi rst-in-man trial involving 30 subjects were 
encouraging, with only one myocardial infarction and no cardiac death, stent thrombosis 
or ischemia-driven target lesion revasculari zation (TLR), resulting in a MACE rate of 
3.6%.43 For the second-generation ABSORB stent, the MACE rate at 12 months was 
7.1% (7 of 101 subjects).44 Other stent systems using poly-L-lactic acid as 
biodegradable polymers, such  as the BioMATRIX and Nobor i stent, have also been 
proven safe and effective.45,46 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 25 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
3.1.4. Delivery System 
The delivery system of the Orsi ro stent is a fast-exchange PTCA catheter compatible 
with a 5F guide catheter, with a working length  of 140 cm.  As shown in Figure 3-4, the 
stent is securely crimped on a ny lon balloon situated  at the distal tip of the catheter 
between two radiopaque markers m ade of a platinum-iridium a lloy.  The proximal shaft 
of the delivery system is a hypotube compos ed of polyamide-covered 304 or 304L 
stainless steel; it has a singl e luer port for connec ting an inflation/def lation device to 
inflate/deflate the balloon. 
The distal section of the catheter comprise s the inflation/deflati on (balloon) lumen and 
the 29-cm-long guide wire lumen, which starts at the catheter tip and ends at the guide 
wire exit port.  It accepts guide wires of 0.014” diameter.  The stent delivery system is 
compatible with gui ding catheters with a mini mal inner diameter of ≥ 0.056” (1.42 mm).  
Shaft exit markers are located on the hypot ube 92 cm (brachial technique) and 102 cm 
(femoral technique) from t he distal end of the catheter to indicate when the delivery 
system tip exits from the guiding catheter. 
Figure 3-4. Orsiro Sirolim us Eluting Stent System 
 
3.1.5. Investigational Device Matrix 
Investigational device matrix for the BIOFLO W-V study is shown bel ow in Table 3-1.  
Device sizes other than shown belo w cannot be used in this study.   
Table 3-1. Orsiro Stent System – D evice Matrix for the BIOFLOW-V Study 
*  Orsiro LL  
Orsiro  Nominal length [mm] 
Stent  
design Nominal Ø  
[mm] 9 13 15 18 22 26 30 35* 40* 
T6S Ø 2.25 x x x x x x x   
Ø 2.5 x  x x x x x x x x
Ø 2.75 x  x x x x x x x x
Ø 3.0 x  x x x x x x x x
T6M Ø 3.5 x  x x x x x x x x
Ø 4.0 x  x x x x x x x x
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 26 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
 
The 2.25 x 35 mm and 2.25 x 40 mm sizes of Orsiro may be available outside of the 
US, but are not permitted to be utilized in the BIOFLOW-V subjects. 
  
3.2. Control Device Description 
The Xience family of Everol imus Eluting Coronary Stent Systems (Xience V™, Xience 
nano™, Xience Prime™, Xience PRIME™ LL, Xi ence Xpedition™, Xience Xpedition™ 
SV, Xience Xpedition™ LL, Xience Alpine™ and Xience Pro / Xience ProX [will be used 
only outside of the United St ates]), manufactured and marketed by Abbott Vascular, will 
be used as a control device in this study.   
Device description details of the differ ent Xience stents can be found in the IFU 
provided with each system. 
3.2.1. Control Device Matrix 
Xience matrix for the BIOFLOW-V study  is shown in Table 3-2 below.   
Table 3-2. Xience Family of Stent Syst ems – Devices Matrix for the BIOFLOW-V 
Study 
3.3. Indications for Use 
The Orsiro Sirolimus Eluting Coronary Stent System  is indicated for improving coronary 
luminal diameter in subjects  with symptomatic ischemic heart disease due to discrete de 
novo  lesions or restenotic lesi ons from PTCA in native coronary arteries with a 
reference vessel diameter of 2.25–4.0 mm and lesion length of ≤ 36 mm. Xience  Nominal length [mm]
Nominal Ø  
[mm] 8 12 15 18 23 28 33* 38* 
Ø 2.25** x x x x x x   
Ø 2.5 x  x x x x x x x 
Ø 2.75 x  x x x x x x x 
Ø 3.0 x  x x x x x x x 
Ø 3.25*** x  x x x x x x x 
Ø 3.5 x  x x x x x x x 
Ø 4.0 x  x x x x x x x 
* Xience Prime™ LL and Xience Xpedition™ LL, Xience Alpine™, Xience ProX 
** Xience nano™, Xience Xpedition™ SV, Xience Prime™,  Xience Alpine™, Xience ProX 
*** Xience Xpedition™, Xience Xpedition™ LL,  Xience Alpine™, Xience ProX 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 27 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
3.4. Contraindications 
The Orsiro Sirolimus Eluting Coronary Stent  System is contraindicated for use in 
subjects with: 
 A known hypersensitivity or allergy to stent coating materials (amorphous 
silicon carbide or PLLA polymer), to L-605 cobalt chromium alloy (including 
the major elements cobalt, chromium, tungsten and nickel) and to Sirolimus 
or its derivatives. 
 Subjects in whom antiplatelet and/or anticoagulation therapy is 
contraindicated. 
 A lesion judged to prevent complete in flation of an angioplasty balloon or 
proper placement of the st ent or the stent system. 
 Transplant patients. 
 Subjects who would be considered unsui table candidates for standard PCI. 
 Treatment of in -stent restenosis. 
3.5. Orsiro Clinical Data Summary 
The Orsiro stent is investigat ional in the United States. Ho wever, the stent received CE 
Mark on February 23, 2011 and is  currently approved for ma rketing in more than 55 
countries worldwide with over 200,000 uni ts distributed as of March 2014.   
The development of the Orsiro stent syst em has been supported by an extensive 
clinical trial program designe d to collect data on over 3,000 Orsiro-treated subjects in 
studies using the Xience Everol imus Eluting Stent System as  a comparator.  The Orsiro 
clinical trial program incl udes the BIOFLOW-I first-in -man study; the BIOFLOW-II 
international randomized study against the Xience Prime™ stent with intravascular 
ultrasound (IVUS) and optical  coherence tomography (OCT) subsets; the BIOFLOW-III 
international all-comers registry; the B IOFLOW-IV international randomized study 
against the Xience Prime™/Xpedition™ stent with a pharmacokinetic subset, and the 
BIOSCIENCE international, randomized all- comers study against the Xience Prime™ 
stent. 
Table 3-3 summarizes the key design element s of each Orsiro study.  A brief 
description of the study, it s status and results is provided in this section. 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 28 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF AN Y PART OF THIS DOCUMENT IS STRICTLY PROHIBITED. 
Table 3-3. Orsiro Clin ical Trials Summary 
 

  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 29 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
BIOFLOW-I 
BIOFLOW-I was a 30-subject feasibility study conducted at two sites in Romania.  The 
purpose of the trial was to eval uate safety and efficacy of the Orsiro stent in treatment of 
single de novo  lesions in native coronary arteries with a reference vessel diameter of 
2.5–3.5 mm and lesion length of ≤ 22 mm.  The primary efficacy endpoint was late 
lumen loss measured at 9 mont hs post–index procedure.  The first subject was enrolled 
on July 2, 2009, and enrollment wa s completed on July 23, 2009. 
The primary endpoint of in-stent late lume n loss at 9 months was 0.05 ± 0.22 mm.  
Secondary safety endpoints in cluded a composite rate of cardiac death, target vessel 
MI and clinically-driven TLR of 6.7% (2/30) at 1 year47 and 13.7% (4/30) at 2 years, and 
a composite rate of all-cause death, any MI and any revascularization of 16.7% (5/30) at 
2 years (Kaplan-Meier estimate). 
BIOFLOW-II 
BIOFLOW-II is a prospective, multicenter, r andomized, controlled, non-inferiority trial 
that enrolled 458 and randomized 452 evaluable subjects at 24 clinical centers in 8 
European countries (clinicaltria ls.gov identifier [STUDY_ID_REMOVED]).  The purpose of this trial 
was to compare the Orsiro SES with the Xience Prime™ Everolimus Elut ing Stent (EES) 
in subjects with single de novo  coronary artery lesions in up to two coronary arteries of 
2.25–4.0 mm in diameter.  Subjects were r andomized in a 2:1 fashion to receive the 
Orsiro stent or the Xience Prime™ stent.  All subjects underwent repeat angiography at 9 
months post–index procedure.  A subset of approxim ately 60 pre-spec ified subjects 
underwent IVUS examination at both baseline and 9 mont hs.  Another subset of 
approximately 60 pre-specifi ed subjects underwent OCT ex amination at both baseline 
and 9 months.  The primary efficacy endpoint wa s late lumen loss at 9 months post–
index procedure.  The first subject was enrolled in July 2011 and enrollment was 
completed in March 2012.  Subjects cont inue in the follow-up phase of the trial. 
Of the 452 enrolled subjects, 298 subjects were randomized to receive the Orsiro stent 
and 154 were randomized to receive the Xience Prime™ stent.  Follo w-up angiography 
was completed in 85% of subjects at 9 months post-procedure and demonstrated a 
mean in-stent late lumen loss of 0.10 ± 0.32 mm for the Orsiro stent  compared to 0.11 ± 
0.29 mm for the Xience Prime™ stent.  The non-inferiority hypothesis was confirmed 
with a P value of < 0.0001 (delta = 0.16 mm). 
At 12 months, clinical event rates were lo w, and there were no significant differences 
between the two arms.  TLF, a composite meas ure of safety (target vessel MI, cardiac 
death) and stent efficacy (clinically-drive n TLR and emergent CA BG) was measured in 
the BIOFLOW-II trial.  The TLF rate was ev aluated, with Kaplan Meier estimates to be 
6.5% in the Orsiro group compared to 8.0% in the Xience Prime™ group at 12-month 
follow-up (log-rank = 0.5832). 
The BIOFLOW-II IVUS/OCT subset analyses showed comparable results between the 
Orsiro and Xience Prime™ groups at 9 months.  IVUS re sults at 9 months demonstrated 
complete stent apposition (no cases of st ent malapposition) in both arms and a 
significantly lower neointimal hyperplasia area for Orsiro compared with the Xience 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 30 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Prime™ (0.16 ± 0.33 mm2 vs. 0.43 ± 0.56 mm2, respectively; P = 0.0428).  The pre-
specified secondary OCT endpoints at 9 mont hs showed a significant difference in 
tissue coverage between the Or siro and the Xience Prime™ groups (98.3 vs. 97.5%, 
respectively; odds ratio 1.51; 95% c onfidence interval [CI] 1.02, 2.45; P = 0.042).  At 9 
months, the Orsiro stent was associated wit h thinner neointima thickness (0.094 vs. 
0.119 mm, P < 0.001).  No significant differences  in incomplete strut apposition (ISA) 
were found between the treatme nt groups at 9 months.   
BIOFLOW-III 
The BIOFLOW-III study is an open-label prospective, non-randomized, multicenter, 
international, observational  all-comers registry that enroll ed a total of 1,356 subjects at  
43 centers in 14 countries across Europe and  Chile (clinicaltrials.gov identifier 
[STUDY_ID_REMOVED]).  The purpose of t he registry was to evaluate safety and performance of 
the Orsiro Sirolimus Eluting Stent (SES) in a large series of subjects under real-world 
conditions. 
The primary endpoint was the 12-month rate of  TLF, defined as cardiac death, target 
vessel Q-wave or non–Q-wave M I, emergent CABG or clinica lly driven TLR.  The first 
subject was enrolled in Au gust 2011 and enrollment was co mpleted in March 2012.  
The subjects are currently in t he follow-up phase of the trial. 
The BIOFLOW-III registry enro lled an unselected subject popu lation, including a high 
proportion of high-risk subjects presenti ng with diabetes (29.6%), small vessels 
(42.4%), acute MI (32. 6%), and chronic total occlusions  (4.3%).  The rate of TLF was 
5.1% at 12 months.  The rate of ARC-defined definite or probable stent  thrombosis at 12 
months was 0.4%. 
While BIOFLOW-I and II had mandatory angi ographic follow-up and BIOFLOW-III did 
not, rates of 12-month TLR were 6.7%, 3. 5%, and 3.3% for BIOFLOW-I, II and III, 
respectively. 
Among subgroups, 12-month TLF rates were 7.7%  in subjects with diabetes compared 
with 4.0% in non-diabetics, and 7.2% in subjects with acute myocardial infarction (AMI) 
compared with 4.0% in subjects without AMI. 
BIOFLOW-IV 
BIOFLOW-IV is a prospective , international, multicente r, randomized controlled trial 
designed to assess the Orsiro stent in the tr eatment of subjects with up to two de novo 
coronary artery lesions (clinicaltrials.gov  identifier [STUDY_ID_REMOVED]).  Approximately  
575–585 subjects at up to 50 sites in Japan and Europe will be enrolled in the trial to 
evaluate the safety and effectiveness of the Or siro stent.  The BIOFLOW-IV clinical trial 
consists of the following: 
1. Randomized controlled trial (RCT) at up to 50 sites in Japan and Europe, which 
will enroll 555 subj ects with up to two de novo  lesions ≤ 26 mm in length in native 
coronary arteries 2.5–3.75 mm in diameter.  Subjects wi ll be randomized in a 2:1 
fashion to receive the Orsiro  stent or the Xience Prime™/Xpedition™ stent. 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 31 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
2. Concurrent, non-randomized pharmacokine tic (PK) sub-trial at 3–5 sites in 
Japan, which will enroll 20–30 subjects with up to two de novo  lesions ≤ 26 mm 
in length in native coronary arte ries 2.5–3.75 mm in diameter.  
The primary endpoint for the main RCT is  the 12-month TVF rate, defined as any 
clinically-driven TVR, target vessel Q-wa ve or non–Q-wave MI, emergent CABG or 
cardiac death.  There is no prim ary endpoint for the PK sub-trial. 
BIOFLOW-IV enrolled the first subject in September 2013.  Enro llment was completed 
on January 25, 2015. 
BIOSCIENCE 
The BIOSCIENCE study is a prospective, mu lticenter, randomized c ontrolled trial that 
enrolled 2,119 subjects at 13 clinical sites in Switzerland (clinica ltrials.gov identifier 
[STUDY_ID_REMOVED]).  The purpose of this study was to  directly compare t he Orsiro stent with 
the Xience Prime™ stent in a large series of ‘all-comer’ subjects.  Subjects were 
randomized in a 1:1 fashion to receive t he Orsiro stent or the Xience Prime™/ 
Xpedition™ stent.  The primary endpoint was 12-mo nth TLF rate, defined as cardiac 
death, target vessel Q-wave or non–Q-wave MI , emergent CABG or clinically driven 
TLR.  The first subject was enrolled in F ebruary 2012, enrollment was completed in May 
2013 and the primary endpoint results were repor ted on September 1, 2014 by Pilgrim 
et al in the Lancet.48. 
Of the 2119 subjects (3139 lesion s) included in the study, 407 (19%) patients presented 
with ST-segment elevation myocardial infa rction.  A total of 1063 subjects (1594 
lesions) were randomized to receive the Or siro stent and 1056 pati ents (1545 lesions), 
were randomized to receive the Xience stent.  At 12 months, the TLF rate for the Orsiro 
stent (69 subjects, 6.5%) was n on-inferior to the Xience st ent (70, 6.6%) at 12 months 
(absolute risk difference −0.14%, upper limit of one-sided 95% CI 1.97%, p for non-
inferiority <0.0004). No significant differences  were noted in rates of clinical events, 
including stent thrombosis.  
  
  
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 32 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
4. STUDY OBJECTIVES AND ENDPOINTS 
4.1. Study Objectives 
The objective of this study is to assess th e safety and efficacy of the Orsiro Sirolimus 
Eluting Coronary Stent System in the treatm ent of subjects with up to three native d e 
novo  or restenotic (standard PTCA only) co ronary artery lesions compared with the 
Xience coronary stent system. 
4.2. Primary Endpoint 
The primary endpoint is target lesion fail ure (TLF) rate at 12 months post–index 
procedure.  Target lesion failure  is defined as all cardiac deat h, target vessel Q-wave or 
non–Q-wave MI, or clinically driven target lesion revascularization. 
4.3. Secondary Endpoints 
Secondary endpoints include the following measures: 
1. Device success, defined as attainment of < 30% residual stenosis of the target 
lesion using the assi gned study stent only.  
Note: Post-dilatation is allow ed to achieve device success. 
2. Lesion success, defined as attainment of < 30% residual  stenosis of target lesion 
using any percutaneous method. 
3. Procedure success, defined as attainment  of < 30% residual stenosis of the 
target lesion using the assigned study st ent only without occurrence of in-hospital 
MACE. 
The following secondary clinic al endpoints will be evaluated prio r to discharge, at 1, 6 
and 12 months and annually thereafte r through 5 years follow-up: 
4. Death. 5. Myocardial infarction. 6. Cardiac death or MI. 7. MACE and individual MA CE components (MACE: composit e of all-cause death,  
Q-wave or non–Q-wave MI, and any clinically-driven TLR). 
8. TLF and individual TLF components (TLF: composite of cardiac death, target 
vessel Q-wave or non–Q-wave MI, and any clinically-driven TLR). 
9. TVF and individual TVF components (TVF: composite of cardiac death, target 
vessel Q-wave or non–Q-wave MI, and any clinically-driven TVR). 
10. Stent thrombosis (all, definite, definite /probable, probable, po ssible) according to 
Academic Research Consortium (ARC) criteria for acute, subacute, late, very late 
and cumulative stent thrombosis. 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 33 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
5. STUDY DESIGN 
The BIOTRONIK BIOFLOW-V clinical trial is  a prospective, multicenter, randomized, 
controlled trial combining data on the randomized subjects wit h data from two historical 
studies by employing a Bayesian approach. 
Subjects with CAD that qualify for PCI wit h stenting will be screened  per the protocol 
inclusion and exclusion criteria to achieve a total of up to 1,400 randomized subjects.  
Eligible subjects will be randomized in a 2:1 ratio, strati fied by study center, to undergo 
percutaneous coronary revascularization with ei ther the Orsiro Sirolimus Eluting Stent 
System (treatment group) or  the Xience Everolimus Elut ing Stent System (control 
group). 
Subjects may receive treatment of up to thr ee target lesions, one or two target lesions 
per target vessel, for a maximum of two tar get vessels.  The target lesion(s) must be de 
novo  or restenotic lesion(s) of ≤ 36 mm in length in native coronary artery(ies), with a 
reference vessel diameter of 2.25–4.0 mm.  Treatment of re stenotic lesions is allowed 
provided that the target lesi on was previously treated with PTCA only.  All treatment 
with study stents is to be performed dur ing a single index  procedure.  Note: Concurrent 
treatment of non-target lesions during the index procedure is not allowed . 
Randomized subjects will have clinical follo w-up at 1 month, 6 m onths, 12 months and 
at 2, 3, 4 and 5 years follo wing the index procedure.   
To assess the non-inferiority of the Orsi ro stent compared to the Xience stent, 
BIOFLOW-V randomized subjects will be combi ned with historical su bjects from the 
BIOFLOW-II and BIOFLOW-IV randomized trials employing a Bayesian  approach.  Only 
subjects who meet all clinical and angiographic eligibility criteria of the BIOFLOW-V trial 
will be included in the analysis.  The tr ial design is shown in Figure 5-1. 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 34 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED U SE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Figure 5-1. Trial Design of the BIOFLOW-V Trial 
 
 
5.1. Clinical Sites 
The trial will be conducted at up to 100 sites in the United States and 50 sites outside of 
the United States. 
5.2. Number of Subjects 
Sufficient number of subjects will be provis ionally enrolled to achieve a total of 1,334 
randomized subjects.  It is expected that  approximately 50% w ill be enrolled in the 
United States.  A maximum of 250 subjects may be enrolled at a single investigational 
site. 
5.3. Study Participation Status 
5.3.1. Status Definitions 
Provisionally enrolled  - Subject who is fully informed about the specifics of the study 
by authorized site personnel and provides  informed consent by properly signing an 
informed consent form after confirmation of  the initial enrollment criteria.   
Subjects for whom consent was not obtained prior to participation in the study will not 
be considered provisionally enrolled.  No data  collected from these “subjects” will be 
included in any analysis.  Failure to obtai n consent will be reported as a protocol 
violation as outlined in Section 12.6.1. 

  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 35 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Screen failure  – Provisionally enro lled subject who withdraws consent prior to 
randomization or is unsuitabl e for randomization following laboratory assessments, pre-
procedure electrocardiogram (E CG), diagnostic angiogram at the index procedure or 
unsuccessful crossing of the first target le sion with a guide wire.  These subjects will be 
exited from the study once scree n failure is confirmed.  S ubject informed consent forms 
will be kept in the site’s  administrative files. 
Enrolled (Randomized)  – Provisionally enrolled subjec t who meets all clinical and 
angiographic eligibility criteria, and has been randomized.  These subjects will be 
followed in accordance with t he protocol requirements.  
Study exit  - early termination of study participat ion applicable to subjects that have 
signed an informed consent form.   
Study completion  - subject who completes all prot ocol-required study procedures.   
5.3.2. Subject Study Exit 
Investigators should make every effort to en sure subjects complete all protocol-required 
procedures, including study follow-up visits.  However, subjects ma y be required to exit 
the study, despite an investi gator’s best efforts.  G ood Clinical Practice (GCP) 
guidelines describe the need for clear subject exit proce dures, to include when and how 
to exit subjects from the study, as well as  to outline the type and timing of the follow-up 
and data collection for these subjects.   
Subjects may be exited from this study  in the following limited situations: 
 Subject death 
 Subject withdrawal of informed consent 
 Investigator believes it is in the best m edical interest of the subject to discontinue 
study participation due to safety reasons  
 Subject is considered a screen failure 
In the event of major protocol non-complianc e, each case will be evaluated individually 
to determine the appropriate course of action regarding subject study participation.  In 
any of the situations noted above, data collected up to and including the exit of the 
subject will be used in data analysis.  No dat a will be collected afte r the exit of the 
subject from the study.  Study exits are ex pected and will be taken into consideration 
during data analysis as described  in Section 8.  Additionally, subject attrition has been 
calculated into the study sample size; therefore, all subjects exited from t he study will be 
counted toward the randomizati on goal and will not  be replaced.  Investigators must 
document, in subject medical records, the reasons and circumstances for all subject 
exits.  
Generally, subjects should not be removed from  the study due to la te identification of 
eligibility criteria vi olations, unless increased subject risk is indicated.  In cases where 
further participation in the study poses potential risk to the subject, study exit should be 
considered.  In addition to subject safety, c onsideration should be given to the scientific 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 36 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
validity of the primar y endpoints when making decisions c oncerning subject exit.  Study 
follow-up options and require ments for subjects exited from the study should be 
determined and applied to all subj ects exited for similar reas ons.  Deviations in subject 
eligibility, as defined in the protocol, should be consider ed protocol violations and 
reported to the Institutional Review Board (IRB) or Ethi cs Committee (EC) immediately 
upon discovery, in accordance with local regulations .  Subjects that are randomized, but 
do not receive a study stent during the i ndex procedure post-randomization (e.g. unable 
to cross the lesion with the predilatation ball oon or stent, randomization error, or lack of 
sufficient disease, etc.) may be exited from the study after comple tion of the primary 
endpoint visit assessments (12-month follow-up). 
If a subject cannot continue to participate in the study but t he investigator is able to 
maintain contact with the subj ect and they have not withdraw n consent to collect further 
data, then contact should be maintained pe r the original follow-up schedule and vital 
status data will be conf irmed by the investigator and repor ted.  For example, a subject 
may change geographic location or move into  a nursing home, but may still remain in 
contact with the investigator .  Identification of vital status will be handled at the 
investigational site level.  Subjects have t he right to discontinue from the study at any 
time or be discontinued at t he investigator’s discretion. 
 
5.3.2.1. Subject Lost to Follow-up 
Subjects may be unable to adhere to the r egularly scheduled study visits.  Study sites 
should attempt to contact these subjects in or der to maintain study visit compliance and 
all contact attempts should be documented.  At a minimum, the site should make two 
attempts to contact the subject by  phone and one by certified mail.   
If the subject is able to be contacted, all efforts should be made to perform the required 
study visit and complete the relevant case report forms.  However, if a subject is 
contacted and a study visit cannot be perform ed, the study site should complete the 
relevant case report forms with any relevant  data obtained from the subject contact.  
Any missed visits prior to and after contact with the subject will be co unted as protocol 
compliance issues.  If a subject is unable to be contacted at any of the remaining study 
visits, either a missed visit will be entered fo r each visit or the subject may be exited as 
lost to follow-up, using the dat e of last actual contact as th e study exit date.  Subjects 
are not eligible to be exited as lost to fo llow-up until after the 12-month follow-up visit.  
After the 12-month follow-up visi t, if a minimum of two cons ecutive study visits have 
been missed, after making two attempts by phone and one by certified mail at each time 
point, lost to follow-up may be an acceptable reason for exit.   
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 37 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Likewise, due to unforeseen circumstances , subjects may change providers (e.g. 
changes in insurance coverage) or relocate during the course of the study and may no 
longer be able to return for study follow-up visi ts.  Attempts to collect data from these 
subjects should be made by the investigator  in collaboration wit h the subject’s new 
provider.  All data that is obtained may be utilized in data analysis, but should be 
documented that it was colle cted by an unapproved investigat or.  If any data cannot be 
collected from the subject’s new provider, the subject s hould be considered lost to 
follow-up and the site should follow the above procedures for continuing subject contact.  
The investigative site should ma ke an attempt to verify the vi tal status of subjects that 
are lost-to-follow-up through means includi ng, but not limited to, the National Death 
Index/ Social Security Death Index, as ap plicable.  BIOTRONIK and/or its designee may 
provide assistance to investigat ive sites to obtain vital stat us information, as permitted, 
for lost-to-follow-up subjects.  
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 38 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
6. SUBJECT SELECTION 
During the study enrollm ent phase, patients fr om the general interv entional cardiology 
population will be screened according to protoc ol inclusion and exclusion criteria.  
Subjects should be consented and sign the in formed consent prior to initiating any 
study-specific procedures that  are not considered routine standard of care clinical 
assessments. Subjects who have met all clinic al inclusion and exclusion criteria and 
signed the IRB/EC–approved consent form will then be screened for angiographic criteria during an index procedure. 
6.1. Eligibility Criteria 
6.1.1. Clinical Inclusion Criteria 
Subjects must meet all of  the following criteria to participate in the trial: 
1. Subject is ≥18 years or the minimum age required for legal adult consent in the 
country of enrollment. 
2. Subject is an acceptable candidate for PCI. 3. Subject is an acceptable candidate for CABG. 4. Subject has clinical evidence of i schemic heart disease, stable or unstable 
angina pectoris or documented silent ischemia. 
5. Subject is eligible for dual  anti-platelet ther apy treatment with aspirin plus either, 
clopidogrel, prasugrel, tic agrelor or ticlopidine. 
6. Subject has provided written informed consent. 7. Subject is willing to comply with study follow-up requirements. 
6.1.2. Angiographic Inclusion Criteria 
Each target lesion/vessel must meet all of  the following angiographic criteria for the 
subject to be eligible for the trial: 
1. Subject has up to three target lesion s in up to two separate target vessels 
(twotarget lesions in one vessel and one target lesion in a separate vessel). 
2. Target lesion must be de novo  or restenotic lesion in  native coronary artery; 
restenotic lesion must have been tr eated with a standard PTCA only. 
3. Target lesion must be in major cor onary artery or branch (target vessel). 
4. Target lesion must hav e angiographic evidence of ≥ 50% and < 100% stenosis 
(by operator visual estimate).  If the tar get lesion is < 70% st enosed, there should 
be clinical evidence of ischemia such as a positive functional study (e.g. exercise 
treadmill test, thallium stress test, SPECT, or stress echo), cardiac computed tomography (CT), electrocardiography, frac tional flow reserve, or post infarct 
angina. 
5. Target vessel must have a Thrombolysis In  Myocardial Infarcti on (TIMI) flow > 1. 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 39 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
6. Target lesion must be ≤ 36 mm in length by operator visual estimate. 
7. Target vessel must have a refer ence vessel diameter of 2.25–4.0 mm by 
operator visual estimate. 
8. Target lesion must be am enable to treatment with a ma ximum of two overlapping 
stents. 
6.1.3. Clinical Exclusion Criteria 
Subjects will be excluded from the trial if any of the following criteria are met: 
1. Subject has clinical symptoms and/or  ECG changes consistent with acute ST 
elevation MI (STEMI) within 72 hour s prior to the index procedure. 
Note:  Hemodynamically st able non-STEMI (NSTEMI) su bjects are eligible for 
study enrollment.  
2. Subject is hemodynamically unstable. 
3. Subject is pregnant and/ or breastfeeding or intends to become pregnant during 
the duration of the study. 
4. Subject has a known allergy to cont rast medium that cannot be adequately pre-
medicated, or any known allergy to thie nopyridine, aspirin,  both heparin and 
bivalirudin, L-605  cobalt-chromium (Co-Cr) alloy or one of its major elements 
(cobalt, chromium, tungsten and nickel), ac rylic, fluoropolymers, silicon carbide, 
PLLA, sirolimus or everolimus.   
5. Revascularization of any target vesse l within 9 months prior to the index 
procedure or previous PCI of any non-tar get vessel within 30 days prior to the 
index procedure. 
6. Planned treatment of a le sion not meeting angiographic  inclusion and exclusion 
criteria during the i ndex procedure or after the index procedure. 
7. Planned surgery within 6 months of i ndex procedure unless dual antiplatelet 
therapy can be maintained throu ghout the peri-surgical period. 
8. History of a stroke or transient ischem ic attack (TIA) within 6 months prior to the 
index procedure. 
9. Subjects with active bl eeding disorders, active co agulopathy, or any other 
reason, who are ineligible for DAPT. 
10. Subject will refuse blood transfusions. 11. Subject has documented left ventricula r ejection fraction (LVEF) < 30% as 
evaluated by angiography, ec hocardiogram, radionuclide v entriculography or any 
non-invasive imaging method within 90 day s prior to the index procedure. 
12. Subject is dialysis-dependent. 13. Subject has impaired renal function (i .e., blood creatinine > 2.5 mg/dL or 221 
μmol/L determined within 7 days pr ior to the index procedure). 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 40 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
14. Subject has leukopenia (i.e. < 3,000 white blood cells/mm3), thrombocytopenia 
(i.e. < 100,000 platelets/mm3) or thrombocytosis (i .e. > 700,000 platelet/mm3). 
15. Subject is receiving oral or in travenous immunosuppressive therapy (inhaled 
steroids are permitted), or has known life-limiting immunosuppressive or 
autoimmune disease (e.g., human imm unodeficiency virus, systemic lupus 
erythematosus; diabetes mellitus is permitted). 
16. Subject is receiving chronic ant icoagulation (e.g. coumadin, dabigatran, 
apixaban, rivaroxaban or any other agent). 
17. Subject has life ex pectancy of < 1 year. 
18. Subject is participating in  another investigational (medi cal device or drug) clinical 
study.  Subjects may be conc urrently enrolled in a post-market study, as long as 
the post-market study devic e, drug or protocol doe s not interfere with the 
investigational treatment or  protocol of this study. 
19. In the investigator’s opin ion, subject will not be able to comply with the follow-up 
requirements. 
6.1.4. Angiographic Exclusion Criteria 
Subjects will be excluded from th e trial if any of the target lesions/vessels meets any of 
the following angiogr aphic criteria: 
1. Target lesion is located within a s aphenous vein graft or arterial graft. 
2. Target lesion is a restenotic lesion t hat was previously tr eated with a bare metal 
or drug eluting stent (in-stent restenosis). 
3. Target lesion has any of the following characteristics: 
a. Lesion location is within the left ma in coronary artery, or within 3 mm of 
the origin of the left anterior descendi ng (LAD) or left circumflex (LCX). 
b. Involves a side branch of > 2.0 mm in diameter. 
Note: Lesions within 3 mm of  the origin of the righ t coronary artery may be 
treated. 
4. Target vessel/lesion is excessively tort uous/angulated or is severely calcified, 
that would prevent complete  inflation of an angioplasty balloon. This assessment 
should be based on visual estimation. 
5. Target vessel has angiogr aphic evidence of thrombus. 
6. Target lesion is totally occluded (100% stenosis). 7. Target vessel was treated with brachy therapy any time prior to the index 
procedure. 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 41 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Figure 6-1. Clinical St udy Design Flowchart 
  
 
Review Medical Record
Does sub ject meet pre-screenin g criteria?
Yes
Identif y Potential Sub ject
Does subject have CAD and 
qualify for PCI procedure?  
Randomization
2:1 
Orsiro (889) : Xience (445) 
Follow-up Visits
 Hospital discharge 
 1-month (± 7 days) 
 6-month (± 14 days) 
 12-month (± 30 days) 
 2 year (± 60 days) 
 3 year (± 60 days) 
 4 year (± 60 days) 
 5 year (± 60 days) Yes
Yes
Pre-Procedure Testin g
Are pre-procedure tests (performed according 
to investigative site’s standard of care) 
acceptable with protocol? 
Index Procedure
Does subject satisfy procedure-related eligibility 
criteria following diagnostic angiogram? 
Subject is a screen 
failure: exit from study No
Informed Consent
Did subject provide written informed 
consent (provisionally enrolled)? 
Subject is not a 
study candidate No
Subject is not a 
study candidate No
YesYes
Subject is not a 
study candidate 
No
 Repeat any pre-procedure tests (e.g., ECG or 
labs) according to protocol timing requirements, if 
necessary.  Are all test results acceptable?  
Subject is a screen 
failure: exit from study 
YesNo
Yes
Subject is not a 
study candidate No
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 42 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF AN Y PART OF THIS DOCUMENT IS STRICTLY PROHIBITED. 
7. TRIAL PROCEDURES AND ASSESSMENTS 
7.1. Schedule of Events 
Table 7-1. Schedule of Events 
 Screening/Baseline 
Index 
Procedure  Post-
Procedure2/ 
Discharge  1 Month   
± 7 Days 6 Months  
± 14 Days 12 Months
± 30 Days 2, 3, 4, 5 Years
±60 Days Unsch. 
Visit 
 Within  
7 Days  
Prior to 
Procedure Within  
24 Hours 
Prior to 
Procedure Telephone 
Contact or 
Office Visit Telephone 
Contact or 
Office Visit Office Visit Telephone 
Contact or 
Office Visit  
Informed consent form1 X1         
Demographics, medical and 
cardiac history X         
Physical examination X         
Angina status X   X X X X X X 
CBC with differential X         
Creatinine blood test X         
Pregnancy test3 X         
12-lead ECG  X  X  
(within 24 hours) X4 X4 X   
CK and/ or CKMB5 (CKMB 
required)  X5  X5      
Troponin5 
(only if CKMB not available)  X5  X5      
ACT measurements 
(heparin only)6   X X (immediately 
post-procedure)      
Angiography to assess pre- 
and post- procedure lesion 
characteristics   X X     X7 
Randomization8   X       
AE/SAE monitoring9   X X X X X X X 
Medication regimen X X X X X X X X X 
CBC: complete blood count; ECG: electrocardiogram; CKMB: creati ne kinase myocardial band isoenzyme MB; ACT: activated clotting time; AE: adverse event; 
SAE: serious adverse event; URL: upper range limit; MACE: major adverse cardiac event. 
1 Informed consent may be obtained within 30 days prior to the index procedure. 
2 End of procedure defined as removal of guide catheter. 
  
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 43 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF AN Y PART OF THIS DOCUMENT IS STRICTLY PROHIBITED. 
3 For women of childbearing potential only per standard of care. 
4 12-leads ECG at 1- and 6-month visits is only if there are office visits at these time points. 
5 CKMB testing is required (or Troponin if CKMB is not availabl e). Baseline pre-procedure sample may be obtained from the sheath  during the index procedure 
prior to randomization.  CKMB (or Troponin if CKMB is not availa ble) will be measured at 6–24 hours post index procedure.  If C KMB is > 3x URL or Troponin > 
3x URL, a series of CKMB (or Troponin) mu st be evaluated every 4-12 hours until values have returned to < 3x URL or until disch arge, from when the first 
elevation is noted. 
6 ACT measurements are recommended but not require d if the test is not performed as standar d of care at the investigational insti tution.  If ACT is not performed, 
sufficient anticoagulation should be conf irmed based on standard of care procedur es and applicable clinical guidelines. 
7 Any repeat or unscheduled diagnostic or interventional corona ry angiography performed should include a diagnostic assessment o f the target lesion(s) and 
investigational stent(s).  Angiographic dat a collected during any repeat procedure on the target vessel(s) must be made availab le to the Clinical Events 
Committee (CEC) and angiographic core laboratory. 
8 Randomization only for subjects meeting al l eligibility criteria and successful crossing of the first lesion by a guide wire. 
9 All AEs (serious and non-serious) will be re ported for the entire study period to the ex tent required by national and/or local requirements.  For US sites only: After 
the 12-month follow-up visit, continuing AEs will be followed thr ough to resolution or until event becomes stable, and only ser ious adverse events, including 
MACE and clinical study endpoints, will be recorded. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 44 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
7.2. Screening and Baseline Procedures 
Individuals with CAD who qualify for a PCI procedure will be pre-sc reened by authorized 
site personnel by reviewing the medical re cord.  Potential subjects will undergo CAD 
screening according to each investigative site’s standard of care.  Prior to possible entry 
into the trial, site personnel  will review and compare the subject’s medical history with 
the clinical inclusion and exclus ion criteria to determine if th ey are an eligible candidate 
for the study.   
Pre-screening logs wi ll be kept at each invest igational site of all subjects identified 
through pre-screening who meet the clinical elig ibility criteria.  For subjects who are not 
subsequently enrolled (consent ed), the reason for non-enro llment will be recorded.  
Potential study subjects will proceed with the following sta ndard of care procedures to 
further assess eligibility. 
Pre-Procedure/Baseline Evaluations: 
 Physical assessment within 7 days prior to the index procedure, including weight, 
height and blood pressure. 
 Demographics within 7 day pr ior to the index procedure. 
 Medical history within 7 days pr ior to the index procedure: 
o General medical, cardiac,  neurologic and renal history. 
o Cardiovascular history (e.g., prior MI, prior PCI, history of congestive heart 
failure). 
o Risk factors (e.g., dyslipidemia, hyper tension, diabetes mellitus, tobacco use). 
o History of peripheral vascular disease, stroke, TIA. 
 Ischemic/anginal status assessment (acco rding to Canadian Cardiovascular Society 
Classification [CCSC] or Braunwald). 
 Current cardiovascular and diabetic medi cations, including anti-platelet/anti-
coagulant medications within 7 days prior to the index procedure. 
 12-lead ECG according to each site’s standar d of care to ensure suitability to 
undergo a PCI procedure, within 24 hours prior to the index procedure.  
 Routine laboratory assessments: 
o All subjects must have cardiac enzymes  including CK and/or CKMB (CKMB is 
required [or troponin if CKMB is not av ailable]), evaluated within 24 hours 
prior to the index procedure.  Baseline cardiac enzyme sample may be obtained from the sheath during the inde x procedure, prior to randomization. 
o All subjects must have a creatinine bl ood level assessed within 7 days prior to 
the index procedure.   
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 45 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
o Women of childbearing potential must  have a negative pregnancy (serum 
and/or urine) test within 7 days prior to index proc edure in accordance with 
the institutional stand ard of care.  Female subjects  who are surgically sterile 
or post-menopausal are exempt from having a pregnancy test. 
o Complete blood count (CBC) with differ ential within 7 days prior to the index 
procedure.  If white blood cell count is wi thin normal limits, differential is not 
required. 
If any of the Pre-procedure/ Baseline tests specified above are not routine 
standard of care or are required to be re peated in order to demonstrate protocol 
eligibility criteria leading up to the ind ex procedure, written informed consent will 
be obtained before these tests are performed or repeated.   Subjects are considered 
provisionally enrolled with t he signature on the written informed consent form, however 
a subject will only proceed to t he baseline evaluations and inde x procedure if all initial 
and applicable procedure-related e ligibility criteria are met. 
Written informed consent may be obtained on the day of the index procedure or within 
30 days prior to the index procedure.  The c onsenting process, including discussion of 
the study, with its possible benefits and risks, will be docu mented in the subject’s 
medical record. A copy of the completed informed consent document must be given to 
the subject; the original must be placed in th e medical record.  Failure to obtain a signed 
and hand-dated informed consent prior to the pr ocedure constitutes a protocol violation, 
which must be reported in accordance with all applicable regulations.   
7.3. Concomitant Medications 
Unless clinically contraindicated, al l subjects should re ceive the recommended 
medication regimen listed in Ta ble 7-2 at the investigator’s discretion in accordance with 
clinical guidelines.  The us e of glycoprotein IIb/IIIa inhi bitors is allowed and not 
mandatory. 
Pre-and post-procedure activated clotting ti me (ACT) measuremen ts for subjects 
receiving heparin are strongl y recommended but not required if the test is not performed 
as standard of care at the investigationa l institution.  If ACT is not performed, 
anticoagulation should be in accordance with standard of care procedures and 
applicable guidelines. 
All cardiovascular and diabetic medication s administered should be recorded in the 
medical record and reported in the electronic case re port form (eCRF) from 24 hours 
pre-procedure through the 12-m onth follow-up assessment.  Us e of antiplatelet/anti-
coagulant therapy will be recorded thr oughout the 5-year follow-up period. 
Dual antiplatelet therapy (DAPT) administrat ion post index procedure is recommended 
for a minimum of 6 months and highly recommended for 12 months for subjects who are not at a high risk of bleeding.   
  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 46 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Table 7-2. Concomitant Medi cation Regimen Recommendations 
Timing Medication Regimen 
Prior to 
Procedure Acetylsalicylic acid A minimum of 150 mg (within 24 hours prior to 
procedure). 
Clopidogrel 
or 
Prasugrel/Ticagrelor Loading dose of 600 mg clopidogrel within 24 
hours prior to index procedure or immediately 
post-procedure (within 30 minutes). 
Alternatively, loading dose of 60 mg prasugrel 
or 180 mg ticagrelor. 
No loading dose is required for subjects on 
chronic thienopyridine therapy. 
During 
Procedure Heparin or  
Bivalirudin Per routine hospital practice.   
For heparin, a bolus of 50-80 units/kg is 
recommended.  If heparin is administered, it is recommended to maintain ACT of ≥ 250 
seconds (or ≥ 200 seconds if a glycoprotein 
IIb/IIIa receptor blocker is administered) throughout the interventional portion of the 
procedure. 
Glycoprotein IIb/IIIa inhibitor Per investigator’s discretion. 
Intracoronary nitroglycerin or 
Intracoronary isosorbide 
or dinitrate To eliminate coronary artery spasm that would 
interfere with accurate measurement of lumen 
obstruction due to plaque alone, 100–200 µg 
nitroglycerin or 1–3 mg of isosorbide or dinitrate must be administered prior to baseline 
and post-intervention angiograms. 
Post-Procedure 
DAPT Acetylsalicylic acid A minimum of 75 mg daily indefinitely. 
Clopidogrel 
or 
Prasugrel/ticagrelor/ticlopidine Post-procedure treatment with the same 
thienopyridine agent for a minimum of 6 months, highly recommended for 12 months 
for subjects not at high risk for bleeding, as 
follows:  
Clopidogrel:  75 mg daily: 
Prasugrel:  10 mg daily; a lower dose of 5 mg 
daily is allowed for subjects < 60 kg.  
Ticagrelor:  90 mg twice daily.  
Ticlopidine:  250 mg twice daily. 
OUS investigators may follow medication administr ation recommendations in accordance with ESC 
guidelines, national guidelines and/or hospital standard of care. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 47 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
7.4. Index Procedure 
7.4.1. Subject Preparati on and Baseline Angiography 
Subject preparation and per cutaneous access should be performed according to 
standard hospital policy for care of interven tional cardiology patients unless otherwise 
specified in this investigational plan.  Bo th femoral and radial access techniques are 
acceptable.  The procedure begins once pe rcutaneous access has been established, 
defined as the time of  sheath insertion. 
Following intracoronary injection of nitroglycerin, isosorbide or  dinitrate (see Table 7-2) 
baseline angiography of the vessels(s) will be performed in at least two orthogonal 
views to characterize the target lesion(s) an d to confirm angiographic eligibility criteria.  
Assessment of angiographic eligibi lity criteria is based on vi sual assessment of the pre-
procedure angiogram. 
7.4.1. Randomization 
Subjects who have satisfied all general  and angiographic inclusion and exclusion 
criteria, after successful crossing  of the first target lesion wi th a guide wire, will then be 
randomized in a 2:1 ratio to receive either the Orsiro st ent (treatment group) or the 
Xience stent (control group).  Each subject will receive one unique randomization number associated with a randomization assignment allocated via the BIOFLOW-V 
study EDC electronic Case R eport Form (eCRF) website hoste d by MedNet Solutions.  
Randomization will be stratified by study c enter and to prevent bias, the blocks and 
randomization schedules will be  pre-defined prior to the first study enrollment and will 
be generated by HCRI.   
Once randomization is completed and a treat ment is assigned, crossover is not 
permitted.  Once randomized the subject is c onsidered enrolled in the trial and included 
in the intent-to-treat (ITT) popul ation.  This includes subj ects that are randomized, but 
do not receive the study stent or rece ive a stent not in accordance with the 
randomization assignment. 
7.4.2. Target Lesion(s) Pre-Dilatation 
The target lesion(s) must be pre-dilate d with standard percutaneous transluminal 
balloon angioplasty.  The re commended sizes of pre-dilatation balloons are as follows: 
 2.0 mm for a 2.25-mm vessel. 
 2.0 mm for a 2.5-mm vessel. 
 2.5 mm for a 3.0-mm vessel. 
 3.0 mm for a 3.5-mm vessel. 
 3.5 mm for a 4.0-mm vessel. 
The selected pre-dilatation balloon should be a minimum of 2 mm shorter than the 
length of the stent that is planned to be implanted. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 48 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
The use of rotational atherectomy devices or  cutting balloons is allowed.  If rotational 
atherectomy is performed, it should be follow ed by successful balloon inflation prior to 
stenting. 
7.4.3. Stenting 
All target lesions should be treated with the assigned study stent per randomization.  
The stenting procedur e will be performed according to the randomized stent IFU 
provided with each stent. 
The delivery system should be advanced over  the guide wire, th rough the introducer, 
and to the target lesion site.  The stent  should be positioned across the lesion and 
placement confirmed using th e radiopaque marker bands on the delivery catheter and 
fluoroscopic angiographic test injections.  In  all cases, the stent should extend into 
surrounding healthy tissue by a minimum of 2 mm proximally and distally. 
The stent should be deployed with a single in flation of the delivery system balloon 
according to the compliance table.  It is  recommended that inflation be maintained for 
approximately 15–30 seconds.  The delivery system balloon must not be inflated 
beyond the labeled-rated burst pressure. 
A maximum of two study stents are to be used per target lesion.  If more than one stent 
is needed to cover the target lesion complete ly, the stents must overlap by at least 2 
mm.  However, Investigators are discoura ged from treating two separate lesions with 
overlapping contiguous st ents and should anticipate a mi nimum of 10 mm between 
stents when treating two lesions in  the same target vessel.   
After stent placement, the invest igator should ensure that the stent is in full contact with 
the arterial wall.  To achieve full cont act, post-dilatation may be performed at the 
discretion of the investigator  using the stent delivery syst em balloon or a shorter non-
compliance balloon catheter.  Optimal stent deployment is a visually (or by online 
quantitative coronary angiogr aphy [QCA]) estimated residual stenosis of < 30%. 
Persistent dissections should be treated c onservatively, with low-pressure prolonged 
balloon inflation, or with an a dditional study stent implantati on (in accordance with the 
original randomization treat ment assignment) per standard pr actice.  Haziness, lucency 
or filling defects within or adj acent to the stent, and angiographic complications such as 
distal thromboemboli or no reflow, shoul d be treated per standard practice.  All 
angiographic complications that occur mu st be documented by angiography, reported 
on the appropriate eCRF, and submitted to  the angiographic core laboratory for 
analysis. 
7.4.4. End of Procedure 
In all subjects, final angiography of t he vessel(s) must be performed following 
intracoronary injection of nitroglycerin, isos orbide or dinitrate (see Table 7-2) and in the 
same views that were taken at baseline. 
The end of the procedure is defined as the time  the guide catheter is removed from the 
subject.  If the subject is returned to t he procedure room and a guiding catheter is 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 49 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
reinserted, a dilatation is performed, and an interventional device is inserted into the 
catheter, this should be cons idered a repeat intervention. 
7.4.5. Bailout Procedures 
In the event of a major dissection or an o cclusive complication manifested as decreased 
target vessel flow, chest pain or ischemic ECG changes after index procedure that do 
not respond to repeat balloon inflations or intracoronary vasodilators (nitroglycerin, 
verapamil, diltiazem, nitropr usside), other bailout procedur es may be performed, which 
may include additional stenting.  Should an  additional stent be us ed, it must be the 
assigned study stent unless clin ically contraindicated. Mult iple stenting with the Orsiro 
or Xience stents requires a 2-mm overlap.  Such procedures must be documented in 
the eCRF. 
All bailout procedures are c onsidered adverse events (AEs) in this study.  Bailouts 
procedures that result in any of the conseq uences characteristic of a serious adverse 
event (SAE) (e.g. death, pr olonged hospitalization, etc.  see Section 9.1.3) are 
considered SAEs. 
7.4.6. Bailout-Staged Procedure 
Planned staged procedures are not a llowed in this clinical in vestigation.  If during the 
intervention it becomes clinically necessary to postpone treatment of the second and/or 
third lesion to a later time point, this is regarded as a staged procedure and must be 
documented as such.  For staged procedures, t he use of an investigat ional stent is not 
allowed.  Subjects requiring staged proc edure should be treated according to the 
investigator’s discretion and standard of care.  These subjects should receive an 
approved, commercially available treatment and not a study stent. 
All bailout procedures are considered adverse events (AEs) in this study.   
7.5. Post-Procedure to Hospital Discharge 
7.5.1. Immediately Post-Procedure 
Immediately followi ng the procedure: 
 Heparin or bivalirudi n should be discontinued. 
 ACT should be monitored in accordance with hospital protocol. 
 Vascular sheaths should be removed according to standard hospital practice. 
 Approved vascular closure devices ma y be used at the discretion of the 
investigator in accordance with the manufacturer’s instructions. 
7.5.2. Clinical and Laboratory Assessments 
The following clinical assessments and labora tory tests should be performed after the 
index procedure and befor e hospital discharge: 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 50 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
 Cardiac biomarkers CK and/ or CKMB (CKM B is required, or tr oponin if CKMB is 
not available) will be measured once wit hin 6–24 hours post index procedure.  
CKMB or troponin is required.   
Note: Every effort must be made to obt ain cardiac biomarker values within the 
specified time ranges.  Results of all cardiac biomarker measurements, even 
measurements performed outsi de the time range, will be documented in the 
medical record and reported on the eCRF. 
If CKMB elevation (or troponin in the abs ence of CKMB) > 3x URL is noted post-
procedure, CKMB (or troponin in the abs ence of CKMB) measurements should 
be performed every 4-12 hours and documented in the medical record and reported on the eCRF until values have retu rned to < 3x URL or until discharge, 
starting from when the first elevation is noted. 
 A 12-lead ECG must be completed withi n 24 hours after the index procedure. 
 Ischemic/angina assessment according to CCSC or Braunwald classification just 
prior to discharge. 
 AE and SAE assessment. 
 Anti-platelet/anti-coagulant m edical therapy post procedure. 
 Other cardiovascular and diabet ic medications post procedure. 
Prior to discharge, review of the study follow-up requirements with the subject is 
recommended to help ensure compliance with the follow-up schedule.  In addition, 
confirmation of subject contact telephone num bers, including numbers for home, work 
numbers and primary physici an, as applicable, should be completed.   
7.6. Antiplatelet/Ant icoagulation Regimen 
Subjects will receive a minimum of 75 mg  aspirin daily indefinitely, and 75 mg 
clopidogrel daily for a minimum of 6 mont hs, 12 months are recommended for subjects 
who are not at high risk for bleeding.  
Clopidogrel may be substituted with 5 mg or 10 mg prasugrel daily or 90 mg ticagrelor 
twice daily or 250 mg ti clopidine twice daily. 
OUS investigators may fo llow medication administrat ion recommendations in 
accordance with ESC guidelines, national guide lines and/or hospital standard of care. 
7.7. Follow-Up Assessments 
All randomized subjects will be followed th rough 5 years of follow-up, with assessments 
performed at 1 month, 6 months, 12 months and annua lly thereafter.    
Subjects who are randomized, but do not receiv e a study stent (i.e., subjects who don ot 
receive an Orsiro or Xience stent) will be followed for 12-months only. 
An office visit is required for the 12-month follow-up visi t.  All other visits may be 
performed by telephone interview wit h the subject if the subject is unable to return for an 
office visit within the applicable follow-up window. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 51 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
For each follow-up visit, all clinical assessmen ts should be performed on the same date.  
Requirements of each follow-up evaluation are described below. 
7.7.1. One (1) Month Clini cal Follow-Up (30 ± 7 Days) 
Subjects will be evaluated at  1 month post-procedure (± 7 days) by a telephone 
interview and/or an office visit.  The following assessments must be completed: 
 Ischemic/anginal status (acco rding to CCSC or Braunwald). 
 AEs and SAEs since discharge. 
 Anti-platelet/anti-coagulant m edical therapy since discharge. 
 Other cardiovascular and diabetic  medications since discharge. 
 Any coronary intervention (e.g., repeat re vascularization) that occurred since the 
post-procedure discharge. 
 12-lead ECG (if an office visit is performed). 
7.7.2. Six (6) Month Clinical  Follow-Up (180 ± 14 Days) 
Subjects will be evaluated at 6 months pos t-procedure (180 ± 14 days) by a telephone 
interview or an office visit.  The fo llowing assessments mu st be completed: 
 Ischemic/anginal status (acco rding to CCSC or Braunwald). 
 AEs and SAEs since the previous contact. 
 Anti-platelet/anti-coagulant medical t herapy since the previous contact. 
 Other cardiovascular and diabetic medi cations since the previous contact. 
 Any coronary intervention (e.g., repeat re vascularization) that occurred since the 
previous contact. 
 12-lead ECG (if an office visit is performed). 
7.7.3. Twelve (12)  Month Clinic Visit (360 ± 30 Days) 
Subjects will be evaluated at 12 months post-procedure (360 ± 30 days).  The 12-month 
follow-up is required to be an office visit with the subject.  During the 12-month follow-up 
visit, the following assessm ents must be completed: 
 Ischemic/anginal status (acco rding to CCSC or Braunwald). 
 AEs and SAEs since the previous contact. 
 Anti-platelet/anti-coagulant medical t herapy since the previous contact. 
 Other cardiovascular and diabetic medi cations since the previous contact 
 Any coronary intervention (e.g., repeat re vascularization) that occurred since the 
previous contact. 
 12-lead ECG. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 52 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
7.7.4. Long-Term Clinical Follow-Up at 2, 3, 4 and 5 Years Post-Procedure 
(Annually ± 60 Days) 
Subjects will be evaluated at 2, 3, 4 and 5 years post-procedure (± 60 days) by a 
telephone interview and/or an office visi t.  The following assessments must be 
completed: 
 Ischemic/anginal status (acco rding to CCSC or Braunwald). 
 AEs and SAEs since the previous contact. 
Note: All AEs (serious and  non-serious) will be repo rted for the entire study 
period to the extent required by national and/or local requirements.  For US sites 
only: After the 12-month follow-up visit, c ontinuing AEs will be followed through to 
resolution or until event becomes stabl e and only serious adverse events, 
including MACE and clinical study endpoints, will be recorded. 
 Anti-platelet/anti-coagulant medical t herapy since the previous contact. 
 Other cardiovascular and diabetic medi cations since the previous contact. 
 Any coronary intervention (e.g., repeat re vascularization) that occurred since the 
previous contact. 
7.8. Unscheduled Study Visit 
Subjects may present to the clinic outside of the scheduled follow- up windows.  Such 
unscheduled study visits will be reported if the subject has experienced an AE.  For an 
unscheduled study visit, concomitant cardia c medications and data regarding adverse 
events will be collected. 
Subjects assessed at an unscheduled study vi sit may require diag nostic testing (e.g. 
ECG, angiogram, CK/CKMB levels) and/or a re vascularization procedure to further 
evaluate and treat ischemic symptoms.  Any repeat proc edure must be reported on the 
relevant case report forms, including any unscheduled visits prior to the repeat 
procedure and/or adverse events associated wit h the procedure.  Only commercially 
available stents are allowed during repeat procedures. Use of  investigational stents is 
not permitted. 
Any repeat or unscheduled diagnostic or inte rventional coronary revascularization 
procedure performed should include a diagnostic assessment of the target lesion(s) and 
investigational stent(s).  Angiographic data collected during any repea t procedure on the 
target vessel(s) must be made available to the CEC for an independent review and 
assessment.  Likewise, the angiographic im ages should be submitted to the core 
laboratory for an independent review and a ssessment of the target lesion and 
investigational stent. 
7.9. Angiographic Core Laboratory 
The angiographic core laboratory will provide sites with a written procedural manual 
describing the acquisition and submission pr ocedures for the baseline and subsequent 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 53 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
repeat angiograms.  Sites will be requeste d to obtain and submit a minimum of two 
orthogonal views at baselin e and post-procedure in accordance with the manual. 
Baseline and procedural  angiograms for all su bjects will be sent to the independent 
angiographic core laboratory for evaluation.   In addition, any coronary angiograms 
performed during the trial follow -up period due to suspicion of  restenosis of the target 
lesion(s) will be forwarded to the angiograph ic core laboratory for analysis. 
8. STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN 
The BIOFLOW-V clinical trial is a prospe ctive, multicenter, randomized, controlled 
study.  A total of up to 1,400 subjects will be  randomized, stratified by study center, in a 
2:1 ratio with 933 subjects randomized to re ceive the Orsiro stent and 467 subjects 
randomized to receive the Xience stent. 
The trial is designed to assess the non-inferi ority of the Orsiro stent compared to the 
Xience stent with respect to the primary endpoi nt of 12-month TLF, defined as cardiac 
death, target vessel Q-wave or non–Q-wav e MI, or any clinically-driven TLR. 
For this purpose, data from BIOFLOW-V randomized subjects will be combined with 
data from historical subjects  from the BIOFLOW-II and B IOFLOW-IV randomized trials 
employing a Bayesian approach.  Only subjects who meet all clinical and angiographic 
eligibility criteria of the BIOFLOW-V trial will be included in the analysis. 
8.1. Prior Data 
The Orsiro clinical trial program includes BIOFLOW-II, BIOFLOW-IV and BIOSCIENCE, 
three randomized controlled trials  in which subjects were randomized to the Orsiro stent 
against the Xience Prime™ or Xience Xpedition™ stents.  A brief description of these 
trials is provided in Section 3.5.  The in clusion and exclusion criteria for BIOFLOW-II 
and BIOFLOW-IV are nearly identical to t hose proposed for BIOFLOW-V, whereas the 
inclusion and exclusion criteria in BIOSCIENCE  were more liberal to allow enrollment of 
a broadly inclusive real world population.  We propose to us e data from the BIOFLOW-II 
and BIOFLOW-IV trials prospectively usi ng a Bayesian approach in the final non-
inferiority analysis of the BIOFLOW-V study.  A summary of the com parison of the study 
design of BIOFLOW-II and –IV trials along with the proposed BIOF LOW-V study can be 
found in Table 8-1. The current stat us of the studies is as follows: 
 BIOFLOW-II – Enrollment into the trial was completed and 12-month results are 
available.  A total of 298 subjects were  randomized to receive the Orsiro stent 
and 154 were randomized to receive the Xience Prime™ stent.  Of them, 287 
Orsiro subjects and 148 Xience subjects completed their 12-month follow-up.   
 BIOFLOW-IV - Enrollment into the trial is still ongoing and it is anticipated that 
370 Orsiro subjects and 185 Xience Prime™/Xpedition™ subjects will be 
contributed from this trial.  
To ensure the validity of data from subjects across trials, t he following measures will be 
taken: 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 54 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
 Only subjects that meet all BIOFLOW- V clinical and angi ographic eligibility 
criteria will be included. 
 Evaluation of the 12-month TLF rate (a primary endpoint in the BIOFLOW-V trial 
and a secondary endpoint in the BIOFLOW- II and BIOFLOW-IV trials) will be 
performed in a uniform fashion, using a co nsistent set of definitions and similar 
follow-up schedule: 
o The measurement schedule of cardiac enzymes is similar in all trials: 
cardiac enzymes are collected once within 6-24 hours post index 
procedure.  While all trials mandat ed collection of CK and CKMB, the 
BIOFLOW-II also mandated measurement of troponin.  The BIOFLOW-IV 
and BIOFLOW-V trials allow measurem ent of troponin if  CK and CKMB 
are not used.  To address the differences in the collection of cardiac enzymes between the three trials, a uni form definition of peri-procedural 
MI that is based on CK and CKMB leve ls (with troponin levels used only in 
the absence of CK and CKMB) will be utilized.   
o All trials have similar clinical fo llow-up schedule at 1 month (telephone 
contact/clinic visit), 6 months (telephone contact/clinic visit) and 12 months 
(telephone contact/clinic visit for BIOF LOW-II clinic visit for BIOFLOW-IV 
and BIOFLOW-V). 
o The BIOFLOW-II and BIOFLOW-IV trials used the same independent 
angiographic core laboratory.  To ensure consistency, angiograms from the BIOFLOW-II, BIOFLOW-IV and BIOFLO W-V trials will be analyzed or 
validated by the same angiographic core laboratory. 
o All clinical endpoints (potential TL R, MI and death events) will be re-
adjudicated by the same independent CEC as will be employed for the 
BIOFLOW-V data, using uniform definitions. 
 Data quality will be confirmed in accord ance with the monitoring plan of each 
trial. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 55 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED U SE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Table 8-1. Subjects’ Poolability 
 
 
8.2. Bayesian Analysis 
To assess the non-inferiority of the Orsiro  stent compared to the Xience stent in the 
BIOFLOW-V study, a Bayesian approach usi ng hierarchical models to formally 
incorporate data from the BI OFLOW-II and BIOFLOW-IV trials  will be employed.  The 
approach proposes using Binomi al analysis for the pres ence of a TLF event and a 
Bayesian model that allows for a bias bet ween the TLF event rates of the BIOFLOW-II 
and BIOFLOW-IV trials and the TLF event ra tes of the BIOFLOW-V trial in both the 
Orsiro and Xience groups.  The parameters def ining the bias are selected so that the 
proposed method is robust to misspecifications  of the initial assumptions.  Further 
details are presented in Section 8.7.  
8.3. Software 
Simulations were run in R statistical package (R citation) and OpenBUGS software,49 
version 3.2.2.  For each scenario, 10,000 datasets were generated in R.  OpenBUGS 
was then used to obtain samples from the pos terior distribution of each parameter and 
to calculate the probability of success.   For each analysis, 50,000 samples were 
obtained from the posterior distributions  after 1,000 samples were discarded. 

   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 56 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
8.4. Criteria for Success 
The criterion for success is based on the posterior probabi lity of the alternative 
hypothesis (i.e., of non-inferiority being me t).  The Orsiro group will be declared non-
inferior to the Xience group if the posterior  probability of the alternative hypothesis H୅ is 
large, that is 
ܲሺܪ஺|ܽݐܽܦሻൌܲሺߨ௑௏െߨை௏൐െ ߜ|ܽݐܽܦሻ൐ߨ∗ 
where πଡ଼୚ and π୓୚ are the 1-year TLF for the Xience  and Orsiro groups of the BIOFLOW-
V study, respectively, δ is the non-inferiority margin and H୅:	πଡ଼୚െπ୓୚൐െ δ  is the 
alternative hypothesis indicating that non-inferiority is met and π∗ is the level of 
evidence we require to declare t he alternative hypothesis true.  
8.5. Sample Size Determination 
The BIOFLOW-V trial will assess non-inferiorit y of the 12-month TLF rate for the Orsiro 
stent vs. TLF rate in subjec ts treated with the Xience stent. 
The null hypothesis is that the Orsiro stent will have a primary endpoint (TLF) rate equal 
to or exceeding that of the Xience group by the non-inferiority margin or more. 
The alternative hypothesis is  that the Orsiro stent wi ll have TLF rate less than the 
Xience group rate plus the non-infe riority margin.  Specifically: 
H଴:	ߨ௑௏െߨை௏൑െ ߜ  
H୅:	ߨ௑௏െߨை௏൐െ ߜ  
Where ߨை௏ is the true 12-month TLF ra te for the Orsiro stent, ߨ௑௏ is the true 12-month 
TLF rate for the Xience arm, and ߜ is the non-inferiority margin. 
The assumptions for this analysis are: 
 True 12-month TLF rate is 7.0%  in both treatment groups ( ߨ௑௏ൌߨை௏). 
 Power is 89%. 
 3.85% is the absolute non-inferiority margin  (55% relative non-inferiority margin). 
 Discount the results of the BIOFLOW- IV data by 20% and BIOFLOW-II data by 
30%. 
 Standard deviation of the bias terms between the ODDS of BIOFLOW-II TLF 12-
month rates and ODDS of BIOFLO W-V 12-month rates is 0.3. 
 Standard deviation of the bias terms bet ween the ODDS of BIOFLOW-IV TLF 12-
month rates and ODDS of BIOFLO W-V 12-month rates is 0.3. 
 Non-inferiority assessment will be assesse d using the posterior probability of the 
alternative hypothesis as  specified above, where ߨ∗ൌ 0.975   
Rejection of the null hypothesis will signify that t he Orsiro stent is not inferior to the 
Xience stent with regards to 12-month TLF.  A total of 1,200 subjects (800 in the Orsiro 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 57 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
group and 400 in the Xience gr oup) will have 89.6% power to  reject the above null 
hypothesis in favor of the alternative under the stated assumptions.  To account for loss 
to follow-up (expected to be approximately 10% ), a total of 1,334 s ubjects will need to 
be randomized.  The one-sided type I error esti mates are 4.0%, 3.3%, and 4.2% if the 
actual ODDS for the 12-month TLF rate of event in the Xience group of the BIOFLOW-
IV study are the same, 10% lower and 10% higher when compared with the ODDS for 
the 12-month TLF rate of event in t he Xience group of the BIOFLOW-V study. 
True Rate 
The current assumption of the 12-month TL F rate of 7.0% is based on expected 
inclusion criteria for BIOFLOW studies and re sults from recent everolimus eluting stent 
trials.  
The BIOFLOW-IV trial remains in follow-up for its primary endpoint results.  An interim 
analysis of the observed TLF rate for Orsiro and Xience combined for the two historical 
trials will not be performed due to  the timing of data availabili ty.  To mediate the effect 
on power of possible discrepan cies between the assumed rate in BIOFLOW-V and 
BIOFLOW-IV, the sample size  may be increased by up to 60 additional subjects (40 in 
the Orsiro and 20 in the Xience arm).  T he resultant group sizes, 840 Orsiro and 420 
Xience, for a total of 1260 subjects, will resu lt in 89% power or higher. Taking into 
consideration loss for follow-up, the up to 1400 subjects may be enrolled.  
Non-Inferiority Margin 
The non-inferiority margin was calculat ed based on a meta-analysis rate of the 
difference in treatment effect between D ES and BMS.  Randomized clinical trials 
comparing treatment wit h DES and treatment wit h BMS with 9 months or longer clinical 
follow-up data were included in the meta-analysis.  Nine-month rates were used 
whenever 12-month rates were not available,  as shown in Tabl e 8-2.  Depending on 
study definitions, TVF or MACE rates were used to match as closely as possible the 
TLF definition in this study. 
The meta-analytic rate of the difference in  treatment effect bet ween DES and BMS was 
10.0% with a lower bound of the 2-sided 95% CI of 8.2%.  A common practice is to take 
50% of this lower bound of the DES-BMS di fference as the non-inferiority margin, 
therefore an absolute non-inferiority margin  of 3.85%, which is approximately 46% of 
the lower bound, is supported.  
 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 58 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF AN Y PART OF THIS DOCUMENT IS STRICTLY PROHIBITED. 
Table 8-2. TVF/MACE  Rates at 9 or 12 Months, DES vs. BMS 
 Target Vessel Failure Rate Major Adverse Cardiac Event Rate 
 9 Months 12 Months 9 Months 12 Months 
Trial DES BMS DES BMS DES BMS DES BMS 
RAVEL1 
(MACE: death, MI, CABG, target lesion percutaneous 
revascularization) – – – – – – 5.8% 
(7/120) 28.8% 
(34/118) 
SIRIUS2 
(TVF: cardiac death, MI, target vessel repeated 
percutaneous or surgical revascularization) – – 9.8% 
(52/533) 24.8% 
(130/525) – – – – 
E-SIRIUS3 
(MACE: death, MI, CABG, TLR) – – – – 8.0% 
(14/175) 22.6% 
(40/177) – – 
C-SIRIUS4 
(MACE: death, MI, emergent CABG, clinically-driven TLR) – – – – 4.0% 
(2/50) 18.0% 
(9/50) – – 
TAXUS-I5 
(MACE: death, Q-wave MI, TVR, stent thrombosis) – – – – – – 3.3% 
(1/30) 10.0% 
(3/30) 
TAXUS-II6 
(MACE: death, MI, TVR) TAXUS-SR arm – – – – – – 10.9% 
(14/129) 22.0% 
(29/132) 
TAXUS-MR arm – – – – – – 9.9% 
(13/131) 21.4% 
(28/131) 
TAXUS-IV7 
(TVF: death, MI, ischemia-driven TVR; MACE: cardiac 
death, MI, ischemia-driven TVR) – – – – – – 10.8% 
(69/639) 20.0% 
(126/633)
TAXUS-V8 
(TVF: death, MI, ischemia-driven TVR; MACE: cardiac 
death, MI, ischemia-driven TVR) – – – – 15.0% 
(84/560) 21.2% 
(120/567) – – 
TAXUS- VI9 
(MACE: death, MI, TLR and TVR) – – – – 16.4% 
(36/219) 22.5% 
(51/227) – – 
ENDEAVOR II10 
(TVF: TVR, recurrent MI, cardiac death not clearly attributed 
to non-target vessel; MACE: death, MI, emergent CABG, 
TLR) 7.9% 
(47/592) 15.1% 
(89/591) – – – – – – 
1 Morice MC, Serruys PW, Sousa E et al. for the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary 
revascularization. New Eng J Med  2002;346:1773–1780. 
2 Weisz G, Leon MB, Holmes Jr DR et al. Two-year outcomes after sirolimus-eluting stent impl antation results from the Sirolimus-Eluting Stent in de Novo  Native 
Coronary Lesions (SIRIUS) Trial. J Am Coll Cardiol  2006;47:1350–1355. 
3 Schofer J, Schlüter M, Gershlick AH et al. for the E-SIRIUS Investigators. Sirolim us-eluting stents for treatment  of patients with long at herosclerotic lesions in 
small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet  2003;362:1093–1099. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 59 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF AN Y PART OF THIS DOCUMENT IS STRICTLY PROHIBITED. 
4 Schampaert E, Cohen EA, Schlüter MS et al. for the C-SIRIUS Investigators. The C anadian study of the sirolimus-eluting st ent in the treatment of patients with 
long de novo  lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol  2004;43:1110–1115. 
5 Grube E, Silber S, Hauptmann KE. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-releas e paclitaxel-eluting stent for de 
novo  coronary lesions. Circulation  2003;107:38–42. 
6 Colombo A, Drzewiecki J, Banning A et al. for the TAXUS II study group. Randomized study to assess  the effectiveness of slow- and moderate-release polymer-
based paclitaxel-eluting stents for coronary artery lesions. Circulation  2003;108:788–794. 
7 Stone GW, Ellis SG, Cox DA et al. One-year clinical results with the slow-release, polyme r-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation  
2004;109:1942–1947. 
8 Stone GW, Ellis SG, Cannon L et al. for the TAXUS V investigators. Comparis on of a polymer-based paclitaxel-eluting st ent with a bare metal stent in patients 
with complex coronary artery disease: A randomized controlled trial. J Am Med Assoc  2005;294:1215–1223. 
9 Dawkins KD, Grube E, Guagliumi G et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions 
from a multicenter, randomized trial: Support for the use of drug-eluting stents in cont emporary clinical practice. Circulation  2005;112:3306–3313. 
10 Fajadet J, Wijns W, Laarman G-J et al. Randomized, double-blind, multicenter st udy of the Endeavor zotarolimus-eluti ng phosphorylcholine-encapsulated stent 
for treatment of native coronary artery lesions: Clinic al and angiographic results of the ENDEAVOR II trial. Circulation  2006;114:798–806. 
 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 60 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
8.6. Statistical Analysis Sets 
8.6.1. Intent-to-Treat Analysis Population 
The Intent-to-Treat (ITT) populat ion is defined as all randomiz ed subjects.  Subjects are 
analyzed according to the stent to which they  were randomized (regar dless of the actual 
stent that they received).  This  is the primary analysis population. 
8.6.2. Per-Protocol Population 
The Per-Protocol (PP) population is defined as all randomized subjects who received at 
least one assigned study stent, have sufficient  follow-up data (at least 11 months of 
follow-up or experienced t he primary endpoint) and no majo r protocol eligibility 
violations (i.e. inclusion/excl usion criteria violations t hat could impact  the primary 
endpoint).  
8.6.3. Modified Intent-to-T reat Analysis Population 
The Modified ITT population is defined as all randomized subjects who received at least 
one study stent according to t heir treatment assignment.   
8.7. Endpoint Analyses and Reporting of Results 
Descriptive statistics will be used to summari ze clinically relevant demographic and 
background characteristics, and  safety and effectiveness data collected in this study.  
The statistics for continuous variables will include sample sizes, means, medians, 
standard deviations, inter-quartile ranges, mi nimum and maximum values.  Categorical 
variables will be descr ibed with counts and perc entages.  Proportions will be calculated 
using known non-missing values.  Unless otherwis e indicated, all stat istical tests and/or 
confidence intervals will be performed at α = 0.05 (2-sided). 
All descriptive statistical analyses will be pe rformed using Statistical Analysis Software 
(SAS) for Windows (version 9.1 or higher). 
8.8. Analysis of Primary Endpoint 
Bayesian analyses will be performed using OpenBUGS49 version 3.2.2 or higher. This 
study will assess non-inferiority of the 12-month TLF rate fo r the Orsiro stent vs. the 
Xience stent.  The analysis will be carried out on the ITT set (primary) and PP analysis 
sets. 
The null hypothesis is that t he Orsiro stent will have a pr imary endpoint (12-month TLF) 
rate equal to or exceeding that  of the Xience group by the non-inferiority margin or 
more. 
The alternative hypothesis is that the Orsi ro stent will have a 12-month TLF rate less 
than the Xience group rate plus the non-inferiority margin.   
H଴:	ߨ௑௏െߨை௏൑െ ߜ  
H୅:	ߨ௑௏െߨை௏൐െ ߜ  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 61 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
where ߨை௏ is the true 12-month TLF ra te for the Orsiro stent, ߨ௑௏ is the true 12-month TLF 
rate for the Xience arm, and ߜ is the non-inferiority margin chosen to be 0.0385 (or 
3.85%). 
Due to the randomized nature of the study, we do not expe ct the two treatment groups 
to differ on clinically important baseline c haracteristics, therefore no adjustment is 
proposed in the primary analysis.   
The proposed model is a Bayesi an hierarchical model that assumes a bias between the 
12-month TLF rates in BIOFLOW-II and B IOFLOW-V as well as BIOFLOW-IV and 
BIOFLOW-V studies.  Full details  will be provided in the SAP. 
Center heterogeneity 
To assess consistency of treatment effect size across study cent ers, Bayesian models 
will be employed for the subj ect level data.  Any study c enter with less than 5 subjects 
per treatment group wi ll be pooled with ot her study centers by geographic region prior to 
carrying out this assessment. 
Individual data,  for treatment ݅ ,study ݆ and individual ݇ will be assumed to follow a 
Bernoulli distribution: 
ܻሾ݇,݆,݅ሿ~݊ݎܾ݁݀ሺ݌ሾݎ݁ݐ݊݁ܿ,݆,݅ሾ݇ሿሿሻ  
where center is an index variable that i ndicates the center t hat the individual ݇ was 
recruited in.  
The assumptions are based on a similar model to the model propos ed in Legrand et al. 
2005.50  The event rate is assumed to have an addi tive effect for center that varies with 
study: 
ݐ݅݃݋݈൫݌ൣݎ݁ݐ݊݁ܿ,݆,݅ ሾ݇ሿ൧൯ ൌ ߜൣݎ݁ݐ݊݁ܿ ሾ݇ሿ൧൅൫ܽݐܾ݁ ሾ݆ሿ൅ߛൣݎ݁ݐ݊݁ܿ ሾ݇ሿ൧൯∗ሺܴܶܶ ௞ൌ݅ሻ 
The two random effects can be interpreted as the influence of the center on the overall 
TLF rate and on the overall tr eatment effect, respectively .  The center effects, 
ߜൣݎ݁ݐ݊݁ܿ ሾ݇ሿ൧ and ߛൣݎ݁ݐ݊݁ܿ ሾ݇ሿ൧, are assumed to be exchangeabl e and a priory to follow a 
normal distribution with mean mu_delta  and mu_gamma  and standard deviation 
sigma_delta  and sigma_gamma , respectively.  As recommended by Geltman et al. 199551 
uniform prior on (0.1, 100) will be assumed on the two variances.  The standard deviation of the random effects can be vi ewed as a measure of heterogeneity across 
centers and treatment effect.  As indicated in Spiegelhalter 2004 (S pielgelhalter, D.J., 
Abrams, K.R. and Myles, J.P. (2004). Baye sian Approaches to Cli nical Trials and 
Health-Care Evaluation, J ohn Wiley and Sons, page 169) a value of 1 for standard 
deviation of random effects ‘…corresponds to substantial heterogeneity.’, therefore, if 
the posterior probability that ܽ݉݃݅ݏ_ܽݐ݈݁݀ ൐ 1  or ܽ݉݃݅ݏ_ܽ݉݉ܽ݃ ൐ 1  exceeds 0.85 and 
the credible intervals discussed above indicate  the interaction is qualitative in nature, 
then this may preclude all sites from being pooled for the primary analysis, in which 
case the primary analysis may be re-run excluding study centers causing the 
interaction.  Additional details will be provided in the full SAP.     
Region (US/OUS) heterogeneity 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 62 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
To assess consistency of treatment effect si ze across regions (United States [US] vs. 
Outside United States [OUS]) region and an interaction of region and treatment will be 
included in the mode l. For the interaction coefficient, we will calculate p_int as the 2-
sided posterior probability of observing an intera ction value that is more extreme than 0. 
This value is similar to a traditional p- value. If p_int<0.15 we will conclude that 
heterogeneity across region is si gnificant and the treatment effect will be calculated and 
tested within region. 
 
8.9. Handling of Missing Data in the Analysis of Primary Endpoint 
Every effort will be undertaken to limit pr emature discontinuations and ascertain 
completeness of data collection.  The foll owing analysis strategies  will be adopted to 
handle missing data with results compared for consistency prior to carrying out the 
above analysis:  
1. Only subjects who experienced the pr imary endpoint (TLF at 12 months) or who 
had appropriate follow-up (at least 330 days post baseline, given the 30-day visit 
window allowed around the 12-month visit) will be included in the analysis. 
2. All subjects will be included in the analysi s set including data fo r subjects missing 
primary endpoint status due to not experi encing the event and not reaching at 
least 330 days of follow-up.  Data for t hese subjects will be included as ‘NA’. A 
model will be used for t he event probabilities: 
ܻሾ݇,݆,݅ሿ~݊ݎܾ݁݀ሺ݌ሾݎ݁ݐ݊݁ܿ,݆,݅ሾ݇ሿሿ  
with 
ݐ݅݃݋݈൫݌ൣݎ݁ݐ݊݁ܿ,݆,݅ ሾ݇ሿ൧൯ ൌ ܽݐܾ݁∗ܺሾ݇ሿ൅ݐ݅݃݋݈ሺ݌ሾ݆,݅ሿሻ  
where ܺሾ݇ሿ are predictors values for subject ݇ .A noninformative prior will 
be assumed on the slope parameters ܽݐܾ݁ and similarly to the analysis of 
the primary endpoint, bias will be assumed between TL F rates in different 
studies. 
The following variables will be included in the model as covariates: 
 Age 
 Gender 
 Diabetes 
 Lesion length 
 Others (the complete set will be detailed in the full SAP) 
3. Time to event analysis using a Bayesi an Cox regression an alysis.  For each 
study, a separate hazard ratio comparing Xience to Orsiro stent will be included.  
Similar to the method proposed as a prim ary method, a bias will be assumed 
between the hazard ratio of BI OFLOW-II or BIOFLOW-IV and the hazard ratio of 
the BIOFLOW-V.  Further details  will be provided in the full SAP. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 63 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
4. A tipping point analysis will be carried out.  He re, it is assumed that for all Xience 
patients with missing primary endpoint (12 -month TLF) status, TLF did not occur. 
For Orsiro patients with missing data, it  will be first assum ed that the primary 
endpoint of TLF occurred for exactly one such patient; then the primary analyses 
will be re-run to assess if non-inferiority is  met under this assumption.  Then it will 
be assumed the primary endpoint occurred for exactly two Orsiro patients with 
missing data, and the primary no n-inferiority analysis will be rerun.  The process 
will continue sequentially in this manner unt il all Orsiro patients with missing data 
are considered to have met the primary endpoint of TLF.  Of interest is the 
“tipping point”, or i.e., the number of imputed Orsiro TLFs  where non-inferiority is 
not met in this analysis. 
 
8.10. Analysis of Secondary Endpoints 
Analyses of secondary endpoints will be carried out on the ITT, Modified ITT and PP 
analysis sets using the same method prop osed for the primary endpoint.  Secondary 
Endpoints include the following measures:  
1. Device success 2. Lesion success 3. Procedure success 
The following secondary clinical  endpoints will be eval uated prior to discharge, at 1-, 6- 
and 12-months and annually thereafte r through 5 years follow-up: 
4. Death 5. MI 6. Cardiac death or MI 7. MACE and individual MACE components  8. TLF and individ ual TLF components  
9. TVF and individ ual TVF components  
10. Stent thrombosis according to ARC criteria  
Included in the analysis, will be subjects ex periencing the event or who have adequate 
follow-up (e.g., at least 23 days for 1-month time point, at least 166 days for the 6-month time point, and at least 330 da ys for the 12-month time point). 
As an additional anal ysis, for time-to-event endpoints, Bayesian Cox regression will be 
used.  For each study, a separate hazard ratio comparing Xience to Orsiro stent will be 
included.  Similarly to t he method proposed as a primar y method, a bias will be 
assumed between the hazard ratio of BIOFLO W-II or BIOFLOW-IV and the hazard ratio 
of the BIOFLOW-V.  All subjects will be included, where subjects  not experiencing the 
event will be censored at last  known follow-up or at the end of the relevant follow-up 
time, whichever is earlier.  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 64 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
8.11. Analysis of Baseline Demograp hics and Procedural Characteristics 
Although we do not expect differences between the two treatment groups due to 
randomization, a comparison of the demographic and base line characteristics in 
between the two treatment groups  will be performed.  Dem ographic, medical history and 
other clinically relevant baseline variabl es will be summarized by treatment using 
descriptive statistics (i.e. number of observa tions available, mean, standard deviation, 
minimum, and maximum for continuous va riables and counts and percentages for 
qualitative variables).  Treatm ent difference on dichotomous variables will be evaluated 
using Fisher’s exact tests.  Categorical variables will be  compared between treatments 
using the Cochran-Mantel-Haen szel (CMH) Modified Ridit Scor es, i.e. CMH of general 
association for nominal variables and CMH of  row mean score for ordinal variables).  
Continuous variables will be compared between treatments usi ng a two-sample t-test.   
8.12. Subgroup Analysis 
Subgroups for secondary analysis of  clinical endpoints include: 
 Reference vessel diameter ≤ 2.75 mm/ > 2.75 mm. 
Note: Subjects with at least one target lesion ≤ 2.75 mm will be classified with the 
small vessel subgroup.  
 Subjects > 75 years of age/subjects ≤ 75 years of age. 
 Women/men. 
 Subjects with diabetes/subjects without diabetes. 
 Lesion length > 26 mm and ≤ 26 mm in length  
 Single stents versus overlapping stents for lesion lengths > 26 mm  
Treatment group difference (Ors iro minus Xience) in the primary endpoint rate and the 
two-sided 95% credible interval of the difference will be presented within each 
subgroup.  A test of interact ion on the primary endpoint w ill be performed to formally 
assess heterogeneity of treatment effect on the primary endpoint across subgroups in 
the same manner that will be used the a ssessment of region heterogeneity discussed 
above.  The purpose of this analysis is not to  formally assess non-inferiority within each 
subgroup, but simply to assess consistency of results across the various subgroups.  
Subjects with an event or with appropriate fo llow-up will be included in this analysis. 
8.13. Adverse Event Analysis 
Only AEs whose frequency exceeds 10 will be compared between the two groups. For 
those AEs, if ݌ை	and ݌௑	are the probability of the AE with the Orsiro and Xience stents, 
we will report the poste rior distribution that ݌ை൐݌௑	, that is, the poste rior probability that 
the probability of the AE is larger with the Orsiro stent than with Xience stent. Non-
informative independent priors Beta (0.1,0.1) will be assumed on ݌ை	and ݌௑, 
respectively.   
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 65 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
9. ADVERSE EVENTS 
In this study, subjects should be encou raged to report adverse events (AEs) 
spontaneously or in response to general, non- directed questioning (e.g., “How has your 
health been since the last visit?”).  Any time  during the study, the subject may volunteer 
information that resembles an adverse even t.  If it is determined that an AE has 
occurred, the investigator should obtain all information required to complete the AE 
eCRF. 
 
9.1. Definitions 
9.1.1. Adverse Events 
An adverse event is defined as any untoward medical o ccurrence, unintended disease 
or injury, or untoward clinical signs (inclu ding abnormal laboratory findings) in clinical 
trial subjects, whether or not related to the investigational medical device. 
NOTE 1:  This definition includes events rela ted to the investigational medical 
device or the comparator. 
NOTE 2:  This definition includes events re lated to the procedures involved. 
NOTE 3:  Abnormal laboratory findi ngs will be considered AE s, only if determined 
by the investigator to be clinically significant . 
Any current condition that is recorded as a pr e-existing condition either in the medical 
history of physical examination section, unle ss there is a change in nature, severity, or 
degree of incidence, is not an AE. 
Adverse events shall be assessed and docum ented throughout the cour se of the trial 
beginning after the subject has been enrolled.  All adverse events should be recorded 
on the appropriate subject e CRF and followed through to t heir resolution regardless of 
time window. 
9.1.2. Adverse Device Effect 
An adverse device effect (ADE) is a device-related adverse event, i.e., any adverse 
event for which a causal relationship betw een the device and the event is at least a 
reasonable possibility (the relationship cannot be excluded).  Note that this definition 
includes adverse events resulting from insu fficient or inadequate instructions for use, 
deployment, implantation, installation or operation, or any malfunction of the 
investigational medical device, as well as any event resulti ng from user error or from 
intentional misuse of the in vestigational medical device. 
Device Failure : A device has failed if it is used in accordance with the IFU, but 
does not perform according to IF U and negatively impacts treatment. 
Device Malfunction (ISO 14155:2011) : Failure of an inve stigational medical 
device to perform in accordance wit h its intended purpose when used in 
accordance with the IFU or Clinical Investigation Protocol (CIP). 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 66 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Device Deficiency (ISO 14155:2011) : Inadequacy of a medical device with 
respect to its identity, quality, durability, re liability, safety or performance.  Device 
deficiencies include malfunctions, user  errors and inadequate labeling. 
Near Incident : Malfunction or deterioration in characteristics and/or performance 
of the device, which might have led to dea th or serious deterioration in health; 
incident occurred and is such that if it  occurred again, it might lead to death or 
serious deterioration in health. 
User Error : Act or omission of an act that resu lts in a different medical device 
response than intended by the manufacturer or expected by the user.  User error 
includes slips, lapses and mistakes.  An unexpected physiological response of 
the subject does not in itself constitute a user error. 
9.1.3. Serious Adverse Event 
Due to the international conduct of the study, the ISO 14155 definition of serious 
adverse events and device effects will be utilized.  
A serious adverse event (SAE) is an adverse event that leads to: 
 Death. 
 Serious deterioration in the health of t he subject that either results in life-
threatening illness or injury; permanent im pairment of a body structure or a body 
function; hospitalization or  prolonged hospitalization; or medical or surgical 
intervention to prevent life- threatening illness, injury or permanent impairment to 
a body structure or a body function. 
 Fetal distress, fetal death, congenital abnormality or birth defect 
Note that planned hospitaliz ation for pre-existing cond ition (scheduled prior to the 
subject signing the informed consent for t he study), or a procedure required by the 
clinical study plan, without a serious deterioration in health, is not considered to be an 
SAE. 
Also note that in the Eu ropean Union and OUS countries, SAEs also include device 
deficiencies that might have led to an SAE if suitable  action had not been taken, 
intervention had not been made, or if circum stances had been less fortunate.  These 
are handled under the SAE reporting system. 
9.1.4. Serious Adverse Device Effect 
A serious adverse device effect  is an adverse device effect that results in any of the 
consequences characteristic of a serious adverse event. 
9.1.5. Anticipated Adverse Event 
An anticipated adverse event is any undes irable experience (si gn, symptom, illness, 
abnormal laboratory value or ot her medical event) occurring to  a subject, whether or not 
considered related to the in vestigational product(s) or dr ug regimen prescribed as part 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 67 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
of the clinical protocol, pre-defined in the clinical protocol and/or IFU, that is identified or 
worsens during a clinical study. 
For anticipated AEs that have been identified as possible co mplications of the Orsiro 
stent, please see Section 13.1. 
9.1.6. Unanticipated Adverse Device Effect or Unanticipated Serious 
Adverse Device Effect 
An unanticipated adverse devic e effect (UADE) is defined in 21 CFR 812.3(s) as any 
serious adverse effect on health or safety  or any life-threateni ng problem or death 
caused by, or associated with, a device, if  that effect, problem or death was not 
previously identified in natur e, severity or degree of incidence in the protocol, or any 
other unanticipated serious prob lem associated with a device that relates to the rights, 
safety or welfare of a subject. 
In the European Union and other OUS c ountries, the term unanticipated serious 
adverse device effect (USADE) as defined  in ISO14155:2011, is any serious adverse 
device effect which by its natur e, incidence, severity or out come has not been identified 
in the current version of  the risk analysis report. 
9.1.7. Device Failures, Malfunctions and Misuse 
Investigators are instructed to report all possible device failure s, malfunctions or misuse 
observed during the course of the trial.   These incidents will be documented in the 
electronic case report form provided as follows: 
Device Failure : A device failure has occurred when the device is used in 
compliance with the IFU, but does not per form as described in the IFU and also 
negatively impacts treatment of the study subject. 
Device Malfunction : Failure of an investigational  medical device to perform in 
accordance with its intended purpose when used in accordance with the IFU or 
CIP. 
Device Misuse : Any use of the investigational devi ce by an invest igator that is 
contradictory to the applic ation described in the IFU will be categorized as device 
misuse and is to be reported as a significant protocol deviation. 
9.2. Documentation 
Adverse events must be listed on the appropriate eCRF.  All adverse events will be 
characterized by t he following criteria: 
 Relatedness to the st udy device and procedure 
 Outcome 
 Treatment or action taken 
All adverse events (serious and non-serious) will be reported for t he entire study period 
in accordance with national laws.   
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 68 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
For US sites only: All adverse  events will be reported for the first 12 months of the 
subject’s study participation until the primary endpoint is determined.  After the 12-
month follow-up visit, continuing AEs will be followed through to  resolution or until event 
becomes stable and only serious adverse ev ents, including MACE and clinical study 
endpoints, are required to be reported.   
9.3. Relatedness 
The Principal Investigator (PI) will eval uate if the AE or SAE is related to the 
investigational device or st udy procedure.  Relatedness is defined in the following 
manner: 
Not related : The PI has determined that the co mplication is not related to the 
study device. 
Possible : The PI has determined that the event  has a possible relationship to the 
use of the investigational device. 
Definite : The PI has determined that the complication is related to the 
investigational device. 
Both possible and definite relationship desig nations will be considered device-related for 
reporting purposes. 
9.4. Reporting of Serious Adverse Events 
All participating study sites should report SAEs to BIOTRONIK or its designee as soon 
as possible, preferably by completing an Adverse Event eCRF.   
OUS centers should report SAEs immediat ely upon awareness of the event and 
completes the AE eCRF Serious Adverse Event section, which will then trigger an initial 
SAE notification to a pre- defined recipient list.  
The investigator should notify BIOTRONI K or its designee as  soon as possible 
concerning any subject death during the st udy in EDC.  The death should be reported 
on the Study Exit eCRF.  In addition, t he precipitating cause of death should be 
recorded on an Adverse Event eCRF, reflecting an outcome of death, once determined.  Documentation of the death ev ent should be sent to BIOT RONIK as soon as it is 
available, and should include the appropriate completed CRFs,  a death certificate and a 
copy of the notification of the death sent to the IRB/EC, as required.  If a death 
certificate is not available, a detailed statement (death report) signed by the investigator 
should be provided.   
The death report should include all of  the following, if available: 
 Date, time and place of death 
 Immediate cause of death 
 Circumstances surrounding the death 
 Relationship to the investigational st ent and/or any study-related procedures 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 69 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
It is the responsibility of eac h investigator to report all SAEs to the reviewing IRB/EC, 
according to national regulations and IRB/EC  requirements.  A copy of the IRB/EC 
report should be forwarded to the sponsor  or its authorized representative. 
Additionally, at OUS sites, SAEs will be reported to the com petent authorities in 
accordance with applicable regional/national r egulations.  BIOTRONIK or its authorized 
representative, and/or the in vestigator will r eport SAEs to the applicable regulatory 
agencies in accordance wit h national regulations. 
OUS Sites Primary contact for Serious Adverse Events: 
BIOFLOW–V Safety Team 
Harvard Clinical Research Institute 930-W Commonwealth Ave. Boston, MA 02215-1212  Tel:  +1 617 307–5200 Fax: +1 617 307–5656 HCRIBIOFLOW-VSAFETY@hcri.harvard.edu 
9.5. Reporting of Adverse Events 
Study sites are required to adhere to applic able US FDA regulations, as well as ISO 
requirements for EU sites, as well as local IRB/EC adverse event reporting.  In specific 
OUS regions, there may also be requirements for OUS invest igators to report specific 
adverse events directly to their compet ent authority or nati onal regulatory body. 
Table 9-1. Adverse Events Reporting 
Adverse Event Report in 
EDC 
 Report to 
IRB/EC Report to 
CA – OUS sites only 
Event resulting in death* Required Required CA-dependent 
Unanticipated adverse device effect Required Required CA-dependent 
Procedure and/or stent related 
adverse event Required IRB/EC-dependent CA-dependent 
Serious adverse event (not stent or 
procedure related) Required IRB/EC-dependent CA-dependent 
Other adverse events – not related** Required IRB/EC-dependent CA-dependent 
CA: Competent Authority; EC: Ethics Committee; IRB:  Institutional Review Board; OUS: Outside of 
United States 
* The cause of death to the extent avai lable should be reported as an adverse event, with the outcome reflected 
as death.  Reporting to EC in accordance with local requirements. 
** US sites only: reporting required through the 12-mont h follow-up visit or longer if required by the IRB/EC. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 70 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
9.5.1. Reporting Ad verse Device Effects 
All participating study sites should report adverse device effects (ADE) and serious 
adverse device effects (SADE) to BIOTRO NIK or its designee as soon as possible, 
preferably upon awareness of t he event (OUS sites), by completing an Adverse Event 
eCRF.   
At sites in the OUS or other participating c ountries where the Orsi ro stent is market-
released, these events must also be repo rted in addition to the product complaint 
management department of BIOTRONIK.  The re trievable part of the devices should be 
returned to BIOTRONIK for analysis.  If there is also a suspected relation to accessory 
material (guide wire, etc.) t he accessory material in quest ion should also be sent to 
BIOTRONIK for analysis. 
Complaint Management Department 
BIOTRONIK AG Ackerstrasse 6 8180 Bülach Switzerland cnf.vi@biotronik.com  Fax: +41 44 864 5181 
Investigational stents that are returned to the US will be sent to BIOTRONIK AG, 
Bülach, Switzerland, for analysis.  Those a nalyses will be trended (as appropriate) and 
reported to FDA as soon as  they are available.  
9.5.2. Reporting of Unanticipated Adver se Device Effects or Unanticipated 
Serious Adverse Device Effects 
If an adverse event occurs that the in vestigator believes may be a potential 
UADE/USADE, the site should immediately contact the sponsor or its authorized 
representative to determine repor ting requirements.  In additi on, when there is a reason 
to believe a device may have malfunctioned,  causing potential harm to a subject, the 
site should immediatel y notify the sponsor. 
The investigator shall submit  to BIOTRONIK and the review ing IRB/EC a report of any 
potential UADE occurring during the study as soon as possible, but in no event later 
than 10 calendar days after the investigator first learns of the effect in accordance with 
FDA regulations.  In the EU or other OU S countries, any potential USADE shall be 
reported according to national regulations.  All UADEs/USADEs must be documented 
by the investigator, including date of ons et, complete description of event, possible 
reason(s) for event, severity, duration, ac tions taken and outcome.  Copies of all 
supporting documents should be submitt ed concurrently with the AE eCRF 
documenting the UADE/ USADE. 
Subsequently, BIOTRONIK or its designee will submit a r eport to FDA (and any other 
applicable competent aut horities) and to all reviewing IRBs/ECs and participating 
investigators within 10 calendar days after the S ponsor first receives notice of the effect.  
The Sponsor or its designee will submit other  reports as required by the FDA and other 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 71 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
applicable regulatory agencies.  The final determination of an event being classified as 
an unanticipated event will be initially det ermined by HCRI, and confirmed by 
BIOTRONIK. 
 
9.6. Reporting of Study Endpoint Adverse Events 
Whenever a clinical event related to a study  endpoint is suspected or identified, all 
supporting source documents (i.e. progress notes, discharge summaries, catheterization lab reports, ECGs, lab result s, etc.) should be submitted according to 
CEC source documentation colle ction procedures as soon as they are available.  The 
source documentation required for each report ed event is listed in the CEC charter. 
  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 72 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
9.7. Reporting Responsibilities 
Table 9-2. Investigator Re porting Responsibilities 
ASAP: as soon as possible; EC: Ethics Committee; FDA: Food and Drug Administration; IDE: 
investigational device exemption; IR B: Institutional Review Board. 
* Reporting to IRB/EC only where required by local legal requirements. ** FDA requires 10 working days. 
  Type of Report Investigator Reporting Responsibilities 
Report 
Prepared 
For Reporting Timeframe 
FDA-Defined Reports 
Unanticipated adverse device 
effect Sponsor 
 IRB/EC* As soon as possible, upon awareness of the effect. 
Written:  within 10 calendar** days after the investigator first 
learns of the effect. 
Subject’s death Sponsor and 
IRB/EC* Written: as soon as possible and as required by reviewing 
IRB/EC, but not to exceed 10 days from date of site notification of subject death.  
Withdrawal of IRB/EC approval 
or other action on part of the IRB/EC that affects the study Sponsor Written : within 5 working days of IRB/EC decision. 
Progress reports IRB/EC* At regular intervals, but in no event less than yearly. 
Significant deviations from 
investigational plan Sponsor and 
IRB/EC* Emergency : ASAP but in no event later than 5 working 
days after deviation occurs to protect the life or physical 
well-being of a subject in an emergency. 
Non-emergency : prior approval by Sponsor and, if 
deviation may affect scientific soundness of the trial or the 
rights, safety or welfare of subject, also by the IRB/EC and FDA as an IDE supplement. 
Informed consent not obtained Sponsor and 
IRB/EC* Within 5 working days of use of the investigational device. 
Final report Sponsor and 
IRB/EC* Within 3 months after termination or completion of study or 
termination of site’s participation. 
Other Reports 
Adverse Events Sponsor and 
IRB/EC* In accordance with the protocol, applicable local 
regulations, and IRB/ EC requirements.   
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 73 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Table 9-3. Sponsor Reporting Responsibilities 
Type of Report Sponsor Reporting Responsibilities 
Report Prepared For Reporting Timeframe 
FDA-Defined Reports 
Unanticipated adverse device 
effects/unanticipated serious 
adverse device effects FDA, all reviewing 
IRBs/ECs*, participating 
investigators and appropriate CAs* Written : within 10 calendar** days 
from the time the sponsor first learns 
of the effect. 
Withdrawal of IRB/EC approval FDA, all reviewing 
IRBs/ECs*, participating 
investigators and appropriate CAs* Written : within 5 working days. 
Withdrawal of FDA approval Reviewing IRBs/ECs*, 
participating investigators 
and appropriate CAs* Written : within 5 working days. 
Device recall FDA, all reviewing 
IRBs/ECs*, participating 
investigators and appropriate CAs* Written : within 30 working days. 
Progress reports FDA, all reviewing 
IRBs/ECs*, participating 
investigators and appropriate CAs* At regular intervals, but in no event 
less than yearly. 
Current Investigator List FDA Names and addresses of 
participating investigators at 6-
month intervals (starting at 6 months after FDA approval). 
Informed consent not obtained FDA and appropriate CAs* Within 5 working days of notification. 
Study closure FDA, all reviewing 
IRBs/ECs*, participating 
investigators and appropriate CAs* Within 30 working days of 
completion or decision to terminate 
the study. 
Final report FDA, all reviewing 
IRBs/ECs*, participating 
investigators and appropriate CAs* Within 6 months of study closure. 
Other Reports 
Periodic SAE / ADE summaries Reviewing EC* and 
appropriate CAs* In accordance with EU regulations 
or other OUS national regulations, 
and/or local legal requirements, or upon request.   
CA: Competent Authority; EC: Ethics Committ ee; FDA: Food and Drug Administration;  
IRB: Institutional Review Board *EC and CA reporting to the extent  required by national, local la ws and EC-specific requirements. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 74 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
**FDA requires 10 working days. 
10. DATA HANDLING AND RECORD KEEPING 
The investigator is required to prepare and maintain adequate and accurate case 
histories designed to record all observa tions and other data pertinent to the 
investigation on each individual treated with the investigationa l product or entered as a 
control in the investigation. 
10.1. Electronic Data Capture 
MedNet Solutions Incorporat ed is a privately-held company  that specializes in web-
based clinical database and da ta management technology. MedNet will partner with 
BIOTRONIK in the developmen t, implementation, and on-goi ng support of a system for 
EDC of clinical trial data for the study.  MedNet may host the database utilized for the 
EDC system. This system will be 21 CFR Part  11 compliant and wi ll be the conduit for 
the electronic case report form (eCRF) data ent ry, data validation, and access to real-
time configured functions, tool s, and reports for BIOTRONIK,  specified study sites and 
any other parties authorized by BIOTRONIK. 
10.2. Electronic Case Report Form Completion 
An electronic data capture (EDC) system will be built for the study.  The EDC system 
will include electronic case report forms (e CRFs) designed to capture study information, 
which are completed by trained site staff.   
eCRFs documenting SAEs, U(S)ADEs, device failures and device malfunctions, should 
be submitted via the EDC system as soon as possible, preferably within 24 hours after 
the investigator becomes aware of the event.   
All other eCRFs should be completed in a ti mely manner, preferably within 5-10 days of 
the subject’s enrollmen t or follow-up visit.  
All angiographic media should be  prepared and sent to the angiographic core laboratory 
preferably within 7 working days of data collection. 
All collected study data will be made available (and  sent in the appropriate format) to 
the sponsor, if requested, after the study has reached its primary endpoint at 12 months 
post-procedure. 
10.3. Investigator Records 
Investigators are required to maintain on file the following accurate, complete and 
current records relating to this study: 
 All correspondence relating to the study  with another investigator, an IRB/EC, 
BIOTRONIK, a monitor, the FDA (e.g., a le tter sent from the in vestigator to the 
IRB/EC), or any other regulatory agency. 
 All clinical forms and do cumentation, including: 
o A copy of the signed subject consent form 
o Date and time of exposure to investigational stent 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 75 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
o All procedure and follow-up report fo rms, including supporting documents 
o Records of any adverse event, including supporting documentation 
o Records pertaining to subject deaths during the study 
o Documentation and rationale for any dev iations from the clinical protocol 
o Any other records required by BIOTRONIK 
10.4. Sponsor Records 
BIOTRONIK will maintain the following records: 
 All correspondence pertaining to study with  the investigator(s), IRB/EC and FDA 
(or any other competent authority) 
 Investigational stent shipm ent and inventory reconciliati on reports (US sites only) 
 Investigator agreements, financial di sclosures and current curriculum vitae 
 Name and address of each investigator and each IRB/EC involved with the study 
 Adverse events and complaints 
 Adverse device effects (whet her anticipated or unanticipated) 
 Completed eCRFs 
 Confirmation of completed subject informed consent forms 
 Clinical Investigational Pl an and report of prior studies 
 Screening visit reports 
 Monitoring reports 
 Clinical progress reports 
 Any other records that FDA requires to be maintained by regulation or by specific 
requirement for a category of investi gation or a particular investigation. 
 Records pertaining to DMC and CEC activities. 
 Statement of the extent to which the good manufacturing practi ce regulation Part 
21 CFR 820 will be followed in  manufacturing the stent 
11. STUDY COMMITTEES 
11.1. Steering Committee 
The steering committee is composed of the US  and OUS study principal investigators, 
the steering committee chairman and experts representing the field of cardiology, 
interventional radiology and statistics.  The steering committee participates in sponsor-
requested meetings to review study progr ess and conduct, and to provide feedback to 
the sponsor on an ad hoc basis. Steering committee membership  will be decided by the 
sponsor. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 76 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
11.2. Data Monitoring Committee 
An independent Data Monitoring Committ ee (DMC) will have responsibility for 
monitoring safety and efficacy aspects of t he study.  Its conduct will be governed by a 
written charter describing its rules of operat ion and responsibilities.  It will be composed 
of at least four members with experience in clinical trial re search: three physicians from 
the fields of cardiology and interventional cardiology and one biostatistician who are not 
directly involved in the conduct of the trial. 
The DMC will review aggregate and individual subject data related to safety, data 
integrity, and overall c onduct of the trial on a periodic basis, to be def ined at their first 
meeting prior to enrollment of  the first subject in the st udy.  The DMC will be unblinded 
to BIOFLOW-V treatment group assignment.   
The primary responsibility of the DMC will be to provide over sight on safety aspects of 
the study.  The DMC may make three primary types of reco mmendations to the steering 
committee and study Sponsor as a result  of its monitoring activities:  
 Continuing the study without changes;  
 Stopping the study for safety reasons; or, 
 Continuing the study with changes to its protocol or conduct. 
There is no planned formal interim efficacy analysis for the DMC to inspect.  The study 
will not be stopped for accumulating ev idence of benefit or futility.  
Any material changes to the study protocol  or conduct recommended by the DMC that 
affect the collection or evaluation of scientif ic evidence, or terms and conditions of the 
IDE approval, and which the sponsor desires to implement, will be subject to prior 
review and approval by the FDA. 
11.3. Clinical Events Committee 
The clinical events committee (CEC) for this study will consist of the standing members 
of the CEC who are not participants in t he study.  The CEC is charged with the 
development of specific criteria used for the categorization of clinic al events and clinical 
endpoints in the trial. 
Explicit rules outlining the minimum amount of  data required, and t he algorithm followed 
to classify study endpoint–related clinical  events will be establis hed and provided in a 
separate CEC charter and adjudication manual.  The CEC will then m eet regularly to 
review and adjudicate study  endpoint–related clinical ev ents in which the required 
minimum data are available.  The committee will also review and rule on all deaths that 
occur throughout the trial.  All members of the CEC will be blinded to the randomized 
treatment group of the s ubject and to the primary results of the trial. 
To ensure consistency and poolability of s ubjects across trials, the BIOFLOW-V CEC 
will perform re-adjudication to  validate the potential study  endpoint–related clinical 
events (TLR,  MI and cardiac deaths) o ccurring in the BIOFLO W-II and BIOFLOW-IV 
studies using the same criteria established for the BIOFLOW-V.  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 77 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
12. ETHICAL AND REGULATORY CONSIDERATIONS 
This study will be conducted in accordanc e with the principles  outlined in the 
Declaration of Helsinki and all local GCP requirements. 
12.1. Role of the Study Sponsor 
BIOTRONIK as the study sponsor, has the ov erall responsibility for the conduct of the 
study, including ensuring that  the study meets and is conducted within the regulatory 
requirements specified by each reviewing r egulatory authority.  In this study, the 
sponsor will have certain direct responsibil ities and may delegate other responsibilities 
to Harvard Clinical Research Institute ( HCRI) and/or other designees.  The sponsor, 
HCRI and/or other designees will ensure adherence to the sponsor general duties, 
selection of investigators, monitoring, su pplemental applications, maintaining records 
and submitting reports. 
12.2. General Duties 
BIOTRONIK’s general duties in clude submitting the application to appropriate regulatory 
authorities and obtaining over all regulatory approval. 
BIOTRONIK is responsible to obtain the appr oval from the com petent authority, if 
applicable, prior to any site initiation. BIOTRONIK will report  to the competent 
authorities any new information that may affect the safety of the subjects or the conduct 
of the clinical investigation, as applicable. 
The sponsor or its designees are responsible for ensuring informed consent is obtained, 
proper clinical site monitoring is perform ed, providing quality data that satisfy 
regulations, and informing study investigators of UADE/USADE and de viations from the 
protocol, as appropriate. 
As the designated data coordinating center , BIOTRONIK or its designee will prepare 
written reports and a final report as dire cted, and will coordinate  data collection and 
transfer with the angiography core  laboratory and other vendors. 
12.3. Subject Confidentiality 
Subject confidentiality will be maintained throughout the clinic al study in a way that 
assures that data can always be tracked back to  the source data.  For this purpose, a 
unique subject identification code (ID number and subject nam e code) will be used that 
allows identification of all data reported for each subject. 
Data relating to the study might be made availa ble to third parties (e.g., in case of an 
audit performed by regulatory aut horities) provided the data are treated as confidential 
and that the subject’s privacy is guaranteed. 
“Protected health information” will be treated and maintained in compliance with the 
Health Insurance Portability and Accountabili ty Act (HIPAA) of 1996 privacy rule, the 
directive 95/46/EC (European Directive fo r data protection law) and applicable local 
laws on the protection of individuals with r egard to the processing of personal data and 
on the free movement  of such data. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 78 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
The duration of storage time of  personal data at the invest igational sites will be in 
accordance with national regulations. 
12.4. Informed Consent and Institutiona l Review Board or Ethics Committee 
Prior to the subject's participation in the stud y, written informed consent is required from 
all subjects in accordance with their IRB/ EC.  Informed consent should be obtained in 
accordance with the FDA regulations (21CFR, Part 50), ISO 14155, ICH/GCP 
Guidelines, the Declaration of Helsinki and any other national or local requirements.  
The investigator is required to inform BIOT RONIK and the reviewing IRB/EC within five 
days if any subject has not appropriately consented to participate in the study.  
BIOTRONIK is then required to report any failu re to obtain subject consent to the FDA 
within five working days of lear ning of such an event.  In order  to assist with the consent 
process, BIOTRONIK wil l provide a subject consent template form to study sites as a 
basis for adaptation to local requirements and s ubmission to their IRB/ EC for approval. 
IRB/EC approval is required from  each institution prior to part icipation in this clinical 
study.  Subject enrollment may not begi n until the IRB/EC and BIOTRONIK have 
granted approval for the study site.  IRB/EC  approval is also required throughout the 
duration of this clinical study.  If IRB/EC  approval is withdrawn,  BIOTRONIK must be 
notified within 5 working days. 
12.5. Monitoring 
Qualified monitors representin g the sponsor will conduct on- site monitoring visits to 
ensure that all investigators conduct the st udy in compliance with the protocol and 
investigators’ agreements.  The site will receiv e notification prior to each monitoring visit 
during the course of the study.  It is expected that the inve stigator and/or sub-
investigator, research coordinator assigned to  the study, and other appropriately trained 
study staff will be availabl e on the day of the visit. 
The progress of the study  will be monitored by: 
 Ensuring completed eCRFs match sour ce documents, and resolution of any 
discrepancies.  Direct access to comple te source documents must be made 
available during monitoring visits for verification of eCRF data. 
 Periodic on-site visits and, if nec essary, remote monitoring of data. 
 Frequent telephone or ema il communications between the investigator and 
assigned study site monitors. 
12.5.1. Visits 
Periodic monitoring visits wil l be made in accordance with the approved monitoring plan 
throughout the clinical study to  ensure that the investigator ’s obligations are fulfilled and 
all applicable regulations and guidelines ar e being followed.  These visits will ensure 
that the facilities are still a cceptable, the protocol and investigational plan are being 
followed, the IRB/EC has been notified of approved prot ocol changes as required, 
complete records are being maintained, app ropriate and timely reports have been made 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 79 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
to the sponsor and the IRB/EC, device and device inventory are controlled, and the 
investigator is executin g all agreed-upon activities. 
The sponsor or its designees retain the right to remove either the investigator or the 
investigational site from the study for i ssues of non-compliance with the protocol or 
regulatory requirements.  BIOTRONIK or  its designee will perf orm the monitoring 
responsibilities according to its standard operati ng procedures. 
On one or more occasions, the study site ma y be inspected or audit ed by the sponsor, 
its designee, or applicable regulatory authoritie s.  The investigator will be informed in 
advance of this audit and is expected to allo w access to the original medical records 
and provide all reque sted information. 
A representative or designee of the sponsor may accompany the study site monitor to 
the site. 
12.6. Protocol Compliance 
The investigator is required to conduct the study in accordance with the signed 
investigator agreement and clinic al protocol.  The investi gator shall notify BIOTRONIK 
and the reviewing IRB/EC in wr iting, no later than 5 worki ng days after any significant 
deviation from the study plan, to protect the life or physical well-being of a subject in an 
emergency.  Except in such emergency, pr ior approval by BIOTRONIK is required for 
significant deviations from the study plan.   
BIOTRONIK categorizes instance s of protocol non-compliance as either violations or 
deviations. 
12.6.1. Protocol Violations 
Protocol violations are defin ed as instances where the protocol requirements and/or 
regulatory guidelines were not  followed and are generally more serious in nature.  
Protocol violations are considered to potent ially affect the scientific soundness of the 
study and/or the rights, safety  or welfare of subjects. 
Protocol violations incl ude, but are not limited to: 
 Failure to obtain informed consent 
 An unapproved (BIOTRONIK and IRB/ EC) investigator implanting an 
investigational stent for study purposes 
 Subject inclusion/exclusion violations and protocol r equirement violations that 
affect the primary endpoint s of the study design 
In some instances, compliance issues with the consent process may occur. The 
investigator should seek guidanc e from the site’s IRB/EC to ensure the subject received 
appropriate information to consider their parti cipation in the study.  The investigator is 
obligated to take any action the IRB/EC fe els is necessary, including subject removal 
from the study.   
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 80 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Deviations in the consent process for subjects  that the IRB/EC allows to continue in the 
study will be considered protocol violat ions in the analysis of study data. 
All violations will be reported to FDA in a ccordance with applicable regulatory timelines. 
The study site should report t he protocol violation to the reviewing IRB/EC and provide 
a copy of the notification to  BIOTRONIK.  The site shoul d also report the protocol 
violation to BIOTRONIK on the applicable CRF. 
12.6.2. Protocol Deviations 
Protocol deviations are defined as inst ances where protocol requirements are not 
followed in such a manner whereby data is unusable or unavailable.  Protocol 
deviations are less serious in nature and do not  require IRB/EC notification, as long as 
they do not have an effect on the rights, sa fety or welfare of the study subject. 
Protocol deviations incl ude, but are not limited to: 
 Procedure not performed within the allowed fo llow-up window 
 Required data not obtained 
 Follow-up procedure perform ed at an unapproved location 
The study site should report t he protocol deviation on the ap plicable CRF. Both protocol 
deviations and violations will be repor ted to FDA in progress reports. 
12.7. Device Accountability and Storage 
Tracking of the investigational product used in this study will be consistent with  
21 CFR Part 821 and ISO 14155:2011, and in accordance with location-specific 
requirements. 
If an Orsiro stent is opened, but not implanted,  it must be returned to the sponsor in 
accordance with the sponsor’s packaging and shipping instructions. 
Subject to availability, the sponsor will provide the site with replacement consignment 
inventory of the Orsiro stent.  Additionall y, the PI or designee  will ensure that an 
adequate supply of Orsiro stent s is on hand to support un interrupted enrollment of 
subjects in the study.  Orders for additional devices must originat e from the PI or 
designated study personnel.  Orders for additi onal devices will be fulfilled by delivery 
directly to the PI or to st udy personnel designated by the PI. 
Note: in the EU or other participating count ries where the Orsiro  stent is market-
released, specific investigational handling restrictions may not apply. 
12.7.1. Labeling 
The Orsiro stent and its asso ciated components will have a label that  will be visible on 
the pertinent shipping cart ons and storage containers.  T he required labels or manuals 
will bear the following information: 
 Name, model and lot number of the stent  
 Name and addresses of the ma nufacturer and distributor 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 81 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
 Labeling statement: “CAUTION - Investi gational Device.  Limited by United 
States Law to Investigational Use. ”  - applicable for US sites only 
 Quantity of contents 
 All relevant contraindications, hazar ds, adverse device effects, interfering 
substances or devices, warnings and precautions 
 Expiration date 
12.8. Supplemental Applications 
If required, the sponsor will subm it changes in the investigat ional plan to the appropriate 
regulatory authorities for approv al and investigators to obtain IRB/EC approval to 
implement the changes. 
12.9. Other Institutions and Physicians 
The study is not transferable to other inst itutions attended by the investigator unless 
prior approval is obtained from BIOTRONIK,  the governing competent authority (if 
applicable) and the appropriate IR B/EC.   Additional sites ma y be included in this study, 
but may not exceed the limits set by t he FDA.  Only approved investigators are 
authorized to participate in the study; however , there are certain si tuations where an 
investigator might not be imm ediately available to  provide the necessary medical care 
for a subject with an investigational stent (e.g. when a subject goes to the emergency 
room for medical treatment).   In any such situations, t he IRB/EC and the investigator 
must continue to provide oversight for that  subject’s medical care and rights as a 
research subject. BIOTRONIK wi ll ensure that the necessary support is available to any 
physician providing immediate care for a subj ect in order to answer questions about the 
investigational stent and prov ide guidance in collecting the necessary documentation 
required for the clinical study . Documentation obtained will  then be forwarded to the 
approved investigator for review and signatur e before this data may be used to support 
the endpoints of the study. 
12.10. Subject Insurance 
Subjects who participate in this study will be insured against study related injury 
according to local regulatory requirements.  
BIOTRONIK has issued clinical trial liability insurance with appropriate coverage for the 
continuation of the entire study. 
  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 82 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
13. RISK ANALYSIS 
13.1. Potential Risks 
Risks associated with the use of the Orsiro  stent include those seen with currently 
marketed drug eluting stents. Possible adve rse events associated with PTCA and 
Orsiro stent placement in clude but are not limited to: 
 Cardiac events: Myocardial infarction or ischemia, abrupt closure of coronary 
artery, restenosis of treated artery (gr eater than 50% obstruction), cardiogenic 
shock, angina, tamponade, perforation or di ssection of coronary artery or aorta, 
cardiac perforation, emergency cardiac su rgery, pericardial effusion, aneurysm 
formation 
 Arrhythmic events: Ventricular tachycardia, ventricular fibrillation, atrial fibrillation, 
bradycardia 
 Stent system events: Failure to deliver st ent to intended site, stent dislodgement 
from the delivery system, stent misp lacement, stent deformation, stent 
embolization, stent thrombos is or occlusion, stent fracture, stent migration, 
inadequate apposition or compression of stent/s , inflation difficulties, rupture or 
pinhole of the delivery system  balloon, deflation difficultie s, withdrawal difficulties, 
embolization of catheter material 
 Respiratory events: Acute pulmonary edem a, congestive heart failure, respiratory 
insufficiency or failure 
 Vascular events: Access site hemat oma, hypotension/ hypertension, 
pseudoaneurysm, arteriovenous fistula fo rmation, retroperitoneal hematoma, 
vessel dissection or perforation, restenosis , thrombosis or occlusion, vasospasm, 
peripheral ischemia, dissection, distal em bolization (air, tissue debris, thrombus) 
 Neurologic events: Permanent  (stroke) or reversible (TIA) neurologic event, 
femoral nerve injury, peripheral nerve injury  
 Bleeding events: Access site bleeding  or hemorrhage, hemorrhage requiring 
transfusion or other treatment 
 Allergic reactions to contrast media,  antiplatelets, antic oagulants, amorphous 
silicon carbide, L-605 cobalt chromium a lloy (including the major elements cobalt, 
chromium, tungsten and nickel), PLLA po lymer matrix, Sirolimus or Sirolimus 
derivatives. 
 Infection and sepsis 
 Death 
Potential adverse events related to Sirolimus  (following oral administration) include but 
are not limited to: 
 Abnormal liver function tests  
 Anemia  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 83 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
 Arthralgia  
 Diarrhea  
 Hypercholesterolemia 
 Hypersensitivity, including anaphyl actic/anaphylactoid type reactions  
 Hypertriglyceridemia 
 Hypokalemia 
 Infections 
 Interstitial lung disease 
 Leukopenia 
 Lymphoma and other malignancies 
 Thrombocytopenia 
 Renal events: renal in sufficiency/renal failure 
The potential risks related to the Xience stent and Everolimus may be found in the 
current product Instructions for Use.. 
13.2. Potential Benefits 
There are no guaranteed b enefits from participation in this study; however, it is possible 
that treatment with the Orsiro stent may reduce the potential fo r late and very late stent 
thrombosis, a complication associated with the occurrence of MI and death. 
Moreover, in this clinical investigation all subjects will have a more intense medical 
follow-up compared with standard practice, wh ich can be beneficial to the long-term 
clinical outcome of study participants. 
Additionally, information gained from the conduct of this study may be of benefit to 
others with the same medical condition.  Effi cacy and safety data collected on the Orsiro 
stent will contribute to expand  the knowledge of use of drug eluting stents in 
interventional cardiology. 
13.3. Risk Mitigation 
All subjects will receive chronic daily antiplate let therapy for a mini mum of 6 months and 
for the recommended 12 months post-procedur e (per American He art Association 
Scientific Advisory guidelines ) to reduce risk of stent thro mbosis and prov ide extended 
protection for potentially dela yed endothelialization.  Subj ects will also receive a 
minimum of 75 mg aspirin daily, to be taken indefinitely.  
To minimize potential risks associated with st udy procedures, all efforts will be made to 
select investigators who are experienced and skilled in using interventional devices.  
Additionally, at study initia tion all investigators will be  trained regarding the IFU and 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 84 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
protocol.  All enrolling invest igators will be instructed on appr opriate subject selection in 
an effort to minimize the risk of recruiting ineligible  subjects to the study. 
Subjects will be monitored clos ely throughout the trial durati on and will be evaluated at 
pre-specified time points to assess their clinical status. 
An independent data monitoring committee will  monitor safety of study participants 
throughout the trial (see Section 0). 
For participating OUS subjects, the Orsiro stent is CE-marked and routinely being used 
in Europe.  The safety and efficacy profile is known.  Moreover, OUS subjects in 
participating countries with ma rket approval, may be treated wi th this device regardless 
of their participation in the st udy or not, if the physician de termines the device to be the 
best treatment option for that subject. 
13.4. Sex and Gender in Coronary Heart Disease 
Coronary heart disease (CHD) is recognized as the single leading cause of death 
among both American men and women.52,53  Although CHD has historically been 
perceived as affecting more men, heart dis ease killed 26% of both the men and women 
who died in 2006 (http://www.cdc.gov/nchs).  Th is impact of CHD on women highlights 
the need to analyze both disease trends and tr eatment patterns in women to further 
understand if sex-specific outc omes exist in clinical eval uations of investigational 
devices. 
Prevalence 
The total prevalence of CHD among U.S adult men is 8.3% an d is 6.1% for US adult 
women.  Among women, CHD  prevalence is highest among non-Hispanic blacks at 
7.6%.  More specifically, the overall preval ence of MI among US adult men is 4.3% and 
is 2.2% for US adult wo men, with the highest prev alence among women in non-
Hispanic blacks.53 
Diagnosis and Treatment Patterns 
The increasing impact of CHD in women is compounded by the diagnosis and treatment 
patterns of women with heart disease.  Acco rding to the American Heart Association, 
64% of women who die suddenly of CHD hav e no previous symptoms, which greatly 
impacts the evaluation and appropriate managem ent of CHD, leading to potential sex-
based clinical outcomes.  Likewise, the Am erican Heart Association reports that 
following a first MI in subjects over 45 y ears of age, a greater proportion of women are 
likely to die, develop recurrent MI, fatal CHD,  heart failure or stroke.  Because of the 
increased association of asymptomatic, fa tal CHD, along with the increased risk for 
further, fatal CHD associated with a first MI , women have a lower likelihood of receiving 
treatment for their heart disease.  A recent  Mayo Clinic study found that women were 
55% less likely than men to participate in cardiac rehabilita tion following an MI.54  
Likewise, a study at Massachusetts Gener al Hospital in 2005 found that women with 
both diabetes and CHD were significantly less likely to be prescribed aspirin than men 
or when treated for hypertension or hyperlipidemia, were significantly less likely to have 
blood pressure levels < 130/80 mmHg or LDL cholesterol levels < 100 mg/dl.55 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 85 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Proportions and Clinical Outcome Differ ences for Women in Past Studies 
A total of five PMA approvals for coronary, bare-metal stents were found in the past 10 
years.56,57,58,59,60  Each of the IDE clinical studies conducted to support the PMA 
application had a similar subject population as  that proposed for this study.  The 
approximate average proportion of wo men enrolled in the five clinical studies was 30%.  
A gender analysis was provided in four of the safety summaries, with each noting no difference in clinical outcomes for t he investigational device based on gender. 
Clinical Study Enrollment Plan for Women 
Historically, women have been under-represent ed or excluded from enrollment in 
clinical studies, which has led to a lack of information regarding the risks and benefits of 
many medical treatments.  For the purposes of this st udy, an enrollment goal of 30% 
women will be targeted to match the propor tion of women in past coronary clinical 
studies.  In order to enhance enr ollment of women into this IDE study, the following will 
occur: 
 Investigational sites in more densely populated, urban areas w ill be targeted to 
where recruitment of women ca n be more easily facilitated 
 Women physicians will be tar geted as enrolling investigators 
 Screening logs will be periodically revi ewed for screen failures to identify reasons 
for non-enrollment into the study” 
14. USE OF INFORMATION AND PUBLICATION 
BIOTRONIK intends to publish the results of this clinical investigation.  BIOTRONIK 
reserves the right to include the report of th is clinical investigation in any regulatory 
documentation or submission or in any inform ational materials prepared for the medical 
profession.  The ownership of the data s hall at all times be held by BIOTRONIK.  
BIOTRONIK and the Steering Committee reserve t he right for the firs t publication of the 
clinical investigation results.   BIOTRONIK agrees that inve stigators shall be permitted to 
present at symposia, national  or regional professional meetings, and to publish in 
journals, theses or dissertations, or ot herwise of their own choosing, methods and 
results of the clinical investi gation after the first publication.  Any prior publication in any 
way or form is not permitted, without approval by BIOTRONIK.  
Institution and Investigator rese rve the right to publish the re sults of data obtained solely 
at their investigational site for the study.  Before publishing, however, the institution and 
Principal Investigator shall submit copies of any manuscript proposed for publication to 
BIOTRONIK for review at least 30 days in  advance of submissi on for publication or 
presentation to a publisher or other third party.  The Study National Principal 
Investigators and/or Study St eering Committee reserve the ri ght to review and approve 
all manuscripts prior to publication.  The Sponsor reserves the right to delete any 
confidential information or other proprieta ry information (including trade secrets and 
patent protected materials) that is being utilized and i nappropriately released, and to 
provide input from other investigators in the st udy regarding the content and 
conclusions of the publicati on or presentation.  In addi tion, the Sponsor may extend 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 86 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
such review period for another 90 days, if  deemed necessary, but  will not unreasonably 
delay review and comment. 
15. PREMATURE TERMINATION OF THE STUDY 
No formal statistical rule for early termination of the trial due to insufficient effectiveness 
or safety issues has been defined.  Howe ver the DMC may define rules by which an 
early termination may be recommended. 
BIOTRONIK reserves the right to discontinue t he clinical trial at any stage, with suitable 
written notice to the investigat or.  Possible reason(s) may in clude but are not limited to: 
 An unanticipated adverse device effect  occurs and it presents an unreasonable 
risk to subjects. 
 The Data Monitoring Committee or Steering Committee makes a 
recommendation for the early te rmination of the trial. 
 Further product development is cancelled. 
Should discontinuation of the tr ial occur, the investigator s hall return all clinical trial 
materials (including devices) to the spons or, and provide a written statement to the 
IRB/EC explaining reasons  for premature termination .   In the event of a premature 
termination of the clinical investigation enr olled subjects will be followed up as per the 
institution’s standard of care.   
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 87 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
16. APPENDIX A: ABBREVIATIONS AND ACRONYMS 
Abbreviation/Acronym Complete Term 
ACT activated clotting time 
ADE adverse device effect 
AE adverse event 
AMI acute myocardial infarction 
ARC Academic Research Consortium 
atm atmosphere 
BMS bare metal stent 
CABG coronary artery bypass graft 
CAD coronary artery disease 
CBC complete blood count 
CCSC Canadian Cardiovascular Society Classification 
CEC clinical events committee 
CIP clinical investigational plan 
CK creatine kinase 
CKMB creatine kinase myoglobin band 
cm centimeter 
Co-Cr cobalt-chromium 
CT computed tomography 
CRO clinical research organization 
DAPT dual antiplatelet therapy 
DES drug eluting stent 
dl deciliter 
DMC data monitoring committee 
EC Ethics Committee 
ECG electrocardiogram 
eCRF electronic case report form 
EDC electronic data capture 
EES everolimus eluting stent 
EU European Union 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 88 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Abbreviation/Acronym Complete Term 
ESC European Society of Cardiology 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
GPIIb/IIIa glycoprotein IIb/IIIa 
GUSTO Global Use of Strategies to Open Occluded Coronary 
Arteries 
h hour 
HbA1c hemoglobin A1c 
HIPAA Health Insurance Port ability and Accountability Act 
IDE investigational device exemption 
IFU Instructions for Use 
IRB Institutional Review Board 
ISA incomplete strut apposition 
ITT intent-to-treat 
IVUS intravascular ultrasound 
L liter 
LAD left anterior descending 
LBBB left bundle branch block 
LCX left circumflex 
LVEF left ventricular ejection fraction 
MACE major adverse cardiac events 
µg microgram 
mg milligram 
MI myocardial infarction 
mm millimeter 
mmol millimole 
MOP manual of operating procedures 
MRI magnetic resonance imaging 
mTOR mammalian target of rapamycin 
OCT optical coherence tomography 
OpenBUGS OpenBUGS software for Bayesian analyses 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 89 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
 
  Abbreviation/Acronym Complete Term 
OUS Outside the United States 
PCI percutaneous coronary artery intervention 
PI principal investigator 
PK pharmacokinetic 
PLLA poly-L-lactic acid 
PP per-protocol 
PTCA percutaneous transluminal coronary angioplasty 
QCA quantitative coronary angiography 
RCT randomized controlled trial 
RVD reference vessel diameter 
SAE serious adverse event 
SAP Statistical analysis plan 
SAS Statistical Analysis Software 
SES sirolimus eluting stent 
SESS sirolimus eluting stent system 
STEMI ST elevation myocardial infarction 
TIA transient ischemic attack 
TIMI thrombolysis in myocardial infarction 
TLF target lesion failure 
TLR target lesion revascularization 
TVF target vessel failure 
TVR target vessel revascularization 
UADE unanticipated adverse device effect 
URL upper range limit 
USADE unanticipated serious adverse device effect 
WH workhorse 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 90 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
17. APPENDIX B: DEFINITIONS 
ACUTE CLOSURE 
Occurrence of new (during t he procedure) severely reduced flow (TIMI grade 0–1) 
within the target vessel that persists and requi res rescue by stenting or other treatment, 
or results in myocardial infarction or death.   Abrupt closure requires proven association 
with a mechanical dissection of  the treatment site or in strumented vessel, coronary 
thrombus, or severe spasm. Abrupt cl osure does not mean “no reflow” (due to 
microvascular flow limitation), in which the epicardial artery is patent but had reduced 
flow.  Abrupt closure also does not mean tr ansient closure with reduced flow in which 
the index treatment application does reve rse the closure. 
Subacute Closure : Abrupt closure that occurs afte r procedure is completed (and subject 
left the catheterization l aboratory) and before the 1-m onth follow-up evaluation. 
Threatened Acute Closure : Grade-B dissection and 50% diameter stenosis or any 
dissection of grade C or higher. 
ACUTE GAIN 
Immediate dimensional change in minimal luminal diamet er (mm) that occurred after the 
final post-dilatation as compared with the mi nimal luminal diameter at baseline and 
measured by quantitative cor onary angiography from the av erage of two orthogonal 
views. 
ADVERSE DEVICE EFFECT (ADE) 
An adverse device effect (ADE) is a device-related adverse event, i.e., any adverse 
event for which a causal relationship betw een the device and the event is at least a 
reasonable possibility (the relationship cannot be excluded).  Note that this definition 
includes adverse events resulting from insu fficient or inadequate instructions for use, 
deployment, implantation, installation or operation, or any malfunction of the 
investigational medical device, as well as any event resultin g from user error or from 
intentional misuse of the in vestigational medical device. 
ADVERSE EVENT 
An adverse event is defined as any untoward medical o ccurrence, unintended disease 
or injury, or untoward clinical sign (includi ng abnormal laboratory findi ng) in clinical trial 
subjects, whether or not related to the investigational medical device. 
NOTE 1:  This definition includes events rela ted to the investigational medical 
device or the comparator. 
NOTE 2:  This definition includes events re lated to the procedures involved. 
NOTE 3:  abnormal laboratory findi ngs will be considered AEs, only if determined 
by the investigator to be clinically significant . 
  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 91 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
ANTICIPATED ADVERSE EVENT 
Any undesirable experience (sign, symptom, ill ness, abnormal laboratory value or other 
medical event) occurring to a subject, whet her or not considered related to the 
investigational product(s) or drug regimen prescribed as part of  the clinical protocol, pre-
defined in the clinical protocol and/or Instructions for Use, t hat is identified or worsens 
during a clinical study. 
BLEEDING COMPLICATION 
According to the GUSTO (Global Use of  Strategies to Open Occluded Coronary 
Arteries) classification of severe , moderate and mild bleeding events: 
Severe or Life-Threatening : Intracranial hemorrhage or  bleeding that causes 
hemodynamic compromise and requires intervention. 
Moderate : Bleeding that requires bl ood transfusion but does not  result in hemodynamic 
compromise. 
Mild: Bleeding that does not meet criteria for either modera te or severe bleeding. 
BRAUNWALD CLASSIFICATION OF UNSTABLE ANGINA 
Severity 
Class 1 : New onset of severe or accelerated angina.  Patients with new onset (< two 
months in duration) exertion al angina pectoris that is severe or frequent (> three 
episodes/day) or patients with chronic stab le angina who develop accelerated angina 
(i.e., angina distinctly more frequent, severe, longer in duration or precipated by 
distinctly less exertion than previously) but who have not ex perienced pain at  rest during 
the preceding months. 
Class 2 : Angina at rest, subacute.  Patients with one or more episodes of angina at rest 
during the preceding m onth but not within t he preceding 48 hours. 
Class 3: Angina at rest, acute.   Patients with one or more episodes of angina at rest 
within the preceding 48 hours. 
Clinical Circumstances in Whic h Unstable Angina Occurs 
Class A : Secondary unstable angina.  Patients in whom unstable angina develops 
secondary to a clearly identified condition extr insic to the coronary vascular bed that has 
intensified myocardial ischemia.  Such conditions reduce  myocardial oxygen supply or 
increase myocardial oxygen demand and include anemia, fever, infection, hypotension, 
uncontrolled hypertension, tachyarrhythmia, unusual emotional stre ss, thyrotoxicosis 
and hypoxemia secondary to respiratory failure. 
Class B : Primary unstable angina.  Patients who develop unstable angina pectoris in the 
absence of an extra-cardiac condition that has intensified ischemia, as in Class A. 
Class C : Post-infarction unstable angina.  Pati ent who develop unsta ble angina within 
the first two weeks after a documen ted acute myocardial infarction. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 92 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
CANADIAN CARDIOVASCULAR SOCIETY CLASSIFICATION (CCSC) OF 
ANGINA1,2 
Class I : Ordinary physical activity does not cause angina, such as walking and climbing 
stairs.  Angina with strenuous or rapid or prolonged exertion at work or recreation. 
Class II : Slight limitation of ordinary activity .  Angina upon walking or climbing stairs 
rapidly, walking uphill, walking or stair climbing after meals,  or in cold or wind, or under 
emotional stress, or only duri ng the first hours after awakening.  Angina if walking more 
than two blocks on the level and climbing more  than one flight of or dinary stairs at a 
normal pace and in normal conditions. 
Class III : Marked limitations of ordinary physical ac tivity.  Walking one to two blocks on 
the level and climbing one fli ght of stairs in normal conditions and at a normal pace. 
Class IV : Inability to carry on any physical activi ty without discomfort.  Angina syndrome 
may be present at rest. 
CEREBROVASCULAR ACCIDENT or STROKE 
Cerebrovascular accident is def ined as the occurrence of cerebral infarction (ischemic 
stroke) or intracerebral hemorrhage an d subarachnoid hemorrhage (hemorrhagic 
stroke).  Stroke is defined as sudden onset  of vertigo, numbness, dysphasia, weakness, 
visual field defects, dysarthria  or other focal neurological def icits due to vascular lesions 
of the brain such as hemorrhage, embolism,  thrombosis or rupt uring aneurysm that 
either: 
1. Persists > 24 hours or resu lts in death in < 24 hours, or 
2. Persists < 24 hours duration if the following treatments were used: 
a. Pharmacologic, i.e. throm bolytic drug administration, or 
b. Non-pharmacologic, i.e. neurointerv entional procedure (e.g. intracranial 
angioplasty) 
3. Persists < 24 hours but has neuro-radiol ogical (MRI or CT) diagnostic changes 
suggestive of acute tissue injury. 
CLINICALLY DRIVEN TARGET LESION REVASCULARIZATION (TLR) 
Revascularization at the target lesion associat ed with positive functional ischemia study 
or ischemic symptoms and an angiographic minimal lum en diameter stenosis 50% by 
QCA, or revascularization of a tar get lesion with diam eter stenosis 70% by QCA 
without either angina or a positive functional study. 
                                                 
1 Campeau L. The Canadian Cardiovascular Society gr ading of angina pectoris revisited 30 years later. 
Can J Cardiol 2002;18:371–379. 
2 Campeau L. Letter: Grading of angina pectoris. Circulation  1976;54: 522–523. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 93 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
CLINICALLY-DRIVEN TARGET VESS EL REVASCULARIZATION (TVR) 
Revascularization in the target vessel associ ated with positive functional ischemia study 
or ischemic symptoms and an angiographi c minimal lumen diameter stenosis 50% by 
QCA, or revascularization of a ta rget vessel with di ameter stenosis 70% by QCA 
without either angina or a positive functional study. 
DE NOVO  LESION 
A native coronary artery lesi on not previously treated. 
DEATHS 
All deaths are considered cardiac unle ss an unequivocal non-cardiac cause can be 
established.  Specifically, any unexpecte d death even in subjects with coexisting 
potentially fatal non-cardiac disease (e.g., c ancer, infection) should be classified as 
cardiac. 
Cardiac Death : Death due to immediate cardiac caus e (e.g., myocardial infarction, low-
output failure, fatal arrhythmia).  Unwitnes sed death and death of unknown cause will 
be classified as cardiac death.  This inclu des all procedure-related deaths, including 
those related to concomitant treatment. 
Vascular Death : Death due to cerebrovascular diseas e, pulmonary embo lism, ruptured 
aortic aneurysm, dissecting aneurysm  or other vascular cause. 
Non-Cardiovascular Death : Death not covered by the abov e definitions, including death 
due to infection, sepsis, pulmonary c auses, accident, suicide or trauma. 
DEVICE SUCCESS 
Attainment of < 30% residual st enosis of the target lesion us ing the assigned study stent 
only. 
Note: Post-dilatation is allow ed to achieve device success. 
DISSECTION, NHLBI (National Hear t, Lung, and Blood Institute) 
CLASSIFICATION3 
Grade A : Small radiolucent area within vessel lumen disappearing with passage of 
contrast material. 
Grade B : Appearance of contrast m edium parallel to vessel lumen disappearing within a 
few cardiac cycles. 
Grade C : Dissection protruding outside vessel lumen persisting after passage of 
contrast material. 
Grade D : Spiral-shaped filling defect wit h or without delayed run-o ff of contrast material 
in antegrade flow. 
                                                 
3 Detre K, Holubkov R, Kelsey S et al. One-year follow-up results of the 1985–1986 National Heart, Lung, 
and Blood Institute’s percutaneous translum inal coronary angioplasty registry. Circulation  1989;80:421–
428. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 94 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Grade E : Persistent luminal filling defect with de layed run-off of contrast material in 
distal lumen. 
Grade F : Filling defect accompanied by total coronary occlusion. 
DISTAL EMBOLIZATION 
New abrupt cut-off or filling defec t distal to the treated lesion. 
EMERGENT BYPASS SURGERY 
Coronary bypass surgery performed on an urgent  or emergent basis for severe vessel 
dissection or closure, or  treatment failure resulting in new ischemia. 
IN-SEGMENT MEASUREMENT 
Measurements either within st ented segment or within 5 mm pr oximal and distal to stent 
edges. 
IN-STENT MEASUREMENT 
Measurements within boundar ies of the stent. 
INTRACORONARY THROMBUS 
Presence of a filling defect wit hin lumen, surrounded by contrast material seen in 
multiple projections in absence of calcium wit hin the filling defect, or persistence of 
contrast material within lumen, or a visi ble embolization of intraluminal material 
downstream. 
LATE LOSS INDEX 
Ratio of late loss to acute gain. 
LATE LUMEN/LUMINAL LOSS 
Difference between post-procedure minimal lumen diameter and fo llow-up angiography 
minimal lumen diameter. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 95 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
LESION CLASS (American College of Ca rdiology/American Heart Association 
Class)4 
Type A : Minimally complex, discrete (length < 10 mm), concentric, readily accessible, 
non-angulated segment (< 45°), smooth contour, little or no calcification, less than 
totally occlusive, not ostial in location,  no major side branch involvement, absence of 
thrombus. 
Type B : Moderately complex, tubular (length 10–20 mm), eccentric, moderate tortuosity 
of proximal segment, moderat ely angulated segment (> 45°, < 90°), irregular contour, 
moderate or heavy calcification,  total occlusions < 3 months old, ostial in location, 
bifurcation lesions requiring double guide wires, some thrombus present. 
 Type B1 : one adverse characteristic. 
Type B2 : two or more adverse characteristics. 
Type C : Severely complex, diffuse (length > 20 mm), excessive tort uosity of proximal 
segment, extremely angulated segments > 90°, total occlusions > 3 months old and/or 
bridging collaterals, inability to protect major side branches, degenerated vein grafts 
with friable lesions . 
LESION SUCCESS 
Attainment of < 30% residual stenosis of target lesion using any percutaneous method. 
MAJOR ADVERSE CARDIAC EVENTS (MACE) 
All-cause death, myocardial infarction (Q-wav e or non–Q-wave), any clinically-driven 
target lesion revascularization. 
MINIMAL LUMINAL DIAMETER 
Average of two orthogonal views (when possible)  of the narrowest point within the area 
of assessment – in lesion,  in stent or in segment.  Visually estimated during 
angiography by the investigator and measur ed during QCA by the angiographic core 
laboratory. 
  
                                                 
4 Smith SC Jr, Dove JT, Jacobs AK et al. ACC/AHA guidelines of percutaneous coronary interventions 
(revision of the 1993 PTCA guidelines) –Executive summary. A report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 
guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001;37:2215–2239. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 96 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
MYOCARDIAL INFARCTION – PROTOCOL DEFINITION5 
I. PCI (PERCUTANEOUS CORONARY INTERVENTION) Ia. Baseline Biomarkers of Myocardial Damage  
Periprocedural < 48 hours post PCI 
A.  Baseline CKMB and Troponin < 1*URL  
Appropriate cardiac enzyme data: 
a1. Confirmed by :  
- CKMB > 3*URL or  
- in the absence of CKMB, Troponin > 3*URL or 
- in the absence of CKMB and Troponin: CEC decision upon clinical scenario 
B.  Baseline CKMB or Troponin > 1*URL  
Appropriate cardiac enzyme data: 
b1. Confirmed by :  
- A rise in CKMB   50% above the previous level and > 3* URL or 
- In absence of CKMB, a rise in Troponin  50% above the previous level and > 
3*URL. 
- in the absence of CKMB and Troponin: CEC decision upon clinical scenario 
 AND 
b2. Evidence that cardiac biomarker values  were decreasing (e.g., two samples at 
least 4 hours apart) prior to the suspected MI.  
C.  New pathologic q waves in  2 contiguous ECG leads 
URL = upper range limit, defined as 99th percentile of normal reference range 
 
Ib. If Baseline Biomarkers of Myocardial  Damage: CK and/or CKMB > 1*URL or 
acute MI in progress  
Myocardial infarction, re-infarction (extension) < 48 hours post PCI 
A. If CK (or CKMB) from index MI has not yet reached its maximum level: 
- Recurrent thoracic chest pain or ischemia equivalent > 20 minutes (or new ECG 
changes consistent with MI)  
                                                 
5 Adapted from Vranckx P, Cutlip DE, Mehran R, Kint  PP, Silber S, Windecker S, Serruys PW. Myocardial 
infarction adjudication in contemporary all-comer st ent trials: Balancing sensitivity and specificity. 
Addendum to the historical MI definitions used in stent studies. EuroIntervention  2010;5:871–874. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 97 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
AND 
- Appropriate cardiac enzyme data: 
- A rise in CK within 24 hours of the index event > 2*URL (confirmed by either 
CKMB or Troponin > 1*URL) and  50% above the previous level or 
- In absence of CK: a (post PCI) rise in CKMB within 24 hours of the index event > 
3*URL and  50% above the previous level 
or 
- In absence of CK and CKMB: a (post PCI) rise of Troponin within 24 hours of the 
index event > 3*URL and  50% above the previous level.  
B. If elevated CK (or CKMB) following the index MI has peaked AND CK level has returned 
< URL then any new rise in: 
- CK > 2*URL(confirmed by either CKMB > URL or Troponin > URL) or 
- in the absence of CK: CKMB > 3*URL or 
- in the absence of CK and CKMB, Troponin > 3*URL 
C. If CK (or CKMB) following the index MI has peaked AND CK level has NOT returned to < 
URL: 
- A rise in CK  50% above the previous level and > 2 URL confirmed by either CKMB 
> URL or Troponin > URL or 
- In absence of CK, when CKMB has NOT returned < URL, a rise in CKMB  50% 
above the previous level and > 3* URL or 
- In absence of CK, when CKMB and Troponin has not returned < URL a rise in 
Troponin  50% above the previous level and > 3*URL 
 
  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 98 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Spontaneous MI > 48 hours(PCI) 
A. Recurrent thoracic chest pain or ischemic equivalent AND  
New pathologic q waves in  2 contiguous ECG leads AND  
- any CKMB > 1*URL or 
- in the absence of CKMB: Troponin > 1*URL or 
- in the absence of CKMB and Troponin: CK > 1*URL or 
- in the absence of CKMB and Troponin and CK: CEC decision upon clinical scenario 
B. Appropriate cardiac enzyme data (respecting top-down hierarchy): 
b1. CK  2* URL Confirmed by: 
- CKMB > 1*URL or  
- in the absence of CKMB: Troponin > 1*URL or 
- in the absence of CKMB and Troponin: CEC decision upon clinical scenario 
OR 
b2. In the absence of CK: CKMB > 3*URL 
OR 
b3. In the absence of CK and CKMB: Troponin > 3*URL 
OR 
b4. In the absence of CK, CKMB and Troponi n, clinical decision based upon clinical 
scenario. 
 
  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 99 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
II. CABG (CORONARY ART ERY BYPASS GRAFTING) 
IIa. Baseline Biomarkers of Myocardi al Damage (CK and CKMB and Trop < 
1*URL) and not acute MI in progress. 
Periprocedural < 72 hours post CABG 
A. New pathologic q waves in  2 contiguous ECG leads or recurrent signs or symptoms 
consistent with myocardial ischemia AND 
- CKMB > 5x URL or 
- in the absence of CKMB: Troponin > 5*URL or 
- in the absence of CKMB and Troponin: CK > 5 URL or 
- in the absence of CKMB and Troponin and CK: CEC decision upon clinical scenario 
B. Appropriate cardiac enzyme data  
- CKMB  10* URL or 
- In the absence of CKMB: Trop > 10*URL. or 
- - In the absence of CKMB and Troponin: CK > 10*URL 
IIb. If Baseline Biomarkers of Myocardial  Damage: CK and/or CKMB > 1*URL or 
acute MI in progress 
Myocardial infarction, re-infarction (extension) < 72 hours post CABG 
A. If Peak CK (or CKMB) from index MI has not yet reached its maximum level: 
- Clinical signs or symptoms consistent  with recurrent myocardial ischemia 
AND 
- Appropriate cardiac enzyme data: 
- A rise in CKMB within 24 hours of the index event > 10*URL and  50% above 
the previous level. 
- In absence of CKMB: a rise in Troponin within 24 hours of the index event 
 > 10*URL and  50% above the previous level. 
- In absence of CKMB and Troponin: a rise in CK within 24 hours of the index 
event > 10*URL and  50% above the previous level. 
B. If elevated CK (or CKMB) following the index MI has peaked AND CKMB level has 
returned < URL, any new rise in: 
- CKMB > 10*URL or 
- in the absence of CKMB: Troponin > 10*URL or 
- in the absence of CKMB and Troponin: CK > 10*URL 
 C. If elevated CK (or CKMB) following the index MI has peaked AND CKMB level has NOT 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 100 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
returned < URL: 
- A rise in CKMB  50% above the previous level and > 10 URL or 
- In absence of CKMB: a rise in Troponin  50% above the previous level and > 10* 
URL or 
- In absence of CKMB and Troponin: a rise in CK  50% above the previous level and 
> 10*URL 
 
  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 101 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
MYOCARDIAL INFARCTION (MI) – ACADE MIC RESEARCH CONS ORTIUM (ARC) 
DEFINITION6 
Classification  Biomarker Criteria * Additional Criteria
Peri-procedural PCI 
(within 48 h after PCI)† or Troponin > 3 times URL
or 
CKMB > 3 times URL Baseline value < URL 
Peri-Procedural C ABG 
(within 72 h after CABG) Troponin > 5 times URL
or CKMB > 5 times URL Baseline value < URL and any of the
following: new pathologic
‡ Q waves or LBBB, 
new native or graft vessel occlusion, imaging evidence of loss of viable myocardium 
Spontaneous (> 48 h following PCI,  > 72 h following CABG) Troponin > URL or
CKMB > URL Baseline value < URL and any of the
following: symptoms of ischemia, ECG changes indicative of new ischemia (new  ST-T changes or new LBBB), development of pathological Q waves, or imaging evidence ofnew loss of viable myocardium or new regional wall motion abnormality 
Silent No biomarker data
available New pa thologic‡Q waves or LBBB 
Sudden Death Death before biomarkers 
obtained or before expected to be elevated Symptoms suggestive of ischemia and any of 
the following: new ST elevation or LBBB, documented thrombus by angiography or autopsy 
Reinfarction, spontaneous and peri-procedural (base definition; infarction extension) Stable or decreasing
values on 2 samples > 6 hapart and 20% increase 3–6 h after second sample If biomarkers not stable (increasing or peak 
not reached), then insufficient data to diagnose recurrent myocardial infarction 
Adapted from Global Task Force Universal Definition of Myocardial Infarction, Thygesen et al. 
 PCI: percutaneous coronary intervention; h: hour; URL: upper range limit (99
th percentile of 
normal reference range); CKMB: creatinine kinase myocardial band isoenzyme MB; CABG: 
coronary artery bypass graft; LBBB: left bundle branch block; ECG: electrocardiogram.  
 
*Baseline biomarker value required before study procedure and presumes a typical rise and fall. 
†Assessment of CKMB is preferred over assessment of troponin for diagnosis of peri-procedural MI, 
if possible. 
‡Pathologic Q waves may be defined according to the Global Task Force, Minnesota code or 
Novacode.  
 
NO REFLOW 
Sustained or transient reducti on in antegrade flow not asso ciated with an obstructive 
lesion at treatment site. 
                                                 
6 Cutlip DE, Windecker S, Mehran R et al. for the Academic Research Consortium. Clinical endpoints in 
coronary stent trials: A case  for standardized definition. Circulation  2007;115:2344–2351. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 102 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
PERCENT DIAMETER STENOSIS 
The value calculated as 100 x (RVD – MLD)/RVD using t he mean values from two 
orthogonal views (when possible) by quant itative coronary angiography.  (RVD: 
reference vessel diameter; MLD:  minimal lumen diameter.) 
PERFORATION 
Perforations will be classified as follows: 
Angiographic Perforation : Perforation detected by clinical site or core laboratory at any 
point during procedure. 
Clinical Perforation : Perforation requiring additional tr eatment (including efforts to seal 
perforation or pericardial draina ge), or resulting in significant  pericardial effusion, acute 
closure, myocardial infarction or death. 
Pericardial Hemorrhage/Tamponade : Perforation resulting in cardiac tamponade. 
PERCUTANEOUS CORONARY INTERVENTION (PCI) 
All interventional cardiology methods for treatment of coronary artery disease. 
PERSISTING INCOMPLETE APPOSITION 
Incomplete apposition at follow-up that was present post-procedure.  See also 
Incomplete Apposition . 
PROCEDURE SUCCESS 
Attainment of < 30% residual st enosis of the target lesion us ing the assigned study stent 
only without occurrence of in-hospital major adverse cardiac events (MACE). 
RESTENOTIC LESION 
Lesion in a vessel segment that has und ergone prior percutaneous treatment with or 
without a stent placement. 
REFERENCE VESSEL DIAMETER (RVD) 
Average of normal segments withi n 10 mm proximal and distal to target lesion from two 
orthogonal views using quantit ative coronary angiography. 
SERIOUS ADVERSE DEVICE EFFECT 
Adverse device effect that results in any of  the consequences characteristic of a serious 
adverse event. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 103 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
SERIOUS ADVERSE EVENT 
Adverse event that leads to: 
 Death. 
 Serious deterioration in the health of t he subject that either results in life-
threatening illness or injury; permanent im pairment of a body structure or a body 
function; hospitalization or  prolonged hospitalization; or medical or surgical 
intervention to prevent life- threatening illness, injury or permanent impairment to 
a body structure or a body function. 
 Fetal distress, fetal death, congenital abnormality or birth defect. 
STENT THROMBOSIS – ACADEMIC RESEAR CH CONSORTIUM (ARC) DEFINITION 
Stent thrombosis should be reported as a cumu lative value at the different time points 
and with the different separate time  points.  Time 0 is defined as the time point after the 
guiding catheter has been removed and the subj ect has left the catheterization lab. 
Timing 
 Acute stent thrombosis*  0–24 hours post–stent implantation 
 Subacute stent thrombosis* > 24 hour s–30 days post–stent implantation 
 Late stent thrombosis†  30 days–1 year post–stent implantation 
 Very late stent thrombosis†  > 1 year post–stent implantation 
*Acute/subacute can also be replaced by early stent thrombosis.  Early stent thrombosis 
(0–30 days) is a definition curr ently used in the community. 
†Including primary as well as secondary late stent thrombosis.  Secondary late stent 
thrombosis is a stent thrombosis afte r a target segment revascularization. 
Categories (Definite, Probable and Possible) 
Definite Stent Thrombosis 
Definite stent thrombosis is considered to have occurred by either angiographic or 
pathologic confirmation. 
Angiographic Confirmation of Stent Thrombosis* 
Presence of an intracoronary t hat originates in the stent  or in the segment 5 mm 
proximal or distal to t he stent, and presence of at least one of the following 
criteria within a 48-hour time window: 
 Acute onset of ischemic symptoms at rest. 
 New ischemic ECG changes that suggest acute ischemia. 
 Typical rise and fall in cardiac biomarkers (refer to definition of 
spontaneous MI). 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 104 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
Non-occlusive : Intracoronary thrombus is defined as a spheric, ovoid or irregular 
non-calcified filling defect or lucency su rrounded by contrast material (on 3 sides 
or within a coronary stenosis) seen in mult iple projections, or persistence of 
contrast material within the lumen, or  a visible embolization of intraluminal 
material downstream. 
Occlusive Thrombus : TIMI 0 or TIMI 1 in tra-stent or proximal to a stent up to the 
most adjacent proximal si de branch or main branch (if originates from side 
branch). 
Pathological Confirmation of Stent Thrombosis 
Evidence of recent thrombus within the stent determined at autopsy or via 
examination of tissue retrie ved following thrombectomy. 
*The incidental angiographic documentation of stent occlusion in the absence of clinical signs or 
symptoms is not considered a confirme d stent thrombosis (silent occlusion). 
Probable Stent Thrombosis 
Probable stent thrombosis is considered to have occurred after intracoronary stenting in 
the following cases: 
 Any unexplained death within first 30 days.† 
 Regardless of time after index procedure,  any MI related to documented acute 
ischemia in the territory of the implanted st ent without angiographic confirmation 
of stent thrombosis and in the absence of any other obvious cause. 
†For studies with ST-elevation MI population, ex clusion of unexplained death within 30 days may 
be considered evidence of probable stent thrombosis. 
Possible Stent Thrombosis 
Possible stent thrombosis is considered to  have occurred with an y unexplained death 
from  30 days after intracoronary stenti ng until end of tr ial follow-up. 
STROKE
 
See Cerebrovascular Accident or Stroke . 
STUDY DEVIATION 
Incident in which the investi gator or site personnel did not conduct the study according 
to the clinical protocol or investigator agreement. 
Major Deviation : Any deviation from subject inclusio n and exclusion crit eria or subject 
informed consent procedures. 
Minor Deviation : Deviation from a clinical pr otocol requirement such as 
incomplete/inadequate subject testing procedures, non-comp liance with study 
thienopyridine medication regimens, follo w-ups performed outside specified time 
windows, etc. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 105 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
TARGET LESION FAILURE (TLF) 
Cardiac death, target vessel myocardial infarction (Q-wave or non–Q-wave), or 
clinically-driven target lesion revascularization.  
TARGET LESION REVASCULARIZAT ION (TLR) – ACADEMIC RESEARCH 
CONSORTIUM (ARC) DEFINITION 
Repeat percutaneous intervention of target lesion or bypass surgery of target vessel 
performed for restenosis or other complication of target lesion. 
Target lesion is defined as t he treated segment starting 5 mm proximal to the stent and 
ending 5 mm distal to the stent. 
See also Clinically Driven Target Lesion Revascularization . 
TARGET VESSEL FAILURE (TVF) 
Composite endpoint comprised of cardiac death,  target vessel myocardial infarction or 
clinically-driven target vessel revascularization. 
Target vessel failure will be reported w hen any of the following events occur: 
 Recurrent MI occurs in te rritory not clearly attributed to a vessel other than target 
vessel. 
 Cardiac death not clearly due to a non-target vessel endpoint. 
 Target vessel revascularization is determined. 
TARGET VESSEL MYOCARDIAL INFARCTION (MI) 
Myocardial infarction that occurs in a terri tory that cannot be clearly attributed to a 
vessel other than t he target vessel. 
TARGET VESSEL REVASCULARIZATION (TVR) – ACADEMIC RESEARCH 
CONSORTIUM (ARC) DEFINITION 
Repeat percutaneous intervention or surgical  bypass of any segment of the target 
vessel. 
Target vessel is defined as the entire major coronary vessel proximal and distal to target 
lesion, including upstream and downstream branches and the target lesion itself. 
See also Clinically Driven Target Vessel Revascularization . 
THROMBOLYSIS IN MYOCARDIAL IN FARCTION (TIMI) CLASSIFICATION7 
TIMI 0 : No perfusion. 
TIMI 1 : Penetration with minimal perfusion.  Contra st fails to opacify entire bed distal to 
stenosis for duration of cine run. 
                                                 
7 TIMI Study Group. The Thrombolysis in Myocardi al Infarction (TIMI) tr ial. Phase I findings. N Engl J Med 
1985;312: 932–936. 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 106 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
TIMI 2 : Partial perfusion.  Contrast opacifies ent ire coronary bed distal to stenosis.  
However, rate of entry and/or clearance is slower in coronar y bed distal to obstruction 
than in comparable areas not perfused by dilated vessel. 
TIMI 3 : Complete perfusion.  Filling and clear ance of contrast equally rapid in the 
coronary bed distal to stenosis as in other coronary beds. 
TOTAL OCCLUSION 
Lesion with no flow (TIMI 0).  Total occlusio ns are usually classified as persisting less 
than or more than 3 months (chronic total occlusion). 
TRANSIENT ISCHEMIC ATTACK (TIA) 
Focal neurological abnormality of sudden on set and brief duration (lasting less than 24 
hours) that reflects dysfunction in the distri bution of the affected artery.  TIAs include 
transient monocular blindness (e.g., amaurosis fugax, defined as a tr ansient episode of 
monocular blindness, or parti al blindness, lasting 10 mi nutes or less) and transient 
hemispheric attacks. 
UNANTICIPATED ADVERSE DEVICE EFFECT (UADE) or  
UNANTICIPATED SERIOUS ADVERSE DEVICE EFFECT (USADE) 
An unanticipated adverse devic e effect (UADE) is defined in 21 CFR 812.3(s) as any 
serious adverse effect on health or safety  or any life-threateni ng problem or death 
caused by, or associated with, a device, if  that effect, problem or death was not 
previously identified in natur e, severity or degree of incidence in the protocol, or any 
other unanticipated serious prob lem associated with a device that relates to the rights, 
safety or welfare of a subject. 
In the OUS countries, the term unanticipated se rious adverse device effect (USADE) is 
used for serious adverse device effect that by its nature, incidence, severity or outcome 
has not been identified in the current version of the risk analysis report. 
UNSTABLE ANGINA 
Per the American College of Cardiology/Ame rican Heart Association 2002 Guideline 
Update for the Management of Patients Wi th Unstable Angina and Non–ST-Segment 
Elevation Myocardial Infarcti on, there are 3 prin cipal presentations of unstable angina8: 
1. Rest Angina : Angina occurring at rest, and prolonged, usually > 20 minutes. 
2. New-Onset Angina : New-onset angina of at leas t CCS class III severity. 
3. Increasing Angina : Previously diagnosed angina that  has become distinctly more 
frequent, longer in duration or lower in thre shold (i.e., increased by greater than 
or equal to one CCS class to at least CCS class III severity). 
                                                 
8 Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 guideline update for the management of 
patients with unstable angina and non-ST-segment elevat ion myocardial infarction – Summary article: A 
report of the American College of Cardiology/Ame rican Heart Association task force on practice 
guidelines (Committee on the Management of  Patients With Unstable Angina). J Am Coll Cardiol 
2002;40:1366–1374.  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 107 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
VASCULAR COMPLICATIONS 
Vascular complications may include the following: 
1. Pseudoaneurysm. 2. Arteriovenous fistula. 3. Peripheral ischemia/nerve injury. 4. Vascular event requiring transfusion or surgical repair. 
  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 108 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
18. REFERENCES 
                                                 
1 WHO. The global burden of disease: 20update. Available at: 
www.who.int/healthinfo/global_burden_di sease/2004_report_update/en/index.html; 
accessed 07 December 2013.  
2 Mathers CD, Loncar D. Projections of gl obal mortality and burden  of disease from 
2002 to 2030. PLoS Med  2006;3:e442. 
 
3 Nikolsky E. "Restenosis following percut aneous coronary interventions: A clinical 
problem," Handbook of Drug-Eluting Stents  3: 2006. 
 
4 Popma JJ, Topol EJ. Factors influencing restenosis after coronary angioplasty. Am J 
Med 1990;88:16N–24N. 
 
5 Erbel R, Schatz R, Dietz U et al. Balloon dilatation and coronary vascular stent 
implantation. Versicherungsmedizin  1989;41:82–84. 
 
6 Stone GW, Ellis SG, Colombo A et al. Offsetting impact of thrombosis and restenosis 
on the occurrence of death and myocardial infa rction after paclitaxel-eluting and bare 
metal stent implantation. Circulation  2007;115:2842–2847. 
 
7 Kastrati A, Mehilli J, Dirschinger J et al. Restenosis after coronary placement of 
various stent types. Am J Cardiol  2001;87:34–39. 
 
8 Al Suwaidi J, Berger PB, Holmes  DR, Jr. Coronary artery stents. J Amer Med Assoc 
2000;284:1828–1836. 
 
9 Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and 
bare-metal stents: A collaborat ive network meta-analysis. Lancet  2007;370:937–948. 
 
10 Doostzadeh J, Clark LN, Bezenek S, Pier son W, Sood PR, Sudhir K. Recent progress 
in percutaneous coronary intervention: Evolut ion of the drug-elutin g stents, focus on the 
XIENCE V drug-eluting stent. Coron Artery Dis  2010;21:46–56. 
 
11 Lagerqvist B, James SK, Stenestrand U, Li ndbäck J, Nilsson T, Wallentin L. Long-
term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J 
Med 2007;356:1009–1019. 
 
12 Kabir AM, Selvarajah A, Seifalian AM . How safe and how good are drug-eluting 
stents? Future Cardiol  2011;7:251–270. 
 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 109 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
                                                                                                                                                             
13 Pfisterer M, Brunner-L a Rocca HP, Buser PT et al. Late clinical events after 
clopidogrel discontinuati on may limit the benefit of drug-el uting stents: An observational 
study of drug-eluting versus bare-metal stents. J Am Coll Cardiol  2006;48:2584–2591. 
 
14 Farb A, Boam AB. Stent thromb osis redux – The FDA perspective. N Engl J Med  
2007;356:984–987.  
15 Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings 
with histopathological analysis of thrombus aspirates in patients with very late drug-
eluting stent thrombosis. Circulation  2009;120:391–399. 
 
16 Guagliumi G, Costa MA, Sirbu V et al. Strut coverage and la te malapposition with 
paclitaxel-eluting stents compared with bare metal stents in ac ute myocardial infarction: 
Optical coherence tomography substudy  of the Harmonizing Outcomes with 
Revascularization and Stents in Acute Myocar dial Infarction (HORIZONS-AMI) Trial. 
Circulation  2011;123:274–281. 
 
17 Sanchez-Recalde A, Moreno R, Barreales L et al. Risk of late-acquired incomplete 
stent apposition after drug-elut ing stent versus bare-metal stent. A meta-analysis from 
12 randomized trials. J Invasive Cardiol  2008;20:417–422. 
 
18 Cook S, Wenaweser P, Togni M et al. Incomplete stent apposition and very late stent 
thrombosis after drug-elut ing stent implantation. Circulation  2007;115:2426–2434. 
 
19 Nakazawa G, Otsuka F, Nakano M et al. The pathology of neoatherosclerosis in 
human coronary implants bare-me tal and drug-eluting stents. J Am Coll Cardiol  
2011;57:1314–1322.  
20 Waksman R, Maluenda G. Polymer drug-eluti ng stents: Is the future biodegradable? 
Lancet  2001;378:1900–1902. 
 
21 Kadota K, Muramatsu T, Iwabuchi M et al. Randomized comparison of the nobori 
biolimus A9-eluting stent with the sirolimus -eluting stent in patients with stenosis in 
native coronary arteries. Catheter Cardiovasc Interv  2011. Doi: 10.1002/ccd.23280. 
 
22 Byrne RA, Kastrati A, Massberg S et al. Biodegradable polymer versus permanent 
polymer drug-eluting stent s in patients with coronary artery disease. J Am Coll Cardiol  
2011;58:1325–1331.  
23 Xu B, Dou KF, Han YL et al. A prospective multicenter parallel-controlled trial of 
TIVOLI biodegradable-polymer- based sirolimus-eluting st ent compared to ENDEAVOR 
zotarolimus-eluting stent for the treatment  of coronary artery disease: 8-month 
angiographic and 2-year clin ical follow-up results. Chin Med J 2011;124:811–816. 
 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 110 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
                                                                                                                                                             
24 Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable 
polymer versus sirolimus-eluting st ent with durable polymer for coronary 
revascularisation (LEADERS): A r andomised non-inferiority trial. Lancet  
2008;372:1163–1173.  
25 Barlis P, Regar E, Serruys PW et al. An optical coherence tomography study of a 
biodegradable vs. durable poly mer-coated limus-eluting stent: A LEADERS trial sub-
study. Eur Heart J  2010;31:165–176. 
 
26 Stefanini GG, Kalesan B, Serruys PW et al. Long-term clinical outcomes of 
biodegradable polymer biolimus-e luting stents versus durable polymer sirolimus-eluting 
stents in patients with coronary artery di sease (LEADERS): 4 year follow-up of a 
randomised non-inferiority trial. Lancet  2011;378:1940–1948. 
 
27 Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: The onset  of a new era in 
interventional cardiology. Heart  2002;87:305–307. 
 
28 Poon M, Marx SO, Gallo R, Badim on JJ, Taubman MB, Marks AR. Rapamycin 
inhibits vascular smooth muscle cell migration. J Clin Invest  1996;98:2277–2283. 
 
29 Suzuki T, Kopia G, Hayashi S et al. Stent-based delivery of sirolimus reduces 
neointimal formation in a porcine coronary model. Circulation  2001;104:1188–1193. 
 
30 Sousa JE, Costa MA, Farb A et al. Images in cardiovascular medicine. Vascular 
healing 4 years after the implantation of  sirolimus-eluting stent in humans: A 
histopathological examination. Circulation  2004;110:e5–6. 
 
31 Sousa JE, Costa MA, Abizaid A et al. Four-year angiographic and intravascular 
ultrasound follow-up of patients treat ed with sirolimus-eluting stents. Circulation  
2005;111:2326–2329.  
32 Klugherz BD, Llanos G, Lieuallen W et al. Twenty-eight-day efficacy and 
pharmacokinetics of the sirolimus-eluting stent. Coron Artery Dis  2002;13:183–188. 
 
33 Sousa JE, Costa MA, Abizaid A et al. Lack of neointimal proliferation after 
implantation of sirolimus-c oated stents in human coronary arteries: A quantitative 
coronary angiography and three-dimensio nal intravascular ultrasound study. Circulation  
2001;103:192–195.  
34 Weisz G, Leon MB, Holmes DR Jr. Five-year  follow-up after sirolimus-eluting stent 
implantation results of the SI RIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary 
Lesions) trial. J Am Coll Cardiol  2009;17;53:1488–1497. 
 
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 111 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
                                                                                                                                                             
35 Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stent s versus standard stents 
in patients with stenosis in  a native coronary artery. N Engl J Med  2003;349:1315–1323. 
 
36 Urban P, Gershlick AH, Guagliumi G et al. Safety of coronary sirolimus-eluting stents 
in daily clinical practice: One-year  follow-up of the e-Cypher registry. Circulation  2006 
21;113:1434–1441.  
37 Gao RL, Xu B, Lu SZ et al. Safety and efficacy of the CYPHER Select Sirolimus-
eluting stent in the “Real World” – Clinical and angiogra phic results from the China 
CYPHER Select registry. Int J Cardiol  2008;125:339–346. 
 
38 Schampaert E, Cohen EA, Schlüter M et al. The Canadian study of the sirolimus-
eluting stent in the treat ment of patients with long de novo  lesions in small native 
coronary arteries (C-SIRIUS). J Am Coll Cardiol  2004;43:1110–1115. 
 
39 In patients with heart attacks, Cypher si rolimus-eluting cor onary stent results 
sustained out to four years compared to bare metal stents. Cordis Corporation, Warren, 
NJ, USA, press release, 19 May 2009.  
40 Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting 
coronary stent system fo r patients with single de-novo  coronary artery lesions 
(ABSORB): A prospective open-label trial. Lancet  2008;371:899–907. 
 
41 Tsuji T, Tamai H, Igaki K et al. Biodegradable polymeric stents. Curr Interv Cardiol 
Rep 2001;3:10–17. 
 
42 Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-l-lactic 
acid coronary stents in humans. Circulation  2000;102:399–404. 
 
43 Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting 
coronary stent system (ABSORB):  2-year outcomes and results from multiple imaging 
methods. Lancet  2009;373:897–910. 
 
44 Serruys PW, Onuma Y, Dudek D et al. Evaluation of the second generation of a 
bioresorbable everolimus-eluting va scular scaffold for the treatment of de novo  coronary 
artery stenosis: 12-month c linical and imaging outcomes. J Am Coll Cardiol  
2011;58:1578–88.  
45 Chevalier B, Serruys PW, Silber S et al. Randomised comparison of  Nobori, biolimus 
A9-eluting coronary stent with a Taxus(R), pac litaxel-eluting coronary stent in patients 
with stenosis in native coronary arteries: The Nobori 1 trial. EuroIntervention  
2007;2:426–434.  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 112 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
                                                                                                                                                             
46 Grube E, Hauptmann KE, Buellesfeld L, Li m V, Abizaid A. Six-month results of a 
randomized study to evaluate safety and effica cy of a Biolimus A9 eluting stent with a 
biodegradable polymer coating. EuroIntervention  2005;1:53–57. 
 
47 Hamon M, Niculescu R, Deleanu D, Dorobantu M, Weissman NJ, Waksman R. 
Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in 
the treatment of single de novo  coronary artery lesions (BIOFLOW-I): A prospective, 
first-in-man study. EuroIntervention . 2013;8:1006–1011 
 
48 Pilgrim T, Heg D, Roffi M, et al. Ultrathin strut biodegra dable polymer sirolimus-eluting 
stent versus durable polymer everolimus -eluting stent for percutaneous coronary 
revascularisation (BIOSCIENCE): a randomised,  single-blind, non-inferiority trial. The 
Lancet 2014 .  Early Online Publication, 01 September 2014.  
http://www.thelancet.com/journals/l ancet/article/PIIS0140-6736%2814%2961038-
2/fulltext.  
 
49 Andrew Thomas, Bob O Hara, Uwe Ligges , and Sibylle Sturtz. Making BUGS Open. 
R News 6: 12-17.  
50 Legrand C, Ducrocq V, Janssen P, Sylves ter R, Duchateau L. A Bayesian approach 
to jointly estimate centre and treatment by  centre heterogeneity in a proportional 
hazards model. Stat Med  2005; 24(24):3789-804. 
 
51 Gelman A, Carlin JB, Stern HS, Rubin DB . Bayesian Data Analysis, 1995 Chapman & 
Hall  
52 Heron MP, Hovert DL, Murphy SL, Xu JQ, Kochanek KD, Tejada-Vera B. Deaths: 
Final Data for 2006. National Vita l Statistics Reports 2009;57(14). 
 
53 Roger VL, Go AS, Lloyd-Jones D et al. Heart Disease and Stroke Statistics – 2010 
Update. Heart Disease and Stroke Statis tics – 2011 Update: A Report From the 
American Heart Association.  
54 Witt BJ, Jacobsen SJ, Weston SA et al. Cardiac rehabilitation after myocardial 
infarction in the community. J Am Coll Cardiol  2004;44:988–996. 
 
55 Wexler DJ, Grant RW, Meigs JB et al. Sex disparities in tr eatment of cardiac risk 
factors in patients with type 2 diabetes. Diabetes Care  2005;28:514–520. 
 
56 U.S. Food and Drug Administration, Cent er for Devices and Radiologic Health. 
Express and Express2 Coronary Stent Systems. P020009 (accessed February 28, 
2011).  
   
 
CIP FINAL V 4.0, 11 FEB 2016 BIOTRONIK CONFIDENTIAL Page 113 of 113  
REPRODUCTION, DISCLOSURE OR UNAUTHORIZED USE OF ANY PART OF THIS DOCUMENT IS STRICTLY 
PROHIBITED. 
                                                                                                                                                             
57 U.S. Food and Drug Administration, Cent er for Devices and Radiologic Health. 
Rithron-XR Coronary St ent System. P030037 (accessed February 28, 2011). 
 
58 U.S. Food and Drug Administration, Cent er for Devices and Radiologic Health. 
MULTI-LINK VISION RX AND MULTI-LINK  VISION OTW Coronary Stent Systems. 
P020047 (accessed February 28, 2011).  
59 U.S. Food and Drug Administration, Center for Devices and Radiologic Health. Driver 
Over-The-Wire, Rapid Exchange and Multi-Ex change Coronary Stent  System. P030009 
(accessed February 28, 2011).  
60 U.S. Food and Drug Administration, Cent er for Devices and Radiologic Health. 
NIRflex Premounted Co ronary Stent System. P020040 (accessed February 28, 2011). 